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Abstract 
The PDE 11 family of dual specificity phosphodiesterases was first identified in 2000, and 
has not been well characterised, although mutations in the gene have been linked to 
multiple disorders, including major depressive disorder, and cancer. DmPDE11 is a dual 
specificity phosphodiesterase, which shows 96% similarity with the catalytic domain of 
HsPDE11A, and around 40% similarity along the length of the protein.  The focus of this 
project was to characterise this important enzyme using the model organism Drosophila 
melanogaster. The resources available to Drosophila researchers are unrivalled, and 
include a sequenced genome, unparalleled transgenic technology, of which stocks are 
freely available, and Homophila, a database of human disease genes and their Drosophila 
orthologues. Drosophila is genetically tractable to an extent not seen in any other 
multicellular organisms. The genetic dissection of gene function in Drosophila has allowed 
the identification and characterisation of numerous cell signalling genes. For example, 
mutations to Dunce were shown to affect olfactory learning. This allowed the identification 
and cloning of the mammalian dnc homologue PDE4. cAMP (and cGMP) were 
subsequently shown to modulate learning and memory in mammals. 
The 5.8 kb expressed sequence tag (EST) SD13096 had previously been shown to contain 
sequence present in the incomplete PDE11 RA ESTs previously released by Flybase, but 
also incorporating a 5‟ UTR, and an in-frame start codon within two novel 5‟ exons. A 
Northern blot of DmPDE11 RA produced one band of approximately 5.8kb; as this 
matches the size of the DmPDE11 RA ORF, was accepted that SD13096 encodes the entire 
PDE11 RA ORF (Day, unpublished). Expression of this EST in S2 cells revealed that the 
construct produced a protein of the accepted size, and the protein localised to the 
cytoplasm. However, PDE assays of S2 cell lysate revealed that the enzyme did not appear 
to encode an enzyme with either cA- or cG-PDE activity. 
DmPDE11 RA was replaced on Flybase by the new isoforms DmPDE11 RB and 
DmPDE11 RC, which had two key changes to the RA isoform. Both new isoforms had 
different N termini, sharing a second exon, with distinct first exons. Furthermore, exon 11 
of the RA exon is not present in the newly predicted isoforms. These new isoforms were 
verified by reverse transcriptase- polymerase chain reaction analysis. In the course of this 
verification, two further novel isoforms were identified, which shared the novel N termini 
with the RB and RC isoforms, but include a novel exon/exon boundary within the original 
exon 19, which results in a truncated isoform. As such the four isoforms were named 
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DmPDE11 RB long, DmPDE11 RB short, DmPDE11 RC long, and DmPDE11 RC short. 
The open reading frames of these isoforms were cloned from Drosophila cDNA using 
high-fidelity DNA polymerase and sequenced for fidelity. The open reading frames were 
tagged with YFP, and this tag was used to verify expression of these isoforms. Each 
isoform expressed a protein of the predicted size when expressed in Drosophila. 
DmPDE11 B and C proteins show distinct localisation in the Malpighian tubule, where the 
long and short isoforms of each isoform display indistinguishable localisations. DmPDE11 
B localises to the apical and basolateral membranes, and DmPDE11 C localises to an 
unknown organelle, or to vesicles. All 4 isoforms were verified as dual specificity cA- and 
cG- PDEs. 
The previous finding (Day, unpublished) that DmPDE11 co-immunoprecipitates with 
cGMP dependent protein kinase activity, and that cGMP dependent protein kinases co-
immunoprecipitate with cG-PDE activity, and thus that cG-PDE(s) interact with at least 
one cGMP dependent protein kinase, directly or indirectly, was investigated. DmPDE11 C 
long and short were co-transfected in Schneider 2 cells with the cGKs DG1, DG2P1 and 
DG2P2. Co-immunoprecipitation of these showed that both the long and short isoforms of 
DmPDE11 C interact with every cGK screened. Time did not permit the application of this 
protocol to screen DmPDE11 B interaction with the cGKs. Whether this interaction is 
direct or indirect was screened by peptide array. Peptide arrays were generated 
representing the sequence of DmPDE11, DG1, and DG2, and proteins were generated 
fusing fragments of these proteins with HIS6 and Glutathione-S-Transferase tags. These 
were expressed in E. coli, and verified by western blotting. HIS6 tagged protein expression 
was shown to be of higher quality, and was thus affinity purified, and used to overlay and 
probe the peptide arrays for putative direct interactions. When the PDE11 array was 
overlaid with tagged protein representing the C terminal half of DG1, and the N and C 
terminal halves of DG2, a putative direct interaction was identified between DG1 and 
PDE11 on two separate regions of the PDE11 array, which both fell within the sequence of 
PDE11 represented by the Middle-HIS6 fragment. As such, this was used to probe the 
PDE11 array. A reciprocal putative interaction was identified on three regions of the DG1 
array, representing sequence in both DG1N-HIS6 and DG1C-HIS6 fragments. 
Unfortunately, although DG1-HIS6 was verified by western blotting at the analytical stage, 
attempts to affinity purify the protein failed. Time did not permit the probing of the array 
with DG1N-GST fusion protein, and so further putative interaction sites on PDE11 may 
remain. The generation of alanine substitution arrays, and subsequent mutagenesis analysis 
with yeast two hybrid or co-immunoprecipitation would be necessary to confirm this direct 
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protein-protein interaction as bona-fide. The investigation into a putative direct interaction 
between PDE11 and DG2 did not yield conclusive data, and so further investigation is 
required.  
The role of DmPDE11 in immunity was investigated by the use of DmPDE11 RNAi and 
deletion lines. The DmPDE11 deletion line showed a qualitative reduction in survival in 
individual survival assays, but when these data were merged a significant decrease in 
survival compared to controls was seen. However, fly numbers did not permit the inclusion 
of all of the necessary controls, and so these assays should be repeated with these. 
However, upon immune challenge, progeny from a DmPDE11 RNAi (line 9) x Act5c (a 
ubiquitous GAL4 driver line) cross did not show a decrease in survival compared to 
parental lines. 
Transgenic Drosophila expressing H. sapiens PDE11A3 were generated. The protein 
localised to the nucleus at low levels of protein; increased expression led to nuclear 
exclusion, and localisation to the basolateral and especially apical membranes, with 
cytosolic localisation also.  
The work has provided the tools needed to further research PDE11. The implication of this 
gene as a tumour suppressor gene, and its role in other processes, means that it is of the 
utmost importance that this enzyme is further characterised. 
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One and three amino acid codes: 
 
A Ala Alanine 
C Cys Cysteine 
D Asp Aspartic acid 
E Glu Glutamic acid 
F Phe Phenylalanine 
G Gly Glycine 
H His Histidine 
I Ile Isoleucine 
K Lys Lysine 
L Leu Leucine 
M Met Methionine 
N Asn Asparagine 
P Pro Proline 
Q Gln Glutamine 
R Arg Arginine 
S Ser Serine 
T Thr Threonine 
V Val Valine 
W Trp Tryptophan 
Y Tyr Tyrosine 
* Stop
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1.1 Summary of Cyclic Nucleotide Signalling 
The cyclic nucleotides adenosine 3‟,5‟-cyclic monophosphate (cAMP) and guanosine 
3‟,5‟-cyclic monophosphate (cGMP) are second messengers that play important roles in 
virtually all cell types (Beavo and Brunton, 2002). Since the purification and 
characterisation of cAMP in 1957 as a second messenger for adrenaline (Rall et al., 1957; 
Sutherland and Rall, 1957; Wosilait and Sutherland, 1957), the enzymes responsible for 
the generation of cAMP, adenylate cyclase (Sutherland et al., 1962), and for the hydrolysis 
of cAMP to the inactive 5‟AMP, phosphodiesterase (PDE) (Butcher and Sutherland, 1962), 
were rapidly identified. Following this, however, it took more than a decade to identify the 
main downstream effector enzyme, cAMP-dependant protein kinase (PKA) (Walsh et al., 
1968b), and a further three decades to identify EPAC, or guanine nucleotide exchange 
factor directly activated by cAMP (de Rooij et al., 1998). cGMP was discovered in rat 
urine in 1963 (Ashman et al., 1963); it took until 1969 to identify guanylate cyclase and 
cGMP-PDEs (Hardman and Sutherland, 1969) cGMP dependent protein kinase (cGK) was 
discovered in 1970 (Kuo and Greengard, 1970). Any functional significance for cGMP 
besides regulation of cA-PDE activity (Beavo et al., 1971) was unknown until it was found 
to regulate light transduction (Miki et al., 1975). cGMP is typically present at a ten-fold 
lower physiological concentration than cAMP; whereas PKA, the main cAMP effector 
enzyme, is ubiquitous, with multiple identified targets, cGK has a more limited tissue 
expression profile, and, still, few identified targets (Hofmann et al., 2006). Nucleotide 
gated channels for both cGMP (Fesenko et al., 1985) and cAMP (Nakamura and Gold, 
1987) were discovered later. Cyclic nucleotide signalling has since been shown to act as a 
second messenger for a great number of hormones and neurotransmitters. Mutations in 
cyclic nucleotide signalling genes have been shown to predispose to a number of diseases. 
The sheer number of genes involved – for example 21 vertebrate PDE genes – hints at a 
tightly spatiotemporally regulated signalling system, with multiple inputs and specific 
downstream effects. Indeed, five Nobel prizes later, a great deal remains to be discovered. 
1.2 cAMP overview 
Upon binding of a hormone or neurotransmitter to their cognate G-protein coupled receptor 
(GPCR), a stimulatory G protein (Gs) stimulates adenylate cyclase, which produces cAMP 
from ATP (Sutherland, 1962). At elevated concentrations, cAMP acts as a second 
messenger, effecting downstream signalling via the stimulation of PKA (Walsh et al., 
1968a), CNG channels (Nakamura and Gold, 1987), and cAMP-activated guanine 
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nucleotide exchange factors (GEFs) (de Rooij et al., 1998; Kawasaki et al., 1998).  cAMP 
is hydrolysed to inactive 5‟AMP by cAMP-PDEs (Butcher and Sutherland, 1962) or is 
transported out of the cell by cyclic nucleotide transporters (Jedlitschky et al., 2000). A-
kinase anchoring proteins (AKAPs) serve to bind PKA in an isoform-specific manner 
(Bregman et al., 1989; Bregman et al., 1991; Sarkar et al., 1984), and place these at 
discrete subcellular localisations, as members of protein complexes incorporating both 
substrates and PDEs to facilitate spatiotemporal control of cAMP signalling (Wong and 
Scott, 2004). cAMP signalling is summarised in figure 1.1. 
Figure 1.1: The cAMP signalling system. Agonist binding to a Gαs coupled GPCR 
activates adenylate cyclase, which generates cAMP from ATP. This then acts as a second 
messenger, activating the downstream effectors PKA, cAMP-gated ion channels, and 
cAMP activated guanine nucleotide exchange factors. Intracellular cAMP concentration is 
reduced by hydrolysis by PDEs, and export from the cell by cyclic nucleotide transporters. 
AKAPs tether proteins to distinct subcellular locations. Abbreviations: GPCR = G-protein 
coupled receptor; GEF = Guanine nucleotide exchange factor; AKAP = A kinase 
anchoring protein; PKA = cAMP dependent protein kinase. 
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1.3 cGMP overview 
cGMP is a second messenger for a number of primary messengers. cGMP is generated by 
guanylate cyclase from GTP. There are two types of guanylate cyclase. Receptor (also 
known as “transmembrane” or “particulate”) guanylate cyclase (rGC) is stimulated 
following the binding of a primary, extracellular messenger to its extracellular binding 
domain (Chinkers et al., 1989) (Schulz et al., 1989). Soluble (cytoplasmic) guanylate 
cyclase is stimulated via the binding of a primary messenger, but via an indirect 
mechanism. A primary messenger binds to a cognate GPCR, resulting in the activation of a 
Gq protein. This stimulates phospholipase C, which cleaves phosphatidylinositol 4,5-
biphosphate (PIP2) into diacyl glycerol (DAG) and inositol 1,4,5-triphosphate (IP3). The 
increase in IP3 stimulates IP3 receptor (IP3R), resulting in the release of calcium (Ca
2+
) 
from internal stores. This increase in intracellular Ca
2+
 concentration in turn stimulates 
nitric oxide synthase (NOS), which produces nitric oxide (NO). This increase in NO 
stimulates soluble guanylate cyclase (sGC), which produces cGMP (Arnold et al., 1977). 
An atypical sGC has also been shown to be stimulated by oxygen (Gray et al., 2004; 
Morton, 2004). cGMP is hydrolysed to inactive 5‟GMP by cGMP-PDEs (Miki et al., 
1975), or is transported out of the cell by cyclic nucleotide transporters (Cropp et al., 2008; 
Dagger et al., 2001; Guo et al., 2003; Jedlitschky et al., 2000) . At elevated concentrations, 
cGMP stimulates cGK (Kuo and Greengard, 1970), CNG channels (Fesenko et al., 1985), 
and cAMP-PDEs (Beavo et al., 1971). cGMP signalling is summarised in figure 1.2. 
 
 
 
 
 
 
 
 
34 
Figure 1.2: The cGMP signalling system. cGMP is generated in response to a primary 
messenger, which either binds and activates rGC, or activates sGC via an indirect 
mechanism, through stimulation of a GPCR-coupled Gq protein. This stimulates 
phospholipase C, which cleaves phosphatidylinositol 4,5-biphosphate (PIP2) into diacyl 
glycerol (DAG) and inositol 1,4,5-triphosphate (IP3). The increase in IP3 stimulates IP3 
receptor (IP3R), resulting in the release of Ca
2+
 from internal stores. This increase in 
[Ca
2+
]cyt in turn stimulates nitric oxide synthase (NOS), which produces nitric oxide (NO). 
This increase in NO stimulates sGC, which produces cGMP. This then acts as a second 
messenger, activating the downstream effectors cGK and cGMP-gated ion channels. 
Intracellular cGMP concentration is reduced by hydrolysis by PDEs, and export from the 
cell. GPCR = G-protein coupled receptor; NOS = Nitric oxide synthase; NO = Nitric 
oxide; sGC = Soluble guanylate cyclase; rGC = Receptor guanylate cyclase; cGK = Cyclic 
GMP-dependent protein kinase. 
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1.4 Drosophila melanogaster as a genetic model 
organism 
The use of Drosophila as a genetic model organism was pioneered by Thomas Morgan, 
who was awarded a Nobel prize for his discovery of the white mutation (Morgan, 1910), 
and subsequent work. The benefits of Drosophila are well known. These include a short 
generation time, low cost, complex body plan, multiple physical and behavioural 
phenotypes, and a high relevance to mammalian systems due to high levels of homology, 
from gene sequence to protein function. Where Drosophila excels, however, is the 
availability of incredible genetic resources. The Drosophila genome has been sequenced, 
and the annotation is constantly updated (Adams et al., 2000). Balancer chromosomes 
prevent homologous recombination, and are lethal when homozygous; as they carry 
dominant genetic markers, stable heterozygote transgenic flies can kept as stocks for 
generations.  The P-element, a mobile genetic element, has been instrumental in 
establishing Drosophila as an unrivalled genetic model organism. Initially used for 
mutagenesis, it was modified to allow enhancer trapping (O'Kane and Gehring, 1987), and 
later to generate transgenic flies under the control of yeast promoters and transcription 
factors, to deliver cell specific overexpression, or downregulation via RNAi, of a gene of 
choice, thus allowing the dissection of gene function at the level of cellular, tissue, and 
whole organism function (Figure 1.3) (Brand and Perrimon, 1993).  
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Figure 1.3: The GAL4/UAS binary system. A driver line carrying the yeast transcription 
factor GAL4 downstream of an endogenous promoter showing tissue specific expression 
of interest is used to drive expression of a transgene (“gene X”) under the control of a UAS 
(Upstream Activation Sequence) GAL4 responsive promoter, in a tissue specific manner. 
Adapted from (Dow and Davies, 2003b). 
               GAL4 driver line                                      GAL4 responsive transgenic 
                 
 
 
 
Genetic manipulation at the cellular level with the aim of understanding entire tissues has 
been termed integrative physiology (Dow and Davies, 2003b). The vast complexity and 
high levels of redundancy within mammalian cyclic nucleotide signalling networks leads 
to difficulties in the understanding of these pathways. Drosophila melanogaster has fewer 
signalling components in a typical signalling network, yet homologues within these 
pathways frequently perform the same tasks. With reduced redundancy comes clearer 
phenotypes; coupled with Drosophila genetics, e.g., cell-specific up- or down-regulation of 
a protein of interest, the elucidation of function is achievable where in mammalian systems 
it may not be. 
 
1.5 cGMP signalling in Drosophila 
cGMP signalling has been the focus of intense research for several decades. Individual 
components of the cGMP signalling pathway have mostly been identified by work in cell 
culture systems. Understanding of the role of cGMP signalling in physiology has been 
GAL4 Endogenous promoter 
   
UAS GENE X 
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advanced through the use of two main model organisms, mouse and fruit fly. Mouse 
deletion and transgenic models have greatly extended understanding of cGMP signalling. 
NOS isoforms have been attributed roles through the use of NOS knockouts (Mashimo and 
Goyal, 1999) and transgenics (Mungrue et al., 2003), as have natriuretic peptide (ANP) 
receptors (transmembrane guanylate cyclases) (Lopez et al., 1997). The use of mouse cGK 
deletion models led to the identification of several cGK substrates (Hofmann et al., 2006). 
The many advantages of Drosophila, discussed above, have led to novel discoveries in 
cGMP signalling. cGMP has been shown to affect learning and memory in larval (Osborne 
et al., 1997) and adult (Pereira and Sokolowski, 1993) Drosophila. cGMP was 
subsequently shown to have a role in learning and memory in mammals (Kleppisch and 
Feil, 2009; Prickaerts et al., 2002). 
 
1.5.1 Dm NOS 
Nitric oxide synthase is a membrane bound enzyme that generates nitric oxide in response 
to a rise in cytosolic Ca
2+
, which is generated in response to an extracellular hormone or 
neurotransmitter binding to a cognate Gq-coupled GPCR. Activation of the Gq protein 
leads to the stimulation of phospholipase C, a membrane bound enzyme that cleaves 
phosphatidylinositol 4,5-biphosphate (PIP2) into diacyl glycerol (DAG) and inositol 1,4,5-
triphosphate (IP3). The increase in IP3 stimulates IP3 receptor (IP3R), resulting in the 
release of Ca
2+
 from internal stores, typically the endoplasmic reticulum. (Regulski et al., 
2004; Regulski and Tully, 1995). In turn, this increase in NO stimulates sGC, which 
produces cGMP (Arnold et al., 1977). Drosophila contains one NOS gene, dNOS, which 
has 10 transcripts (NOS RA-RJ), encoding 6 novel polypeptides 
(http://flybase.org/reports/FBgn0011676.html). dNOS shows closest homology with 
vertebrate neuronal NOS (NOS1) (Davies, 2000; Regulski and Tully, 1995). Generation of 
a null allele leads to embryonic and larval lethality (Regulski et al., 2004). Overexpression 
affects behaviour, where flies demonstrate a reduction in motility (Broderick et al., 2003). 
NO has also been shown to modulate Malpighian tubule function. dNOS is expressed in 
principal cells, and increases fluid secretion in response to the neuropeptides capa-1 and 
capa-2 by the stimulation of cGMP production via sGC (Davies et al., 1997). NOS also has 
a role in immunity; activation leads to the production of immune peptides in the fat body 
(Foley and O'Farrell, 2003), the canonical immune tissue of the fly, and also in the 
Malpighian tubule, a tissue also of great importance to fly immunity (Davies and Dow, 
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2009; McGettigan et al., 2005). dNOS has been shown to play vital roles in imaginal disc 
development,  regulation of organ growth, negative regulation of DNA replication and cell 
proliferation (Kuzin et al., 1996), synaptogenesis and nervous system development 
(Bicker, 2005), and the defence response (http://flybase.org/reports/FBgn0011676.html). 
Not all of these are necessarily modulated by the cGMP signalling pathway, but this array 
of processes clearly underlies the importance of cGMP signalling in Drosophila. 
 
1.5.2 Dm soluble guanylate cyclase 
Soluble (cytoplasmic) guanylate cyclase generates cGMP from GTP in response to NO 
(Arnold et al., 1977). Drosophila sGC exists as a heterodimer, composed of an alpha 
(guanylate cyclase α-subunit at 99B/ Gycα99B) and a beta (guanylate cyclase β-subunit at 
100B/Gycβ100B) subunit, which generates cGMP upon NO binding (Stone and Marletta, 
1996). A homodimer composed of two beta2 subunits was subsequently shown to bind NO 
and produce cGMP (Koglin et al., 2001). Gyc-88E, Gyc-89Da, and Gyc-89Db encode 
atypical guanylate cyclase subunits, which probably form Gyc-88E/89Da and Gyc-
88E/89Db heterodimers in vivo (Morton et al., 2005). Gyc-88E also forms active 
homodimers. All atypical subunits were shown to generate cGMP under anoxic conditions 
(Morton, 2004), which suggests a potential role in feeding behaviour (Vermehren et al., 
2006).  Gyc-89Da and Gyc-89Db express in neurons responsible for adult eclosion and 
ecdysis respectively (Morton et al., 2008). Drosophila and mammalian sGCs are highly 
similar, showing similar structure and enzymatic properties (Shah and Hyde, 1995). A 
soluble GC hypomorph displays altered photoreceptor development, which can be 
phenocopied by inhibiting dNOS (Gibbs et al., 2001). sGC and NOS have been shown to 
regulate vesicle release at the larval neuromuscular junction (Wildemann and Bicker, 
1999).  
1.5.3 Dm Receptor guanylate cyclase 
Receptor guanylate cyclase generates cGMP from GTP following the binding of a primary, 
extracellular messenger to its extracellular binding domain (Schulz et al., 1989). There are 
at least 7 receptor/receptor like guanylate cyclases encoded by the Drosophila genome 
(Davies, 2006). These are not well characterised, with no identified ligands. However, they 
share high sequence similarity with mammalian transmembrane guanylate cyclases. They 
have been linked to a number of phenotypes in Drosophila. Gyc32E is involved in 
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oogenisis  and egg chamber development (Malva et al., 1994). Gyc76C has been shown to 
mediate semaphorin-1a (Sema-1a)-plexin A repulsive axon guidance of motor axons 
(Ayoob et al., 2004). A unique rGC was identified in Drosophila that is inhibited by O2, 
CO, and NO, and appears to function as an oxygen sensor (Huang et al., 2007). Flyatlas 
reveals that multiple rGCs are expressed in the Malpighian tubule (Chintapalli et al., 2007), 
and in situ hybridisation has localised expression to the main fluid secreting segment of the 
tubule (Guo, 2007), suggesting a role in fluid secretion. 
 
1.5.4 Dm Cyclic nucleotide gated channels 
Cyclic nucleotide gated channels are tetrameric proteins that bind cyclic nucleotides under 
conditions of increased intracellular cyclic nucleotide concentration, which facilitates the 
permeation of extracellular cations, and thus the depolarisation of the plasma membrane. 
There are at least four CNG channel genes in Drosophila (Littleton and Ganetzky, 2000). 
Cng is expressed in eye and antenna, and forms a cGMP sensitive homomeric channel 
(Baumann et al., 1994). Cng-like is expressed in neuronal cells and in the mushroom 
bodies, and is a homologue of the mammalian CNG channel beta subunit. It does not form 
functional monomeric channels (Miyazu et al., 2000). CG3536, and CG17922 both encode 
CNG channels although very little is known about them.  
cGMP has been shown to stimulate Ca
2+
 influx into the tubule, which expresses cng, in a 
verapamil sensitive manner. As verapamil can be used as a CNG channel blocker, this 
suggests that cGMP gated ion channels modulate fluid secretion via Ca
2+
 signalling 
(MacPherson et al., 2001). 
 
1.5.5 Cyclic nucleotide transport in Drosophila 
Drosophila has contributed to the understanding of cyclic nucleotide transport, and the 
Malpighian tubule has been the tissue of choice in this area of study. Cyclic nucleotides are 
transported across the Malpighian tubule (Riegel et al., 1998). PDE6 has been found to 
regulate cGMP transport across the Malpighian tubule (Day et al., 2006); targeted 
overexpression in tubule principal cells completely ablates the process, whereas 
knockdown in principal cells significantly increases transport. This is the first 
demonstration of a direct role played by a PDE in cyclic nucleotide efflux. White, a 
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member of the ATP binding cassette G2 (ABC G2) transporter family, has classically been 
used as an eye colour marker in Drosophila. It was shown to participate in vesicular 
transepethilial transport of cGMP in the Malpighian tubule; the same study demonstrated 
that cyclic nucleotide transport is performed by the ABC G2 subfamily in Drosophila, and 
not the ABC C transporter subfamily as in mammals (Evans et al., 2008).  
 
1.5.6 Dm cGKs 
There are two Drosophila cGMP-dependent protein kinase genes; dg1, and dg2 (foraging 
or for), which has eleven transcripts, forRA - forRK. DG2P1 and DG2P2 are the 
catalytically active isoforms (MacPherson et al., 2004b). DG2 shares 64% sequence 
identity with its nearest homologue in mammals, bovine lung cGK, with 75% sequence 
identity to the catalytic domain, and 64% to the cGMP binding domain. cGK is a 
holoenzyme, which is active as a homodimer (Gamm et al., 1995), and is maintained in a 
catalytically inactive state by a pseudosubstrate-like regulatory region located in the N 
terminus of the enzyme. At an elevated concentration of cGMP, the regulatory region is 
displaced, and the enzyme becomes enzymatically active. DG1 is a dimer, (Foster et al., 
1996) whilst DG2 purifies as a dimer under gel filtration (MacPherson, 2004). Malpighian 
tubules express dg1, and the four main transcripts of dg2, P1-P4.  cGKs show differential 
localisation in the Malpighian tubule. DG1 is localised to the cytosol and to the basolateral 
membrane. DG2P1 is localised to the apical and basolateral membranes, whereas DG2P2 
is localised to the apical membrane. cGK activity is high in tubules, where the cGKs play 
distinct roles in the modulation of fluid transport in the Malpighian tubule. When 
overexpressed in tubule principal cells, DG1 increased fluid secretion in response to 
exogenous cGMP, which is transported into the tubule via cyclic nucleotide transporters 
(Riegel, 1998). DG2P2 overexpression, on the other hand, increased the fluid secretion 
response to capa-1 (MacPherson et al., 2004b). A naturally occurring polymorphism in dg2 
has been shown to determine the food search pattern employed by larval Drosophila (de 
Belle et al., 1989), where rovers (for
R
) travel further to find food than the sitter (for
S
) 
isoform (Pereira and Sokolowski, 1993). It was shown that as well as a 10% reduction in 
catalytic activity, the sitter isoform shows a slight reduction in transcript and protein levels 
(Osborne et al., 1997). The for
S
 and for
R
 isoforms were further characterised using the 
Malpighian tubule, where the polymorphism did not affect cGK activity, but rather the 
sitter polymorphism was shown to slightly increase the cGMP-PDE activity of an 
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unidentified PDE, with the result of lowering cGMP content (MacPherson et al., 2004a). 
As capa-1 neuropeptide increases fluid transport via cGMP, it follows that fluid transport 
of the Malpighian tubules from a forS background shows hypersensitivity to exogenously 
applied Capa-1 (MacPherson et al., 2004a) and cGMP (Dow and Davies, 2003b).  
 
1.5.7 Dm PDEs 
A cytogenic analysis of the Drosophila genome for regions that increase cAMP-PDE and 
cGMP-PDE activity when duplicated yielded four such regions; two of which, 3D3 / 3D4 
and 90E-91B, increased cAMP-PDE activity in fly extracts when duplicated; the other two, 
5D-9C and 88C-91B, increased cGMP-PDE activity in fly extracts when duplicated  
(Kiger and Golanty, 1977). Biochemical analysis of Drosophila extracts showed cAMP 
specific/Form II, and dual specificity (cAMP and cGMP) specific/Form I PDE activity 
(Davis and Kiger, 1980). Dunce (dnc) was identified in a screen for mutants in learning 
(Dudai et al., 1976) , and was later characterised as having Form II (cAMP) PDE activity, 
and mapped to 3D4 (Byers et al., 1981). The form I PDE was characterised as Ca
2+
 
dependent, whereas the form II PDE was shown to be unaffected by Ca
2+
, which suggested 
that the neurological defects seen in dnc mutants were linked directly to defects in cAMP-
PDE activity, as opposed to cAMP mediated Ca
2+
 influx in presynaptic transmission 
(Byers et al., 1981). Work on several dnc mutants showed aberrant cAMP metabolism 
(Davis and Kiger, 1981), and molecular analysis of the enzyme verified the dnc gene as 
encoding a cAMP-PDE (Chen et al., 1986). This lead to the identification of mammalian 
PDE4 in rat (Colicelli et al., 1989; Davis et al., 1989; Swinnen et al., 1989) and 
subsequently the human PDE4 family (Conti et al., 2003). Following the discovery of 
dunce, it took several years for the cloning and characterisation for the other Drosophila 
PDEs to occur. 
There are 11 mammalian PDE families encoded by 21 genes, which in total yields over 
100 novel proteins. These have been grouped into 11 families, to reflect a shared sequence 
similarity, nucleotide specificity, regulatory properties, and inhibitory profile. Such a 
diverse array of proteins all responsible for degrading cyclic nucleotides allows for tight 
control and shaping of these signals, and contributes to the incredible specificity that these 
signalling events display (Beavo and Brunton, 2002). These all share a highly conserved 
catalytic domain, which contain a metal binding motif (HX21-23HX3D/E) (Charbonneau et 
al., 1986), the identification of which allowed homologous PDEase domains to be 
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identified, and the corresponding 11 phosphodiesterase gene families to be cloned. 
Mammalian PDE sequences were used to screen the Berkeley Drosophila Genome Project 
database (http://flybase.net/) for Drosophila PDE orthologues. Positive hits were then 
screened for the HX21-23HX3D/E cyclic nucleotide motif. This analysis revealed that 
Drosophila contains orthologues to mammalian PDE1 (CG14940), PDE4 (CG32498), 
PDE6 (CG8279),  PDE8 (CG5411), PDE9 (CG32648) and PDE11 (CG10231) (Day et al., 
2005). These were also identified in a separate study (Morton and Hudson, 2002). Other 
than Dunce (Qiu, 1991), these PDEs were cloned and verified by Day et al, 2005. PDEs in 
Drosophila show widespread expression (Chintapalli et al., 2007; Day et al., 2005), 
underlying their importance. 
 
1.6 Drosophila PDEs share biochemical, 
pharmacological, and structural characteristics with 
their mammalian orthologues 
Analysis of Drosophila PDEs reveals a high degree of homology with respect to 
specificity, and the presence and arrangement of conserved domains (table 1.1). 
 
Table 1.1: Drosophila contains homologues to PDE1, 4, 6, 8, 9, and 11. Drosophila 
PDEs show a high degree of homology with respect to specificity, and the presence and 
arrangement of conserved domains. From (Day et al., 2005). 
Vertebrate PDEs Specificity Domains Drosophila  PDEs Specificity Domains 
(predicted PDE 1 Dual spec CaM binding PDE 1 Dual spec CaM binding
PDE 4 cA-PDE UCR Dunce cA-PDE -
PDE 6 cG-PDE GAF PDE 6 cG-PDE GAF
PDE 8 cA-PDE REC, PAS PDE 8 unknown REC, PAS
PDE 9 cG-PDE - PDE 9 unknown GAF
PDE 11 Dual spec GAF PDE 11 Dual spec GAF
 
When compared to their mammalian homologues, a high level of sequence 
similarity/identity was found in the catalytic domains (69-96%), with generally over 50% 
similarity over the length of the protein (table 1.2). 
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Table 1.2: A comparison of Drosophila and mammalian PDEs. Drosophila PDEs 
display high levels of homology with their mammalian homologues, especially within the 
catalytic domain. Adapted from (Day et al., 2005). 
Percentage amino acid identity (similarity)
Gene Human homologue Human homologue Catalytic domain 
Predicted length 
of polypeptide 
(amino acids) 
CG14940 PDE1 40 (56) 63 (79) 1818
CG8279 PDE6 28 (46) 51 (69) 1131
CG32498 transcript A PDE4 59 (74) 79 (91) 701
CG32498 transcript B PDE4 59 (74) 79 (91) 1209
CG32498 transcript C PDE4 60 (76) 79 (91) 1057
CG32498 transcript D PDE4 59 (74) 79 (91) 1068
CG32498 transcript E PDE4 59 (74) 79 (91) 642
CG32498 transcript F PDE4 60 (76) 79 (91) 662
CG32498 transcript G PDE4 58 (73) 79 (91) 814
CG32498 transcript I PDE4 59 (74) 79 (91) 1070
CG32498 transcript J PDE4 59 (74) 79 (91) 1070
CG32498 transcript L PDE4 61 (76) 79 (91) 521
CG32498 transcript M PDE4 60 (74) 79 (91) 903
CG32498 transcript N PDE4 59 (74) 79 (91) 983
CG5411 transcript A PDE8 34 (52)  60 (79) 914
CG5411 transcript B PDE8 35 (53) 60 (79)  904
CG5411 transcript C  PDE8 47 (66) 60 (79) 400
CG5411 transcript D PDE8 37 (57) 60 (79)  805
CG5411 transcript E  PDE8 34 (52)  60 (79)  914
CG5411 transcript F PDE8 23 (9 [sic]) 60 (79)  400
CG32648    PDE9 26 (34) 63 (76) 2080
CG10231    PDE11 38 (55) 77 (96) 1545
 
1.6.1 DmPDE1 (CG14940) 
CG14940 has an ORF of 1815 nucleotides (nt), which encodes a single polypeptide of 605 
amino acids (aa). DmPDE1 has been shown to be a dual specificity, Ca
2+
/calmodulin 
dependent PDE (Walter and Kiger, 1984). Western blotting of CG14940 transiently 
transfected S2 cell lysate using an antipeptide antibody to the epitope 
EQAVKDAEARALAT confirmed that the gene produces a protein product of 75 kDa. 
Immunoprecipitation of PDE1 using this specific antisera from Drosophila head lysate, 
and subsequent PDE assays confirmed that DmPDE1 is a Ca
2+
/calmodulin sensitive dual 
specificity PDE, with a Km for cAMP of 20.5 ± 1.5 μM, and a Km for cGMP of 15.3 ± 1 
μM. DmPDE1 is inhibited by zaprinast at an IC50 of 71 ± 39 μM and by sildenafil at an 
IC50 of 1.3 ± 0.9 μM. Structurally, DmPDE1 is similar to its mammalian orthologue; it 
shares an autoinhibitory domain at the N terminus, although it has one calmodulin binding 
domain, whereas mammalian PDE1 has two (figure 1.4).  
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Figure 1.4: Protein structure of DmPDE1. DmPDE1 contains an N-terminal 
autoinhibitory motif, and a calmodulin binding site at the N terminus. From (Day et al., 
2005). 
 
 
 
1.6.2 Dunce (CG32498) 
The PDE best understood in Drosophila is dunce (dnc), the mammalian PDE4 orthologue, 
a cAMP-PDE which was discovered independently in screens for mutations affecting 
olfactory learning and female fecundity (Byers et al., 1981). Dnc expresses predominantly 
in the neuropil of the mushroom bodies (Nighorn et al., 1991), and at lower levels in the 
neuropil of the nervous system, which is in agreement with its role in learning (Dauwalder 
and Davis, 1995). Since the identification of dnc involvement in olfactory learning, cAMP 
and cGMP have both been shown to have a role in learning and memory in mammals 
(Kleppisch and Feil, 2009).  Dnc has been shown to play important roles in several 
additional processes. Dnc mutants have altered pacemaker functioning (Levine et al., 
1994). Analysis of the larval neuromuscular junction in dnc mutants revealed a role in the 
plasticity of synaptic morphology (Zhong et al., 1992) and modulation of synaptic kinetics 
(Corfas and Dudai, 1990; Zhong and Wu, 1991). Dnc is involved in egg chamber and 
ovary development, and some dunce mutants are infertile (Lannutti and Schneider, 2001). 
Interestingly, dnc mutant learning, fertility and synaptic morphology phenotypes can be 
partially rescued by introduction of rutabaga1, an adenylate cyclase hypomorphic mutant, 
and indeed these mutations were identified in a screen for mutations that rescue the dnc 
mutant sterility phenotype (Feany, 1990; Zhong et al., 1992). Dnc has been biochemically 
characterised, with a Km of 2.2 ± 0.5 μM for cAMP (Davis et al., 1989), and is partially 
inhibited by SQ20009 at 140 mM, although the IC50 for the compound is unknown. Dnc 
encodes 12 transcripts, resulting in 12 unique polypeptides (Qiu et al., 1991), 
(http://flybase.org/reports/FBgn0000479.html)  
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1.6.3 DmPDE6 (CG8279) 
CG8279 has an ORF of 3393 nt, which encodes a single polypeptide of 1131 aa. Western 
blotting of CG8279 transiently transfected S2 cell lysate using an antipeptide antibody to 
the epitope HGSEDSHTPEHQRS confirmed that the gene produces a protein product of 
130 kDa. Immunoprecipitation of DmPDE6 using this specific antisera, and subsequent 
PDE assays confirmed that DmPDE6 is a high Km cG-PDE, with a Km for cGMP of 37 ± 
13 μM. PDE6 shows high sensitivity to both zaprinast and sildenafil, as it is inhibited by 
zaprinast at an IC50 of 0.65 ± 0.15 μM and by sildenafil at an IC50 of 0.025 ± 0.005 μM 
(Day et al., 2005). Interestingly, although CG8279 has been designated as a vertebrate 
PDE6 homologue, it shares functional and structural characteristics with vertebrate PDE5 
and PDE6, and also has high sequence similarity to PDE11 in the catalytic domain, 
although this is a dual specificity PDE. In common with mammalian PDE6, Drosophila 
PDE6 is prenylated via a CAAX-box prenylation motif, resulting in the recruitment of the 
protein to the plasma membrane, where it interacts with a prenyl binding protein (Day et 
al., 2008). As such, it was designated a PDE6 orthologue, although it is commonly referred 
to as a PDE5/6 homologue. DmPDE6 has been implicated in the active transport of cGMP, 
as discussed above (Day et al., 2006). DmPDE6 contains an N-terminal autoinhibitory 
motif, a consensus PKA/cGK phosphorylation site at each end of the protein, and a 
calmodulin binding site at the N terminus (figure 1.5). 
 
Figure 1.5: Protein structure of DmPDE6. DmPDE6 contains a serine rich region at the 
N terminus, and a polybasic region at the C terminus, both of unknown function. There are 
consensus PKA/cGK phosphorylation sites at the N- and C-termini, and twin GAF 
domains N-terminal of the catalytic domain. The protein has a CAAX-box prenylation 
motif at the C terminus. From (Day et al., 2005). 
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1.6.4 DmPDE8 (CG5411) 
CG5411 is a complex gene, with 5 transcripts (A-E) encoding 4 different polypeptides, 
where the ORFs of transcripts A and E are identical. DmPDE8 has not been well 
characterised, although analysis of the sequence reveals that, in common with mammalian 
PDE8, DmPDE8 contains a REC and a PAS domain to the N terminal of the catalytic 
domain, and an N-terminal myristoylation/palmitoylation motif (figure 1.6) (Day et al., 
2005). 
 
Figure 1.6: Protein structure of DmPDE8. DmPDE8 contains REC and PAS domains N-
terminal of the catalytic domain, and a myristoylation/palmitoylation motif at the extreme 
N-terminus. From (Day et al., 2005).  
 
 
1.6.5 DmPDE9 (CG32648) 
PDE9 has not been well characterised, although the gene encoding DmPDE9 resides within 
an area identified by Kiger and Golanty that resulted in increased cGMP-PDE activity 
when duplicated (Kiger et al., 1981). No ESTs are available; while the predicted 
polypeptide for this gene is 963 aa in length, the gene was designated a homologue of 
mammalian PDE9 based upon homology of 54% within the catalytic domain; outwith this 
region there is little homology (figure 1.7) (Day et al., 2005). As such, future research into 
this gene will require validation of the Flybase prediction of the gene structure. 
 
Figure 1.7: Protein structure of DmPDE9. DmPDE9 contains two consensus PKA/cGK 
phosphorylation sites C-terminal of the catalytic domain. From (Day et al., 2005). 
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1.6.6 DmPDE11 (CG10231) 
CG10231 encodes a single ~5.8 kb transcript (DmPDE11 RA) which encodes a 
polypeptide of 1366 aa. A full length EST clone was sequenced in order to verify 
CG10231, and northern blotting confirmed that CG10231 produced a single transcript of 
~5.8 kb. Western blotting of CG10231 transiently transfected S2 cell lysate using an 
antipeptide antibody to the epitope PTSTQPSDDDNDAD confirmed that the gene 
produces a protein product of 100 kDa. Immunoprecipitation of PDE11 using this specific 
antisera from Drosophila head lysate, and subsequent PDE assays confirmed that 
DmPDE11 is a dual specificity PDE, with a Km for cAMP of 18.5 ± 1.5 μM, and a Km for 
cGMP of 6 ± 2 μM. DmPDE11 shares high sequence identity/similarity with mammalian 
PDE5, PDE6β, and PDE11A. However, the protein has highest sequence identity within 
the catalytic domain to PDE11A (77%), and has twin GAF domains N-terminal of the 
catalytic domain, a characteristic shared with the HsPDE11A isoforms PDE11A3 and 
PDE11A4 (http://www.biochemj.org/bj/388/bj3880333add.htm). As the enzyme was 
shown to be a dual specificity PDE, DmPDE11 was designated as a PDE11A3/PDE11A4 
orthologue. Interestingly, the Km for cGMP indicates that PDE11 has the highest affinity 
for cGMP of any of the DmPDEs screened. PDE11 is inhibited by zaprinast at an IC50 of 
1.6 ± 0.5 μM and by sildenafil at an IC50 of 0.12 ± 0.06 μM. DmPDE11 has four PKA/cGK 
consensus phosphorylation motifs (http://www.biochemj.org/bj/388/bj3880333addhtm), 
suggesting that it may be a substrate of the enzyme. The enzyme contains glutamine and 
histidine rich regions at the N- and C-termini respectively of unknown significance (figure 
1.8) (Day et al., 2005). 
 
Figure 1.8: Protein structure of DmPDE11. DmPDE11 contains glutamine- and 
histidine-rich regions of unknown function at the N- and C-termini respectively, and has 
twin GAF domains to the N terminus of the catalytic domain. From (Day et al., 2005). 
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1.7 H. sapiens PDE11A  
The PDE11 family of phosphodiesterases were first characterised in 2000 (Fawcett et al., 
2000; Hetman et al., 2000; Yuasa et al., 2000a). HsPDE11A is a dual specificity cAMP- 
and cGMP-PDE, with four splice variants from a single gene, each containing progressive 
truncations of the N terminus, with a shared C terminus containing a PDE catalytic 
domain; in the case of HsPDE11A3, the first two exons encode novel N terminal sequence 
of unknown significance. The N terminus of the longest isoform – HsPDE11A4 – has two 
PKA/cGK phosphorylation sites which reduce the EC50 for cGMP ~3 fold when 
phosphorylated (Gross-Langenhoff et al., 2008). The progressively truncated isoforms are 
progressively more sensitive to the inhibitors verdenafil and tadalafil and have a higher 
affinity for substrate. The GAF-A domain has been shown to bind cGMP, but at an EC50 
outside the physiological range (Gross-Langenhoff et al., 2006). Binding of cGMP to the 
GAF-A domain does not stimulate catalytic activity (Matthiesen and Nielsen, 2009). The 
GAF-B domain is necessary for oligomerisation; HsPDE11A1 forms a tetramer, while 
HsPDE11A2-4 form dimers (Weeks et al., 2007). The structure of each HsPDE11A is 
summarised in figure 1.9. 
Figure 1.9: Protein structure of HsPDE11A. HsPDE11A isoforms 1-4 share a conserved 
C terminus containing the catalytic domain, and N termini of varying lengths, which 
contain complete or partial GAF domain(s). Modified from (Weeks et al., 2007). 
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Tissue staining utilising a polyclonal antibody which recognises all four human isoforms 
showed expression in epithelial cells, endothelial cells, and smooth muscle cells of every 
tissue screened. The protein localises to the nucleus. The highest expression was found in 
the prostate, testis, kidney, colon, and the epidermis in the skin (D'Andrea et al., 2005). 
Few physiological roles for PDE11A have been identified. PDE11A3 is reported to be 
confined to testis in both rat and human (Yuasa et al., 2001). PDE11A has been shown to 
regulate spermatozoa physiology. Knockout of PDE11A renders male mice infertile 
(Seftel, 2005a; Seftel, 2005b). It has been linked to erectile function and premature 
ejaculation. Mutations to HsPDE11A are frequent among patients with adrenocortical 
tumours (Horvath et al., 2006) and may predispose to testicular germ cell tumours 
(Horvath et al., 2009). Polymorphisms in HsPDE11A are associated with the diagnosis of 
major depressive disorder (Wong et al., 2006). Taken together, there is a potential role for 
the PDE11A family in the central nervous system.  
 
1.8 The characteristics of PDEs 
1.8.1 Structure of the catalytic domain 
All PDEs share a highly related catalytic domain, which consists of 16 alpha helices that 
form a cleft in which cyclic nucleotides are bound and cleaved. The core contains two 
metal ions, essential for function, which are tightly co-ordinated; a Zn
2+
 is bound by an 
aspartate and a histidine, and a Mg 
2+
 is held by multiple water molecules.  
1.8.2 Nucleotide specificity 
Specificity to one or both cyclic nucleotides is dictated by an invariant glutamine that is 
proposed to form multiple hydrogen bonds with the purine ring of the cyclic nucleotide; it 
is the orientation of this glutamine that determines PDE specificity. Where this glutamine 
is free to rotate, it will bind both cAMP and cGMP; when it is hindered by its neighbouring 
residues it is able to bind either cGMP or cAMP (Zhang et al., 2004). 
 
 
50 
Figure 1.10: The glutamine switch. Crystal structure of PDE1B (red/C and D), PDE4D 
(blue/A), and PDE5A (green/B). Whereas the conserved glutamine, Q421, of PDE1B is 
unhindered, and thus the residue is free to rotate and thus the catalytic domain can 
accommodate both cAMP (C) and cGMP (D), the glutamine of PDE5A (B) and PDE4D 
(A) in both cases is bound in place by hydrogen bonds, and thus the glutamine is unable to 
rotate, resulting in cyclic nucleotide specificity (Zhang et al., 2004). 
 
 
1.8.3 Regulation of PDEs 
PDEs are subjected to multiple levels of regulation. Each phosphodiesterase family 
contains differing regulatory domains that contribute to the unique properties of each 
family (Beavo et al., 2007). To modulate rapid increases in cyclic nucleotide concentration, 
the catalytic activity of PDEs can be rapidly increased or decreased several fold (Conti and 
Beavo, 2007). To facilitate the localised nature of cyclic nucleotide signalling, post 
translational modifications or association with anchoring proteins may redirect the enzyme, 
for example to the cell membrane (Beavo and Brunton, 2002).  
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1.8.4 Cyclic nucleotide binding 
GAF domains have been identified within a range of different proteins, initially cGMP-
regulated PDEs, Adenylate cyclase, and the Fh1A protein, hence the acronym (Ho et al., 
2000). It is a non-catalytic cyclic nucleotide binding domain, which in PDEs can modulate 
catalytic activity allosterically (Charbonneau et al., 1990). Studies of mammalian PDEs 
have shown that one or both GAF domains of PDE2, PDE5, PDE6, and PDE11 bind 
cGMP, and that of PDE10 binds cAMP. This can result in activation of catalytic activity, 
in the case of PDE2 (Martins et al., 1982) and PDE5 (Thomas et al., 1990) (Rybalkin et al., 
2003). In PDE6, it has been shown to aid binding of the inhibitory γ subunit to the catalytic 
domain (Norton et al., 2000). In the case of PDE10 and PDE11, binding does not (directly 
at least) affect catalytic activity (Matthiesen and Nielsen, 2009). The binding of cGMP to 
the GAF domain has also been shown to modulate dimerisation in PDE2 (Martinez et al., 
2002) and PDE6 (Muradov et al., 2003). Interestingly, the four isoforms of PDE11 contain 
four different start sites that represent a progressive truncation of the N terminus; only 
PDE11A4 contains two complete GAF domains, with A3, A2, and A1 each having 
progressively truncated GAF domains .  
 
1.8.5 Post translational modifications of PDEs 
1.8.5.1 Modulation of PDE activity by other proteins 
The behaviour of phosphodiesterases can be modified through phosphorylation by cyclic 
nucleotide dependent kinases, and other kinases. As detailed above, DG2 has been shown 
to modulate an unidentified cG-PDE in Malpighian tubule (MacPherson et al., 2004a). 
PDE1 is stimulated by Ca/Calmodulin by up to 8 fold in mammals (Cheung, 1970) which 
binds sites either side of the inhibitory domains of the N terminus, likely relieving the 
inhibitory action of this domain (Sonnenburg et al., 1995). Calmodulin stimulates PDE1 
almost 2-fold in Drosophila (Day et al., 2005).  In mammalian systems, PDE3 has been 
shown to be phosphorylated by PKA (Manganiello et al., 1995), which rapidly increases 
catalytic activity.  
The long forms of PDE4 are also known to be rapidly stimulated by PKA via 
phosphorylation of a crucial serine residue in the N-terminal regulatory domain 
(MacKenzie et al., 2002), acting as a feedback mechanism to terminate hormonal 
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stimulation. ERK2, a MAP kinase, phosphorylates PDE4B, C and D subfamilies in the 
catalytic domain, where long-form isoforms are inhibited, whereas short-form isoforms are 
stimulated (Baillie et al., 2000). cGK phosphorylates PDE5 when the GAF domains have 
bound cGMP (Thomas et al., 1990; Turko et al., 1998), to increase activity by 50-70%, and 
also increase the cGMP binding capacity of the GAF domain (Corbin et al., 2000). Isoform 
multiplicity, with the resultant sequence changes and changes to the protein‟s interactome 
that brings, may mask or remove putative phosphorylation sites, thus altering the function 
of these proteins.  
1.8.5.2 Addition of lipids  
Lipid kinases play intrinsic roles in many facets of cell signalling, trafficking proteins to 
the cell membrane, possibly resulting in their activation, and association  with membrane 
based proteins or substrates and thus modifying their function (Heath et al., 2003). The 
catalytic subunits of PDE6 are subjected to differential prenylation at the C terminal; PDEα 
is modified by farnesylation, and PDEβ by geranylgeranytion (Anant et al., 1992), to 
ensure targeting to rod outer segment membrane (Qin and Baehr, 1994). The differential 
prenylation also controls binding of the inhibitory γ subunit (Cook et al., 2000). PDE8 has 
an N-terminal myristoylation motif, and PDE9 has an N terminal 
myristoylation/palmitoylation motif, although neither has been shown to occur in vivo 
within the published literature. 
1.9 The use of Drosophila to investigate vertebrate 
phosphodiesterase function 
Previously, Drosophila has been used to transgenically express vertebrate PDE genes, and 
these have proved functional in vivo. Bovine PDE5 has been overexpressed in the tubule, 
resulting in an increase in cGMP-PDE activity and conservation of the pharmacological 
characteristics of PDE5 (Broderick et al., 2004).  The transgene could participate in and 
modulate osmoregulation, which was inhibited by sildenafil at substrate concentrations 
which would affect the enzyme in mammalian systems. The enzyme localised to the apical 
membrane, the site of fluid transport. Such physiologically relevant targeting suggests 
interaction with relevant signalling proteins (Broderick et al., 2004). In another example, 
Rat PDE4A1 increases cAMP-PDE activity in the fly when transgenically over-expressed, 
and can rescue cAMP-PDE levels to normal levels and beyond when expressed in a dunce 
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mutant background that displays 46% dnc cAMP-PDE activity. Furthermore, when rat 
PDE4A1 is expressed in this mutant background, it rescues a learning phenotype resulting 
from the knockdown of dunce activity (Dauwalder and Davis, 1995). Such functional 
conservation suggests that Drosophila and vertebrate genes originated from common 
ancestral genes, and as such a high degree of functional complementation still exists. That 
Drosophila and vertebrate PDE genes share functional and structural homology, yet 
display key differences, may allow the side by side study of PDE genes, to shed light on 
the function of PDEs in both areas. As such, it was decided to clone the closest orthologue 
to DmPDE11, HsPDE11A3, and to express this in fly, to allow the investigation of human 
PDE11A function in an in vivo context. The results of this investigation are presented in 
chapter eight. 
 
1.10 Compartmentalisation in cyclic nucleotide signalling  
A cell can transduce multiple extracellular cues simultaneously, using cAMP and cGMP as 
second messengers, with specific activation of target effector proteins, and resulting 
downstream actions. To maintain specificity, cyclic nucleotide concentration must be 
tightly regulated spatiotemporally. As well as the localisation of the cyclase, gene and 
isoform multiplicity of phosphodiesterases, and AKAPs, which modulate PDE localisation, 
allow the placement of PDEs with distinct subcellular localisation, which act as a “sink” to 
generate multiple, simultaneous intracellular domains (“pools”) of elevated cyclic 
nucleotide concentration (Baillie, 2009). The signal transduced within these pools depends 
upon the effector proteins within it, and the substrates that they are directed to. 
 
1.10.1 cAMP compartmentalised signalling 
 The idea the cAMP signalling may be compartmentalised was postulated as early as 1980 
(Brunton et al., 1981; Hayes et al., 1980), following the discovery that within cardiac 
myocytes, stimulation of different adenylate-stimulatory GPCRs lead to differing 
physiological outputs. Advances in cAMP reporters revealed that microdomains of cAMP 
exist, which have distinct subcellular localisation, and show differing changes to the 
magnitude and duration of cAMP concentration, depending upon the upstream signal 
(Zaccolo and Pozzan, 2002). It was proposed that PKA is compartmentalised within these 
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distinct subcellular microdomains, thus allowing the phosphorylation of distinct PKA 
substrates, and so convey a specific signal depending upon the upstream GPCR activated 
(Hayes and Brunton, 1982). It was subsequently shown that PKA type I and type II are 
differentially tethered by A-Kinase Anchoring Proteins (AKAPs) (Di Benedetto et al., 
2008). Indeed, the formation of AKAP-tethered complexes has been shown to mediate 
compartmentalisation at every level of cAMP signalling. Gene and isoform multiplicity of 
PDEs, cyclases, downstream effector proteins, and AKAPs, and the various associations 
between these, allow the formation of cAMP microdomains. Particular combinations of 
GPCRs, Gs proteins, and adenylate cyclases occupy distinct membrane localisations 
(Rybin et al., 2000). This allows feedback whereby PKA can phosphorylate AC to 
terminate the cAMP signal (Bauman et al., 2006), ensuring rapid transmission of signal, 
while ensuring spatiotemporal control over the cAMP signal. The formation of adenylate 
cyclase-AKAP-PKA complexes allows the tying of PKA-substrate association by AKAPs 
to the site of cAMP generation. AC activity may be modulated by serine/threonine kinases 
and Ca
2+
, in addition to Gs. Combined with the subcellular targeting and association with 
AKAPs, this level of control ensures that microdomains may be modulated by multiple 
signals and proteins (Willoughby and Cooper, 2007). The formation of PKA/PDE 
signalling complexes allows crosstalk, where the PDE regulates local cAMP concentration, 
and thus PKA activity, while the kinase can modulate PDE function by phosphorylation, 
thus facilitating feedback. An AKAP18δ-PDE4D3/9-PKA signalling complex localised to 
vesicles has been shown to regulate water permeability in human renal principle cells. The 
water channel aquaporin 2 (AQP2) is recycled from the membrane in these vesicles. 
Arginine vasopressin (AVP) activates PKA, which stimulates the trafficking of vesicles 
containing AQP2 to the plasma membrane; thus water permeability is directly modulated 
by PKA activity. PKA then activates PDE4D, thus reducing local cAMP concentration 
inhibiting PKA activity, and stimulating the endocytosis of the AQP2 bearing vesicles 
(figure 1.11) (McSorley et al., 2006). 
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Figure 1.11: AQP2, PDE4D and PKA form an AKAP18δ mediated complex.  AQP2, 
PDE4D, and PKA are tethered to intracellular vesicles by AKAP18δ, where PKA 
stimulates trafficking of the AQP2 bearing vesicle to the membrane; when at the 
membrane PKA phosphorylates PDE4D3/9, thus reducing localised cAMP and initiating 
vesicle endocytosis. From (Stefan et al., 2007).  
 
 
 
1.10.2 cGMP compartmentalised signalling  
Like cAMP signalling, a cell may receive different signals that initiate a cGMP signalling 
event, such as a natriuretic peptide or nitric oxide, which result in distinct and perhaps 
simultaneous cellular responses. There is a great deal of evidence to suggest that cGMP 
microdomains facilitate the faithful transmission of these signals, and that this is facilitated 
by compartmentalisation of cGMP signalling at every level. cGK is recruited to the 
membrane upon binding of atrial natriuretic peptide, and directly interacts with NPRA, a 
type 1 ANP receptor/rGC. cGK phosphorylates the receptor, increasing the potency of the 
response to ANP (Airhart et al., 2003). Although both soluble and receptor guanylate 
cyclases exist, the terms are misleading, in that activated sGC translocates to the 
membrane in a Ca
2+
 concentration-dependent manner, where it is sensitised to NO 
stimulation (Zabel et al, 2002). NO has a very short half life, and NO is 9 times less 
soluble in water than in hydrophobic environments, suggesting that NO would be present 
in the cell in a concentration gradient highest at the membrane, and reduced in the cytosol. 
Thus, the modulation of sGC localisation by Ca
2+
 to bring sGC into close proximity of 
NOS, a membrane bound enzyme, points to a tight spatial control of cGMP signalling. The 
localisation of NOS itself is tightly regulated. Endothelial NOS (eNOS) is doubly acylated, 
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which mediates interactions with distinct caveolin isoforms in various cell types, thus 
dictating the localisation and activity of eNOS, and therefore the site of release of NO. 
These signal transducing microdomains are termed caveolae (Feron et al., 1998).  In a 
landmark paper using a exogenously expressed CNG channel as a biosensor, by measuring 
cGMP-induced uptake of Ca
2+
 and Mn
2+
 in HEK cells overexpressing rGC, it was found 
that the “pool” of cGMP generated by rGC has stimulatory effects at the membrane, 
whereas cGMP generated by sGC is not accessible to membrane-localised cGMP sensing 
proteins (Castro et al., 2006). A similar finding was made in vascular smooth muscle cells; 
while stimulation of sGC led to higher cellular cGMP than stimulation of rGC, it was 
stimulation of rGC that resulted in the stronger CNG channel activation (Piggott et al., 
2006). PDE1C and PDE5 show differing subcellular localisation across multiple cell types, 
and thus sample and modulate distinct pools of cGMP (Dolci et al., 2006).  Inhibition of 
PDE2 and PDE5 has differential effects on cGMP produced by soluble and receptor GCs; 
PDE2 is responsible for modulating cGMP produced by rGC at the membrane, whereas 
PDE5 modulates cGMP generated in the cytosol by sGC, and furthermore acts as a 
physical barrier to prevent this pool from diffusing to the cell membrane (Castro et al., 
2006). Signalling complexes have been identified in cGMP signalling, similar to those 
formed in cAMP signalling, which facilitate the tight spatiotemporal control of cGMP 
signalling events. Transmembrane conductance in enterocytes is induced by the activation 
of cystic fibrosis transmembrane conductance regulator (CFTR) Cl
-
 channels. Although 
both cGK type I and II can phosphorylate CFTR in vitro, only cGK type II can induce 
transmembrane conductance in vivo, due to its localisation at the apical membrane 
(Vaandrager et al., 1998). In smooth muscle cells, cGK type I forms a dimer with vimentin, 
with the association occurring outside of the catalytic domain at the N-terminus; this dimer 
then targets histone F2b, and other target peptides (MacMillan-Crow and Lincoln, 1994). 
cGMP-dependent protein kinase anchoring proteins (GKAPs) have been identified, which 
bind cGKs in the regulatory domain of the N terminus. GKAP42 serves to localise cGKIα 
to the Golgi apparatus of male germ cells. cGK phosphorylates GKAP42, where activation 
of cGKIα terminates the interaction (Yuasa et al., 2000b). GKAPs which bind cGK type II 
have been identified in multiple tissues (Vo et al., 1998). One such GKAP, myosin heavy 
chain, may facilitate cGK type II mediated smooth muscle relaxation (Lincoln et al., 1994), 
which is still not well understood. In platelets, a PDE5-cGK1β signalling complex is 
recruited to inositol 1,4,5 triphosphate receptor type 1 (IP3R1) enriched membranes. 
cGK1β mediates a reduction in Ca2+ release from the endoplasmic reticulum by 
phosphorylating IP3R1 (Schlossmann et al., 2000). cGK phosphorylates PDE5 at the ER, 
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causing a localised reduction in cGMP, and a subsequent inhibition of cGK activity, yet 
PKA does not affect PDE5 function in the cytosol (Wilson et al., 2008). Taken together, 
these data suggest that cGMP microdomains play a vital role in shaping signal specificity 
and the spatiotemporal nature of cGMP signalling events. 
Understanding of cGMP signalling has been advanced by genetically encoded cGMP 
reporters. The first generation of FRET based cGMP reporters were generated by 
sandwiching PKG1α, rendered catalytically null, with the dimerisation domains removed, 
with differing emission-shifted green fluorescent protein at either terminus, called CGY 
(Sato et al., 2000) and cygnet-2 (Honda et al., 2001). Cygent-2 was used to investigate 
cGMP signalling in vascular smooth muscle, where natriuretic peptides induce muscular 
relaxation via an NO-cGMP signalling cascade. Cygnet-2 permitted the temporal 
characterisation of this cGMP response; it was shown that stimulation with NO, 
irrespective of the rate or duration of the NO release, resulted in rapid, transient cGMP 
“peaks”, and that the kinetics of this cGMP response are controlled by the actions of 
soluble guanylate cyclase and PDE 5, which are not desensitised during the process, thus 
facilitating continuous response to NO (Cawley et al., 2007). Such a study was previously 
not feasible. This finding was advanced by the use of a novel, non-FRET based cGMP-
indicator, where cGMP-binding domains of cGKIα and β were fused to a single GFP, 
named FlincGs. They found a similar, global elevation of cGMP upon application of NO to 
vascular smooth muscle. However, upon the application of natriuretic peptide, elevation of 
cGMP was limited to the sub-membrane, where inhibition of PDE5 saw global elevations 
(Nausch et al., 2008). 
Many such advances in these sensors have been achieved, including the development of 
membrane permeable cynet-2 (Honda et al., 2005), which avoids the issues associated with 
maintaining cells in culture while transfecting the reporter, and the development of 
reporters with higher specificity and more rapid responsiveness, where rather than fuse 
whole proteins or truncates with fluorescent proteins, single cGMP-binding domains were 
sandwiched by CFP and YFP; constructs using cGMP binding domains from various 
proteins were generated, that of PDE5 was selected based on its selectivity of cGMP over 
cAMP, and its rapid responsiveness, and named cGES-DE5 (Nikolaev et al., 2006). Such 
systematic development of sensors is producing tools of increased quality (Russwurm et 
al., 2007), and will permit a fuller understanding of the tight spatiotemporal control cGMP 
signalling is evidently subjected to. 
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1.10.3 Cyclic nucleotide cross talk 
cAMP and cGMP cross talk has been shown to widely occur in mammalian systems; 
further development of cGMP reporters could be used to answer whether there is overlap 
between cAMP and cGMP microdomains during a signalling event. Phosphorylation of 
PDE5 by PKA or cGK increases cG-PDE activity by 50-70%, and also increases the 
cGMP binding capacity of the allosteric cGMP binding sites in vitro (Corbin et al., 2000). 
Cyclic nucleotide cross talk occurs in PDEs; cAMP-PDE activity of PDE2 is allosterically 
increased by cGMP (Martins et al., 1982), whereas for PDE3, cGMP acts as a competitive 
inhibitor against cAMP, thus reducing cAMP-PDE activity (Shakur et al., 2001). This 
cGMP regulation of cAMP signalling has been shown to have several regulatory effects in 
cardiac cells, including a reduction in responsiveness to beta-adrenergic agonists, and the 
potentiation of Ca
2+
 currents (Zaccolo and Movsesian, 2007). Interestingly, cAMP and 
cGMP signalling often have opposing effects on cardiac function, partly due to PKA and 
cGK targets mediating differing physiological outputs (Shah and MacCarthy, 2000).  
 
1.11 Immunity in Drosophila 
Drosophila are presented with immune challenges through septic injury, and through the 
ingestion of infected food, termed natural infection. Whereas mammals use innate and 
acquired immune systems, insects use innate immunity to counter immune challenges 
(Janeway, 1989). Drosophila has informed a great deal of our knowledge towards insect 
immunity. There are two main types of innate immunity employed by Drosophila, the 
humeral response and the cellular response. The main humeral response is the systemic 
production of anti microbial peptides (AMPs), which are secreted into the hemolymph, and 
function to kill infectious microorganisms (Lemaitre et al., 1995). Barrier epithelia are 
presented with a microbial challenge when food containing microbes is ingested. The 
generation of ROS eliminates microbes in tissues such as the gut, trachea and Malpighian 
tubules (Bogdan, 2001; Ha et al., 2005). Melanisation (Nappi and Vass, 1993) and 
coagulation (Muta and Iwanaga, 1996) occur at the wound site to prevent further infection. 
The primary cellular response is performed by the haemocytes, which are responsible for 
phagocytosis (Meister, 2004) and also produce AMPs (Charroux and Royet, 2009; 
Dimarcq et al., 1997). As well as systemic production  of AMPs, they are also produced in 
epithelial tissues (Tzou et al., 2000).  
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The best characterised immune response of Drosophila is the systemic response 
(Silverman and Maniatis, 2001). Pathogen detection results in the activation of the NFκB-
like Toll or IMD pathways, depending upon the nature of the pathogen. Fungi and gram 
positive bacteria recognition occurs extracellularly, and results in the cleavage of Spaetzle 
by microbe-specific serine protease cascades. Cleaved Spaetzle is recognised by the toll 
receptor, and stimulates the production of the antimicrobial peptide drosomycin through 
activation of the NFκB factors Dif and Dorsal. Gram negative bacteria are recognised by 
peptidoglycan recognition protein (PGRP), and through activation of the NFκB homolog 
Relish, a transcription factor, stimulate the production of the antimicrobial peptide 
Diptericin. The toll and IMD pathways are summarised in figure 1.12. 
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Figure 1.12: The Toll and IMD pathways. Toll pathway: Gram positive bacteria and 
fungi induce a specific protease cascade, resulting in the proteolytic activation of C-106 
Spaetzle (Spz). Upon binding of Spz, the Toll receptor forms a dimer. MyD88 interacts 
with Toll via TIR domains, and initiates a signalling cascade through Tube and Pelle, 
resulting in the activation of cactus kinase, which phosphorylates cactus, which is then 
targeted for degradation. This frees the transcription factor Dif, which translocates to the 
nucleus and initiates AMP transcription.  
IMD pathway: Gram negative bacteria are recognised by PGRP-LC and –LE isoforms, 
which dimerise and initiate a signalling cascade through IMD, dFADD, and Dredd. Dredd 
can directly activate Relish by cleavage, or can signal through the IKK complex, consisting 
of Ird5 and Kenny; cleaved Relish translocates to the nucleus, whereupon it initiates 
transcription of AMPs. Diagram from (Cherry and Silverman, 2006). 
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1.11.1 NO modulates innate immunity in Drosophila 
NO has been shown to activate the IMD pathway, although the mechanism is unclear 
(Foley and O'Farrell, 2003). NO has been assigned an immune role as both an autocrine 
and a paracrine messenger (Silverman, 2003); (Foley and O'Farrell, 2003); where a tissue 
senses an immune challenge, NOS is upregulated, and generates NO, in order to signal to 
other tissues to induce an anticipatory immune reaction in distal tissues, perhaps signalling 
via hemocytes (Basset et al., 2000). Underlying its role in immunity, NOS is upregulated 
following immune challenge to the tubule (McGettigan et al., 2005). 
 
1.11.2 The Malpighian tubule is a critical immune tissue 
cGMP plays an critical role in Malpighian tubule immunity (Aitchison, 2008; Dow et al., 
1994; McGettigan et al., 2005). NO has been shown to activate the IMD pathway in tubule, 
and transgenic upregulation of NOS in only principal cells of the Malpighian tubule leads 
to increased whole organism survival under immune challenge (McGettigan et al., 2005). 
Unpublished data, which will be discussed in the relevant results chapter, suggests a 
possible role for DmPDE11 in immunity. This was further investigated during the course 
of this study, and is discussed in chapter seven.  
 
1.12 Aims  
Phosphodiesterase 11 is not well characterised, but is known to be of importance within a 
number of disorders. PDE11A regulates spermatozoa physiology through an unknown 
mechanism (Wayman et al., 2005), where inhibition of PDE11A impacts upon sperm 
quality (Pomara and Morelli, 2005). Certain PDE11A haplotypes are associated with major 
depressive disorder and affect the response to antidepressant drugs (Luo et al., 2009). 
Familial mutations within PDE11A may predispose to Cushing syndrome and testicular 
cancer (Horvath et al., 2009; Libe et al., 2008). Yet the physiological role of HsPDE11 is 
not well understood. 
As the gene model of CG34341 (DmPDE11) is “weakly supported”, the ORF must be 
verified. Following the verification of DmPDE11, the generation of genetic tools will allow 
the characterisation of the protein by expression in S2 cells and in Drosophila 
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melanogaster, predominantly focusing on the Malpighian tubule, as this tissue utilises 
cAMP and cGMP signalling (Dow and Davies, 2003a), and cGMP signalling modulates 
fluid secretion in the tubule (Davies et al., 1995). Previous data have suggested that 
DmPDE11 and cGK interact; an aim is to determine the relationship between DmPDE11 
and the cGKs using co-immunoprecipitation and peptide arrays. The interaction of 
DmPDE11 and cGKs may permit each to regulate the function of the other, as DmPDE11 
can hydrolyse cGMP (Fawcett et al., 2000), and HsPDE11A4 is subject to regulation by 
cGK (Gross-Langenhoff et al., 2008). DmPDE11 has also been implicated in immunity; an 
aim is to acquire further data with regards to how PDE11 might influence the immune 
reaction. HsPDE11A will be subjected to phylogentic analysis, and the closest homologue 
to DmPDE11 will be subject to analysis by transgenic expression in Drosophila, a tool that 
should prove valuable for future research into this important enzyme family. 
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2.1 Drosophila melanogaster 
2.1.1 Drosophila stocks 
The Drosophila melanogaster strains used in this study and their purpose are listed in table 
2.1. Lines in grey boxes were existing lab stocks, and those in darker grey were generated 
during this study. Those in white were supplied by Bloomington stock centre. 
Table 2.1: Drosophila melanogaster lines used in this study 
Strain Genotype Description and use
Oregon R Wild type Protein, DNA, RNA, survival assays
w 1118 (Hazelrigg et al., 1984) w 1118 Microinjection
c42 GAL4 w -; +/+; c42 tubule principal cell GAL4
c42 Aequorin GAL4 (Rosay 
et al., 1997)
w
-
 aeq/aeq; +/+; 
c42/c42
Aequorin/GAL4 expression in principal cells; calcium assays
UO (Terhzaz, in prep.) UO; +/+; +/+ tubule principal cell GAL4
Actin GAL4/CyO w -; ActGAL4/Cyo; +/+ Ubiquitous GAL4
Actin GAL4/GFP CyO
w -; ActGAL4/GFP 
Cyo; +/+
Ubiquitous GAL4; non-expressors GFP
UAS-DG1 w -; +/+; UASDG1 UAS DG1 overexpressor
UAS-DG2 P1 UASDG2P1; +/+; +/+ UAS DG2 P1 overexpressor
UAS-DG2 P2 w -; UASDG2P1; +/+ UAS DG2 P2 overexpressor
UAS-PDE11 RNAi
w -; +/+; 
UASPDE11RNAi
UAS PDE11 RNAi
Relish E20 (Hedengren et al, 
1999)
w -; +/+; relishE20, e- homozygous relish null with ebony marker; survival assays
TS10
w -; Bristle/CyO; 
TM2/TM6
Balancing
Ato Gal4 w -; +/+; ATO GAL4 paired DC neurons GAL4
D42 Gal4 w -; +/+; D42 GAL4
GAL4: embryogenesis: broad, larvae: 
motorneurons, interneurons, adult: nervous 
system
Appl Gal4 (Torroja et al., 1999) appl GAL4; +/+; +/+ adult and larval neuron specific GAL4
Repo Gal4 
w -; +/+; Repo 
Gal4/Tm3, Sb
glial cell GAL4
Sgs3 Gal4 w -; +/+; sgs3 GAL4 salivary gland GAL4
UAS-HPDE11A3 YFP
w-; Bristle/CyO; 
H11A3/TM6 UAS human PDE11A3 YFP Overexpressor
UAS-HPDE11A3 YFP w-; H11A3YFP/Bristle; 
TM2/TM6 UAS human PDE11A3 YFP Overexpressor
UAS-HPDE11 A3 w-; Bristle/H11A3; 
TM2/TM6 UAS human PDE11A3 Overexpressor
UAS-HPDE11 A3 w-; 8H11/CyO; 
TM2/H11A3 UAS human PDE11A3 Overexpressor
11∆121 w-; 11∆121/CyO ; +/+ PDE11 deletion line; survival assays  
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Strain Genotype Description and use
UAS-Dm  RB Long PDE11 YFP w-; B11LYFP/CyO; +/+ UAS-Dm  RB long PDE11 YFP overexpressor
UAS-Dm  RB Long PDE11 YFP w-; +/+; B11LYFP/Tm5 UAS-Dm  RB long PDE11 YFP overexpressor
UAS-Dm  RB Short PDE11 YFP w-; +/+ ; B11SYFP/Tm5 UAS-Dm  RB short PDE11 YFP overexpressor
UAS-Dm RB Short PDE11 YFP w-; B11S YFP/CyO ; +/+ UAS-Dm  RB short PDE11 YFP overexpressor
UAS-Dm RB Short PDE11 YFP w-; B11S YFP ; +/+ ; +/+ UAS-Dm  RB short PDE11 YFP overexpressor
UAS-Dm RC Long PDE11 YFP w-; +/+ ; RCLYFP/TM5 UAS-Dm  RC long PDE11 YFP overexpressor
UAS-Dm RC Long PDE11 YFP w-; RCLYFP/CyO; +/+ UAS-Dm  RC long PDE11 YFP overexpressor
UAS-Dm RC Short PDE11 YFP w-; RCSYFP/CyO; +/+ UAS-Dm  RC long PDE11 YFP overexpressor
UAS-Dm  RC Short PDE11 YFP  w-; +/+; RCS/TM5 UAS-Dm  RC short PDE11 YFP overexpressor
UAS-Dm  RC Short PDE11 YFP w-; RCSYFP; +/+ ; +/+ UAS-Dm  RC short PDE11 YFP overexpressor
UAS-Dm  RC Short PDE11 w-; +/+; RCS/TM5 UAS-Dm  RC short PDE11 overexpressor
UAS-Dm RC Short PDE11 w-; RCS/CyO; +/+ UAS-Dm  RC short PDE11  overexpressor  
 
2.1.2 Drosophila rearing 
Drosophila were raised in vials or bottles containing standard food medium (recipe in 
appendix), on a 12 hr: 12 hr light: dark cycle at 22-26˚C, or 18˚C when GAL4 activity 
proved developmentally lethal. 
 
2.1.3 Generation of balanced transgenic flies 
In order to localise P-element insertions and generate stable, balanced transgenic fly lines, 
homozygous transgenic flies were crossed to the TS10 balancer line (w
-
; Bl/CyO; TM2e
-
/TM6Tb
-
), where TM2e
-
/TM6b
-
 is ebony. Red eyed f1 progeny were then back-crossed to 
TS10, and red eyed f2 progeny analysed for markers. Where flies are Bl/CyO and ebony, 
the insertion is on the X chromosome. Where flies are ebony, with the curly phenotype or 
the bristle phenotype, the insertion is on the 2
nd
 chromosome. Where flies have the curly 
phenotype and the bristle phenotype, but are not ebony, the insertion is on the third 
chromosome. Two flies of the same balancer status were backcrossed to generate balanced 
transgenic flies. 
 
2.1.4 Dissection of Drosophila tissues 
Where tissue was required, 5-7 day old flies were anesthetised on ice, before dissection in 
sterile Schneider‟s medium (Invitrogen) using forceps.   
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2.1.5 Heat shock of Drosophila 
Where transgenics were crossed to heat shock GAL4 Drosophila, to induce GAL4 
expression and subsequently transgene expression, flies were transferred from food vials 
into screw top 10 ml universals, and were subjected to 3 x 30 min heat shocks in a 37˚C 
incubator on subsequent days. Following heat shock flies were transferred back to food 
vials to room temperature to recover 
 
2.1.6 Fluid secretion assays 
The diagram below shows the experimental setup used for fluid secretion assays. A dish is 
half filled with molten wax, which sets. A number of small depressions are made in the 
wax, and adjacent to these, an array of fine metal pins are arranged a half centimetre away. 
The dish is filled with mineral oil (Sigma), and each small depression has added to it 9 μl 
of a 50:50 solution of Drosophila saline: Schneider‟s solution, with a trace amount of 
amaranth, a red dye that allows visualisation of the bubble formed at the ureter. Drosophila 
Saline is made from a stock solution stored at -20˚C (7.5 mM NaCl, 20 mM KCl, 2 mM 
CaCl2, 8.5 mM MgCl2, 10.2 mM NaHCO3, 4.3 mM NaH2PO4, 15 mM HEPES (4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid, pH 7.5) by the addition of 20mM glucose. 
Intact Malpighian tubules are dissected from Drosophila as above, and are picked using a 
fine drawn glass rod; one end is wrapped around the metal pin, and the other is submerged 
in the bubble, with the ureter mid way between. Once it was established that the tubules 
were secreting, the secreted drops were removed from the ureter, and a timer started. Every 
ten minutes, the size of the drops was measured using a microscope graticule. When 
baseline secretion had been established, cGMP was added to the 9 μl bubble at a 
concentration of 10
-3
, for a final concentration of 10
-4
. Secreted drops were again measured 
every ten minutes to measure an increase in secretion rate. The process is summarised in 
figure 2.1. 
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Figure 2.1: The fluid secretion assay 
 
2.1.7 Microinjection 
Drosophila transgenics were generated by Bestgene Inc. using the w
1118
 stain of 
Drosophila melanogaster, by co-injection of pP{UAST} and pP{D2-3} plasmids into 
larvae. Transgenic lines were delivered balanced, or were balanced upon arrival using the 
TS10 balancing line. 
2.2 Escherichia coli 
2.2.1 E. coli strains 
Table 2.2 lists the strains of E. coli used in the course of this study, and their genotype. 
Table 2.2: E. coli strains used in this study 
Strain Genotype
DH5aTM subcloning efficiency 
competent cells (Invitrogen)
F- φ80lac ZΔM15 Δ(lac ZYA-arg F)U169 rec A1 end A1 
hsd R17(rk-, mk+) pho Asup E44 thi -1 gyr A96 rel A1 λ-
DH5aTM l ibrary efficiency 
competent cells (Invitrogen) hsdR17(rk-, mk+) phoA supE44 thi-1 gyrA96 relA1 λ-
One Shot TOP10 competent 
cells (Invitrogen)
(F- mcrA, D(mrr-hsdRMS-mcrBC), f80lacZ DM15, 
DlacX74, recA1, deoR, araD139, D(ara-leu)7697,galU, 
galK, rpsL, (StrR), endA1,nupG)
BL21 pLysS competent cells 
(Novagen)
hsdS gal (lcIts857 ind1 Sam7 nin5 lacUV5-T7 gene 1)
XL10-gold Kan Ultracompetent 
cells 
Tetr Δ(mcrA)183 Δ(mcrCB-hsdSMR-mrr)173 endA1 
supE44 thi-1 recA1 gyrA96 relA1 lac Hte [F´ proAB 
lacIqZΔM15 Tn10 (Tetr) Tn5 (Kanr) Amy]  
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2.2.2 Plasmids 
Table 2.3 lists the plasmids used in the course of this study, and their purpose. 
 
Table 2.3: Plasmids used in this study 
Plasmids used Purpose
pP{UAST}
germline transformation of coding sequence downstream 
of UAS (Brand and Perrimon, 1993). 
pP{D2-3} co-transformed with pP{UAST} as transposase source
pP{YFP UAST}
germline transformation of coding sequence downstream 
of UAS with a C-terminal YFP tag (Kind gift of John Day)
pCR 2.1 TOPO® TOPO® vector used for sub-cloning
pMT/V5-His-TOPO® (DES) inducable S2 cell TOPO® expression vector
pAC V5 HIS
Constituitive S2 cell expression vector under control of 
actin promoter, C terminal V5 and HIS6, 
pGEX-6P-1 
E. Coli expression vector, fusing ORF to N-terminal GST 
tag
pET-28c 
E. Coli expression vector, fusing ORF to N-terminal 
His6/thrombin/T7 tag, plus optional C-terminal His6 tag 
pcDNA3.1  PDE11A3 Mammalian cell expression vector containing PDE11A3
DES PDE11 RA DES containing PDE11 RA
DES DG1 DES containing DG1
DES DG2 P1 DES containing DG2 P1
DES DG2 P2 DES containing DG2 P2
 
 
2.2.3 Transformation of E. coli 
2.2.3.1 Transformation of DH5α™ subcloning/library efficiency competent 
cells 
Cells were thawed on ice, and aliquotted into pre-chilled 1.5 ml falcon tubes to a volume of 
50 μl. 50-100 ng of plasmid or 2 μl of ligation reaction were added under sterile 
conditions, and gently mixed. The cells were incubated on ice for 30 min, and heat shocked 
for 45 s in a 42°C water bath. The tube was immediately transferred to ice, and following a 
2 min recovery step, 250 μl of pre-warmed SOC broth (Invitrogen) was added. The tube 
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was shaken horizontally at 200 rpm at 37°C for one hour, and spread on a pre-warmed L-
agar plate containing the appropriate antibiotic. The plates were incubated, inverted, 
overnight at 37°C. 
 
2.2.3.2 Transformation of One Shot TOP10 competent cells 
Vials of cells were thawed on ice. 2 μl of a TOPO® reaction was added under sterile 
conditions, gently mixed, and incubated for 30 min on ice. They were heat shocked in a 
42˚C water bath for 30 s, and left on ice for 2 min. 250 μl of SOC was added, and the cells 
were incubated 37˚C on a flat-bed shaker for 1 hour. In the vicinity of a Bunsen burner, 
cells were plated at a variety of volumes on agar plates (appendix) containing an 
appropriate concentration and type of selective antibiotic to ensure well spread colonies. 40 
μl of a 40 mg/ml X-GAL (5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside) 
dissolved in dimethylformamide (DMF) was added to the selective L-agar plate 30 min 
prior to use where blue/white selection was employed. The plates were incubated, inverted, 
overnight at 37°C. 
 
2.2.3.3 Transformation of XL10-GOLD 
Cells were thawed on ice, and aliquoted into pre-chilled 1.5 ml falcon tubes to a volume of 
50 μl.  To each tube, 2 μl of the β-Mercaptoethanol mix provided was added, and incubated 
on ice for 10 min, swirling gently every two min. 50 ng of plasmid or 2 μl of ligation 
reaction were added, and gently mixed. The cells were incubated on ice for 30 min, and 
heat shocked in a 42°C water bath for 30 s. The tube was immediately transferred to ice, 
and following a 2 min recovery step, 250 μl of pre-warmed SOC broth was added. The 
tube was shaken horizontally at 200 rpm at 37°C for one hour, and spread on a pre-warmed 
agar plate containing the appropriate antibiotic. The plates were incubated, inverted, 
overnight at 37°C. 
 
2.2.4 Antibiotic usage 
Selection for ampicillin resistance on L-Agar or in L-Broth was performed at 200 g/ml, 
from a 100 mg/ml stock solution (w/v) in 50% H2O, 50% ethanol which was stored at -
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20C. Selection for kanamycin resistance on L-Agar or in L-Broth was performed at 50 
g/ml from a 50 mg/ml solution (Sigma), which was stored at 4C.  
 
2.2.5 Selection of positive colonies 
Individual colonies (white colonies where blue/white selection was employed) were picked 
under sterile conditions using a sterile toothpick, and added to 3-5 ml of liquid broth 
containing an appropriate concentration and type of selective antibiotic (1.2.4), and 
incubated in a flat bed shaker at 37˚C overnight. Transformants were analysed using PCR 
or restriction digests, detailed below.  
 
2.2.6 Isolation of plasmid DNA 
For plasmid purification, where up to 20 μg of plasmid DNA was required, the QIAprep 
Spin Miniprep Kit was used; where up to 100 μg of plasmid DNA was required, the 
QIAGEN Midi Kit was used, and where up to 500 μg of plasmid DNA was required, the 
QIAGEN Maxi Kit was used, following manufacturer‟s instructions. 
 
2.2.7 E-Z-Prep 
A 3 ml overnight culture was generated as detailed above; 1.5 ml of cells was spun down 
for 60 s at 13,000 x g to pellet the cells, and resuspended by vortexing in 80 μl of EZ lysis 
buffer (Appendix). After a 10 min incubation, a needle was used to prick a hole in the top 
of the eppendorf, and the sample was boiled for 1 min in a boiling water bath. Following a 
2 min incubation on ice, the tube was centrifuged at 17,000 x g for 10 min. 5 μl of 
supernatant was used for a diagnostic digest in a total digest volume of 20 μl, and 2 μl was 
used for a diagnostic PCR. 
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2.2.8 PCR from colony 
Typically one gene specific and one vector specific primers were added at 200 nM to 18 μl 
of ReddyMix MasterMix (Thermoprime) in a sterile PCR tube to a total of 20 μl. A colony 
was picked using a sterile pipette tip, and mixed into the PCR mix by pipetting. The tubes 
were added to a PCR block, set to the following protocol: 
 
92C 2 min 
92C 30 s 
50-65C 30 s             30 cycles               
72C 30 s/kb 
72C 5 min 
 
Samples were held at 4°C until they were run on an agarose gel. 
 
2.2.9 Generation of a Glycerol stock 
For each plasmid, 2 glycerol stocks were generated. 850 μl of overnight culture was added 
to a 1.8 ml Ultra Surity Cryo Vial (Alpha Labs), and 150 μl of glycerol was added. The 
tube was vortexed to mix, and stored at 80°C. To reanimate, the frozen stock was scraped 
with a sterile pipette tip, and streaked on an agar plate containing the appropriate antibiotic. 
A colony from this plate was picked and added to 5ml LB containing selective antibiotic to 
grow overnight. 
 
2.3 Molecular protocols 
2.3.1 Oligonucleotide synthesis 
Oligonucleotides were synthesised by MWG biotech on a 0.01 or 0.05 μmol scale, and 
purified using High Purity Salt Free (HPSF) technology. Primers were assessed for quality 
using Matrix Assisted Laser Desorption Ionisation - Time of Flight (MALDI-TOF) 
72 
analysis. Primers were received as a lyophilised pellet, and were resuspended in distilled 
H2O to generate a 100 μM stock solution, stored at -20˚C. Further dilution in distilled 
water to 10 μM gave working aliquots used for PCR. A list of primers used is given in the 
appendix. 
 
2.3.2 Quantification of nucleic acids  
Nucleic acids were quantified using a NanoDrop™ spectrophotometer ND-1000, where an 
OD260 of 1 equals 50 μg/ml of double stranded DNA, and 40 μg/ml of single stranded 
DNA, or RNA. The spectrophometer was zeroed with the elution buffer used. Purity was 
measured by the ratio of OD260:OD280, where a reading of >1.8 for DNA and >2.0 for RNA 
indicated acceptable levels of purity.     
 
2.3.3 Polymerase Chain Reaction (PCR) 
Where fidelity of amplified DNA was not a critical issue, Taq pol (NEB) was used. The 
reaction mix was set up according to manufacturer‟s instructions; 1x DNA polymerase 
buffer, dNTPs each at 200 M, primers at 200 nM each, 50 ng of cDNA / 10 ng of plasmid 
template, 0.25 U of Taq polymerase, to a final volume of 50 l with H2O. Amounts of 
template DNA varied according to the type of DNA, and the abundance of the desired 
sequence within the DNA. The tubes were flicked to mix, and briefly centrifuged.  Cycling 
was performed in thin walled 0.2 ml PCR tubes in a Hybaid OmnE, Hybaid PCR Sprint or 
Hybaid PCR Express-Gradient thermocycler. Cycling procedures were typically 
 
92C 2 min 
92C 30 s 
50-65C 30 s             25-30 cycles               
72C 30 s/kb 
72C 5 min 
 
Samples were then cooled to 4˚C. 
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2.3.4 Pfu PCR 
Pfu DNA polymerase (Promega) is a thermostable enzyme which exhibits 3‟5‟ 
exonuclease activity, and was thus used for PCR reactions requiring high fidelity. The 
reaction mix was set up as described in the manufacturer‟s protocol as follows: single 
strength Pfu DNA polymerase buffer, dNTPs each at 300 M, primers at 260 nM each, 
plasmid DNA template up to 10 ng, 1.25 U of Pfu DNA polymerase, final volume of 50 l 
with H2O. Cycling procedures were typically: 
 
94C 2 min 
94C 30 s  
50-65C 30 s             25-30 cycles               
72C 2 min/kb 
72C 10 min 
  
Samples were then cooled to 4˚C. 
 
2.3.5 Herculase II PCR 
Herculase II Fusion DNA polymerase (Stratagene) is a thermostable enzyme which 
exhibits 3‟5‟ exonuclease activity, and was thus used for PCR reactions requiring high 
fidelity and high yield from “difficult,” e.g., GC rich template, and thus was frequently 
used for amplification from cDNA. The reaction mix was set up as described in the 
manufacturer‟s protocol as follows: single strength Herculase II DNA polymerase buffer, 
dNTPs each at 400 M, primers at 250 μM each, 50-500 ng cDNA, 1 μl of Herculase II 
Fusion DNA polymerase, final volume of 50 l with dH2O. Cycling procedures were 
typically 
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94C 2 min 
94C 30 s 
50-65C 30 s             25-30 cycles               
72C 1 min/kb 
72C 10 min 
 
Samples were then cooled to 4˚C. 
 
For all PCRs, annealing temperatures were primer- and template-dependent; new primers 
were optimised by running a gradient PCR reaction across a range of annealing 
temperatures. The annealing temperature used gave one strong, clear band when subjected 
to agarose gel electrophoresis. 
 
2.3.6 Fusion PCR 
Fusion PCR was performed in three separate PCR steps. Amplification of DS fragments 
overlapping by ~50bp was performed with a high fidelity DNA polymerase as above. 
These fragments were gel purified, and used in a subsequent fusion PCR containing 
equimolar concentration at ≥0.7μg/50μl, with no primers, with the following PCR 
protocol: 
 
92˚C, 1 min 
92˚C, 30 sec  
50-65˚C, 30 sec            13 cycles                   
72˚C, 1min/kb 
72˚C, 10 min 
 
The product was then PCR purified, and used as a template for full length PCR at 20% of 
PCR volume, with primers for the extreme ends of the target DNA.  
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92˚C, 1 min 
92˚C, 30 sec  
50-65˚C, 30 sec            30 cycles                   
72˚C, 1min/kb 
72˚C, 10 min 
 
PCRs were performed in a gradient PCR machine, with a spread of annealing 
temperatures. 
 
2.3.7 Reverse transcription (RT) PCR 
RT-PCR was performed as per the standard PCR protocol, with cDNA as the template. For 
cloning of an ORF, primers were designed between the ATG encoding the transcription 
start site, and the bases encoding the stop codon. Where the purpose of RT-PCR was to 
establish the presence or absence of a transcript within a tissue, primers spanning 
intron/exon boundaries were used, as a control against genomic contamination. 
 
2.3.8 Quantitative PCR (Q-PCR) 
2.3.8.1 Plate Setup 
To quantify transcription of a gene of interest, Q-PCR was performed using DyNAmo™ 
SYBR® Green (Finnzymes), a 2x master mix that contains Thermus brockianus DNA 
Polymerase, SYBR Green I, a double stranded DNA binding dye, PCR buffer, 5 mM 
MgCl2, and a dNTP mix including dUTP. Gene-specific primers were designed to amplify 
<500 bases across an intron-exon boundary of the gene of interest to ensure only processed 
mRNA would be quantified by the Q-PCR. These primers were used in a PCR to amplify a 
band from cDNA; if a single clean band was achieved, this was gel purified, quantified, 
and used as a standard in the Q-PCR. Each plate was set up on ice, using optical grade 
PCR strips (MJ Research, MLL-9651), and sealed with ultra-clear strip caps (MJ Research, 
TCS-0803). Serial 1 in 10 dilutions were performed with the purified band, to generate a 
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standard curve between 10
-1
 to 10
-7
 ng of template. Alongside this, two blank reactions 
containing 25 μl SYBR green, 25 μl H20, and two “primer only” reactions, containing 25 
μl SYBR green, 21 μl H20, 2 μl forward primer, 2 μl reverse primer (each 0.3μM final 
concentration). For each cDNA condition, 25 μl SYBR green, 20 μl H20, 2 μl forward 
primer, 2 μl reverse primer (each 0.3 μM final concentration), and 1 μl of cDNA, typically 
500ng total, was set up, each in triplicate.  To facilitate quantification against a reference 
gene, primers were designed against an intron-exon boundary of the ribosomal protein 
rp49, considered to have standard expression across cell types. Three biological replicates 
were performed on three different plates.  
 
2.3.8.2 Q-PCR  
Q-PCR strips were briefly centrifuged in a technico mini centrifuge, and added to the 
Opticon™ 3 thermal cycler. The following cycling protocol was followed: 
Table 2.4: Q-PCR cycling protocol 
Step Temperature Time Function
Initial Denaturation 95˚C Template denaturation
Denaturation 95˚C 20 s
Annealing 55˚C 20 s
Determined by gradient 
PCR
Extension 72˚C 5 s/100bp
Data aquisition -
Fluorescence recorded 
after every cycle
Final extension 72˚C
Melting curve 65 - 95˚C
Checks specificity of 
primers
40 cycles
10 min
5 min
-
 
The melting curve was analysed; where more than one clear peak was produced, either for 
the gene and rp49, data was discarded. 
Data was analysed using Opticon™ 3 software, following manufacturer‟s instructions. 
Absolute quantification of gene expression was calculated by comparison of the threshold 
cycle C(t) of the gene to that of the standard curve generated by the gene standards of 
known concentration using an excel spreadsheet. Relative quantification was calculated by 
comparing the ratio of target gene DNA concentration to rp49 DNA concentration. Plotted 
in GraphPad prism 4.0, ±SEM  (where control = 1) Statistical significance determined by a 
1-way ANOVA test. 
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2.3.9 Primer list 
A list of primers used, their sequence, and their applied use are listed in table 2.5. 
 
Table 2.5: Primers used in the course of this study. 
Primer name Sequence Use
PDE11 RAF ATGAAAGTGACACAGAGTGAAGAAAA PCR of full length PDE11 RA
RCfulllengthNSF ATGGCATCATCCCAAATA PCR of full length PDE11
RCfulllengthNSR TTTTTCAACCGCCATAGCG PCR of full length PDE11
RbNtoGAFF ATGGGCCAAGCGGCAA truncation PDE11 cloning
RbNtoGAFR CTCGAGCTCGTTGCAAATGT truncation PDE11 cloning
RCNtoGAFF ATGGCATCATCCCCAAATAA truncation PDE11 cloning
RCNtoGAFR CTCGAGCTCGTTGCAAATG truncation PDE11 cloning
GafF ATGGTGCGCACTTTGTGC truncation PDE11 cloning
GafR AATGGCCTTCTCGTACATGTG truncation PDE11 cloning
CofgaflongF ATGGTGGCAATGGCCAAG truncation PDE11 cloning
CofGAFshortF ATGTGGGCAATGGCCA truncation PDE11 cloning
CofGAFshortR CTGGGCTGGGTGGCTT truncation PDE11 cloning
PDE11spliceBF   CCAAGCGGCAAGTATGTGTC pUAST PDE11 cloning
PDE11spliceR   GGTGTTGTGGCGAGTTGGC pUAST PDE11 cloning
PDE11spliceCF     CCTCAAAGGCGGATAAATACC pUAST PDE11 cloning
dPDE11-RBORF F         ATGGGCCAAGCGGCAAGTAT pUAST PDE11 cloning
dPDE11-RBORF   TTATTTTTCAACCGCCATAGCGG pUAST PDE11 cloning
dPDE11-RC ORF F   ATGGCATCATCCCCAAATAA pUAST PDE11 cloning
dPDE11-RC ORF R    TTATTTTTCAACCGCCATAGC pUAST PDE11 cloning
Pde11ntermRcmyc 
TACAGATCCTCTTCTGAGATGAGTTTTTGTT
CGCAGAAGATGGCGAACGC
pUAST PDE11 cloning
Pde11nterminusR   GCAGAAGATGGCGAACGC pUAST PDE11 cloning
Pde11CtermF  GAGGCGTTCGCCATCTTC pUAST PDE11 cloning
dPDE11cterminusR 
CTACAGATCCTCTTCTGAGATGAGTTTTTGT
TCTTATTTTTCAACCGCCATAGC
pUAST PDE11 cloning
PDE11RBEcoR1F    AAAGAATTCATGGGCCAAGCGGCAAGTAT pUAST PDE11 cloning
PDE11RBkpn1R TTTGGTACCTTATTTTTCAACCGCCATAGCG pUAST PDE11 cloning
Pde11rbYFPEcoR1F  GAATTCATGGGCCAAGCGGCAAGTAT pUAST PDE11 YFP cloning
Pde11rcYFPNot1Rn    GCGGCCGCTTTTTCAACCGCCATAGCGGT pUAST PDE11 YFP cloning
Pde11RCEcoR1F        GAGGAATTCATGGCATCATCCCCAAATAA pUAST PDE11 cloning
Pde11RCKpn1R  GAGGGTACCTTATTTTTCAACCGCCATAGC pUAST PDE11 cloning
Pde11RCYFPEcoR1F           GAATTCATGGCATCATCCCCAAATAAC pUAST PDE11 YFP cloning
Pde11RCYFPNot1Rn      GCGGCCGCTTTTTCAACCGCCATAGCG pUAST PDE11 YFP cloning
RBF72.47   ATGGGCCAAGCGGCAAGTATGTGTC pUAST PDE11 cloning
RBR72.79    TTATTTTTCAACCGCCATAGCGGTGGC pUAST PDE11 cloning
RCF73.39     ATGGCATCATCCCCAAATAACGCGG pUAST PDE11 cloning
RCR72.79  TTATTTTTCAACCGCCATAGCGGTGGC pUAST PDE11 cloning
RBNT_EcoRIF                       GAATTCATGGGCCAAGCGGCAAGTA pUAST PDE11 cloning
RCNT_EcoRIF    GAATTCATGGCATCATCCCCAAATAACG pUAST PDE11 cloning
11NT_BglIIR  CGATTTCGCCAAAGATCTTCCA pUAST PDE11 cloning
11CT_BglIIF     AGATCTTTGGCGAAATCGAATGC pUAST PDE11 cloning
11CT_Kpn1R   GGTACCTTATTTTTCAACCGCCATAGCGG pUAST PDE11 cloning
11CT_Not1NSR GCGGCCGCTTTTTCAACCGCCATAGCGG pUAST PDE11 cloning  
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Primer name Sequence Use
dPDE11xho1F GCTCGAGGTGCGCACTTTG pUAST PDE11 cloning
dPDE11xho1R GTATCTTGTGGCACAAAGTGCGC pUAST PDE11 cloning
dPDE11xho1F GCTCGAGGTGCGCACTTTG pUAST PDE11 cloning
dPDE11xho1R GTATCTTGTGGCACAAAGTGCGC pUAST PDE11 cloning
ShortCtermRevKpn GGTACCTCACTGGGCTGGGTGG pUAST PDE11 cloning
ShortCtermNSRevN GCGGCCGCCTGGGCTGGGTGGCTTG pUAST PDE11 cloning
RBR_3475to3492 GGCAACGTTGGAGCCATT DmPDE11 validation
RBRgap_3475to349 TCATCATCACTGGGCTGG DmPDE11 validation
RCF_45to63 GGCGAGACGTAAAATTGGC DmPDE11 validation
RCR_3350to3368 CTGTTGTTGGCAACGTTGG DmPDE11 validation
RCRgap_3344to336 ATTATCATCATCACTGGGCTG DmPDE11 validation
Forward_3015to30 GAGCATGACTGTCTGTGATTTGT DmPDE11 validation
dg1ntFBamHI GATCCATGCCGCTGGAATGTTGACT Primers for pET cloning
dg1ntFBamHI ACGGATCCATGGCCGCTGGAATGTT Primers for pET cloning
dg1ntRXhoI CTCGAGTTACTTCCTGCTCTCATCGCC Primers for pET cloning
dg1ctFEcoRI CGAATTCGACTAGCCATGAAGCAGGCG Primers for pET cloning
dg1ctFEcoRI CGAATTCCTAGCCATGAAGCAGGCG Primers for pET cloning
dg1ctRSalI ATATATGTCGACTTAGAAATCCGCATCCCAG Primers for pET cloning
dg2ntFEcoRI ATTCGACGTTTCTGCTTTGATCGGC Primers for pET cloning
dg2ntFEcoRI TGAATTCATGCGTTTCTGCTTTGATCG Primers for pET cloning
dg2ntRnotI
GCGGCCGCTTAGATCTGCGTCAGATCCAGAT
TC
Primers for pET cloning
dg2ctFSalI
ATA TAT GTC GAC ACG CGA GAT CGT TGA 
CTG C
Primers for pET cloning
dg2ctFSalI
ATA TAT GTC GAC CGC GAG ATC GTT GAC 
TGC
Primers for pET cloning
dg2ctRNotI
GCG GCC GCT TAT TAG AAG TCC TTG TCC 
CAT CCA G
Primers for pET cloning
rbnNotIR
AGT TGG ATC AGC GGC CGC TTA TTG AGA 
TTT CTC ATA CAG CTG TGC
Primers for pET cloning
middlexhoR
AGA CCT CGA GTT AAC GAT TAT CGC GCA 
CGC
Primers for pET cloning
endxhoR
AGA CCT CGA GTT ATT ATT TTT CAA CCG 
CCA TAG C
Primers for pET cloning
rbnEcoRIFET AGA ATT CGA GGC CAA GCG GCA AGT AT Primers for pET cloning
rcnEcoRIFET ATT CGA GCA TCA TCC CCA AAT AAC G Primers for pET cloning
middleBamHIFET
ACG GAT CCG ACT GGA GAT CAA GCG GAA 
TCA
Primers for pET cloning
endBamHIFET
ACG GAT CCG AGA TCT GGC CGA TGT CGT 
G
Primers for pET cloning
modpuast_f GAA TTC TGC CTC GAG GTT AGA TC Modify pUAST MCS
500+puast_r CAG GTT CAG GGG GAG GTG Modify pUAST MCS
M13 Reverse CAGGAAACAGCTATGAC
Sequencing primers for 
TOPO cloning
M13 Forward GTAAAACGACGGCCAG
Sequencing primers for 
TOPO cloning
 
2.3.10 Automated DNA sequencing 
DNA sequencing was performed at the MBSU sequencing centre of Glasgow University, 
using a MegaBACE1000 96 capillary sequencer, using either Big Dye (Applied 
Biosystems) or ET-Dye Terminator (GE Heathcare) chemistries, both based upon Sanger‟s 
dideoxy sequencing method. Construct and primers were supplies at 1 μg and 3.2 pmol 
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respectively. Constructs were sequenced using primers spaced by 500bp throughout the 
sequence to achieve 100% sequence coverage. Sequencing results were analysed using 
Editview 1.0 (Perkin Elmer) and MacVector software. 
 
2.3.11 RNA extraction 
For purification of RNA, the RNeasy mini kit (Qiagen) was used, following 
manufacturer‟s instructions. mRNA was prepared from either 10 whole flies, 15 heads, 30 
brains, 40 Malpighian tubule pairs or 40 hindguts, dissected in Schneider‟s solution. Tissue 
was transferred to a 1.5 ml eppendorf containing 350 μl RLT buffer with 1% β-
mercaptoethanol on ice, and homogenised with a pestle. Following this, the tissues were 
subjected to brief bursts of L2 sonication by a microson™ ultrasonic cell disruptor. Tissues 
other than the tubules were then centrifuged at 4˚C at 16,200 x g for 3 minutes, and the 
supernatant transferred to a new 1.5ml eppendorf. 350 μl 70% ethanol was added, 
pippetted to mix, and transferred to an RNeasy spin column. Following this, RNA was 
purified following manufacturer‟s instructions, eluted in 25 μl nuclease free water, and 
quantified using a NanoDrop™ spectrophotometer ND-1000 as described in 1.4.2. 
 
2.3.12 First strand cDNA synthesis  
For each amplification of cDNA performed, a further half-volume reaction was performed 
without superscript, and quantified for ds DNA afterwards to discount contamination. 4 l 
5x First Strand buffer, 2 l DTT (0.1 M), l dNTP mix (each, and 1 μl oligo 
DT12-18 (500 μg/ml) were added to a nuclease-free centrifuge tube, mixed, and incubated in 
a PCR block at 65˚C for 5 min. The tube was chilled on ice and briefly centrifuged. 1 
μl/200 units of M-MLV Superscript Reverse Transcriptase, 1 μl/40 U of RNase OUT 
RNase inhibitor, and 1 μg RNA were added, and the mix made up to 20 μl with RNase free 
water. The tube was incubated in a PCR block at 42˚C for one hour; enzyme was 
inactivated by a further incubation at 72˚C for 15 min. cDNA was frozen at -20˚C if not 
used immediately. All reagents were purchased from Invitrogen.  
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2.3.13 Restriction digests 
Digests were performed in a water bath using NEB restriction endonucleases, at the 
recommended concentration of enzyme, buffer and BSA. Digests were performed at the 
recommended temperature for that enzyme. When cloning, inserts were cloned using two 
different restriction sites at the 5‟ and 3‟ ends, where possible. Where double digests were 
performed, digests were either performed in a single reaction, or in sequential digests with 
PCR purification in between digests, depending on buffer compatibility. Where plasmid or 
insert was required for a ligation reaction, 2 – 4 μg DNA was added to a total volume of 
typically 80 μl, to facilitate digest loading into two agarose gel wells. Diagnostic digests 
were performed in 20 μl total volume with 200 μg DNA. Where plasmid was required for a 
ligation reaction, 1 U of alkaline phosphatase was added for the final 30 min to make the 
final amount of enzymes no more than 5% of total digest volume. 
 
2.3.14 Agarose gel electrophoresis of DNA 
DNA was separated by running at 100 V in a 1% agarose gel (1% agarose and 0.1 g/ml 
ethidium bromide dissolved in 0.5 x TBE (appendix)), using 0.5x TBE as the 
electrophoresis buffer as described in (Sambrook and Russel, 2001). DNA fragment size 
was determined by comparison with a 1 kb ladder (Invitrogen). 6x loading dye (0.25 % 
(w/v) bromophenol blue, 0.25 % (w/v) xylene cyanol, 30 % (v/v) glycerol in H20) was 
added to DNA samples to a final 1x concentration prior to loading. 
 
2.3.15 Gel extraction of DNA 
DNA was excised from agarose using a sterile scalpel, and purified using the QIAquick 
Gel Extraction Kit (Qiagen) using manufacturer‟s instructions. 
 
2.3.16 PCR purification of DNA 
DNA was purified from enzymatic reactions using the QIAquick PCR Purification Kit 
(Qiagen) using manufacturer‟s instructions. 
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2.3.17 Ligation reaction 
Ligations were performed using the rapid DNA ligation kit (Roche) at a molar ratio of 6:1 
insert: vector, with typically a total of 200 ng of DNA. Volume of DNA was brought to 5 
μl with EB buffer, and 5 μl of T4 DNA ligation buffer was added, and mixed. To this 0.5 
μl of DNA ligase was added, with thorough mixing. This reaction was left at room 
temperature for 30 min, and frozen at -20˚C if not used immediately. 
 
2.3.18 TOPO cloning 
Where TOPO® cloning was performed with a PCR product produced with a proofreading 
DNA polymerase, the PCR product was incubated at 72°C for 10 min with a non 
proofreading Taq pol to add A overhangs. “Half volume” reactions were used, where 2 μl 
of PCR product had added to it 0.5 μl of salt solution, and 0.5 μl TOPO® vector. The 
reaction was mixed, and left at room temperature for 5 to 30 min. Following 
transformation the reaction was stored at -20°C if not used immediately. 
 
2.3.19 Modification of plasmid multiple cloning site 
Where the restriction sites within a plasmid‟s multiple cloning site were not suitable for the 
insert, a new multiple cloning site was designed. Two sets of primers were designed, which 
represented the new multiple cloning site. These primers overlapped except for 3 bases, 
which were compatible with the terminal restriction sites of the plasmid‟s multiple cloning 
site; upon annealing, the primers form double stranded DNA with sticky ends. Annealing 
was achieved by incubating equimolar amounts of each primer at 92˚C for 2 min, then a 
progressively reduced annealing temperature, 65˚C for 1 min, 60˚C for 1 min, then 55˚C 
for 1 min. The multiple cloning site of the plasmid was removed using the appropriate 
restriction endonucleases, and the plasmid was subsequently treated with calf alkaline 
phosphatase. The double stranded DNA was then ligated into the plasmid.    
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2.3.20 Generation and details of DNA constructs 
A list of DNA constructs generated in the course of this study are listed in table 2.6. 
Table 2.6: DNA constructs generated in the course of this study 
Construct Source Cloning method
Dm PDE11 RB EcoRI-XhoI 2.1 
TOPO
PCR from cDNA TOPO
Dm PDE11 RB XhoI-BglII 2.1 
TOPO
PCR from cDNA TOPO
Dm PDE11 RC EcoRI-BglII 2.1 
TOPO
PCR from cDNA TOPO
Dm PDE11 long C term Stop 
BglII-KpnI 2.1 TOPO
PCR from cDNA TOPO
Dm PDE11 long C term No 
stop BglII-NotI 2.1 TOPO
PCR from cDNA TOPO
Dm PDE11 short C term Stop 
BglII-KpnI 2.1 TOPO
PCR from cDNA TOPO
Dm PDE11 short C term No 
stop BglII-NotI 2.1 TOPO
PCR from cDNA Digest / ligation
PDE11RBl pP{YFP UAST} 
RB EcoRI-XhoI/RB XhoI-
BglII/Cl NS
Digest / ligation
PDE11RBs pP{YFP UAST} 
RB EcoRI-XhoI/RB XhoI-
BglII/Cs NS
Digest / ligation
PDE11RCl pP{YFP UAST} 
compiled from RCN and 
Cl NS TOPO fragments
Digest / ligation
PDE11RCs pP{YFP UAST} 
compiled from RCN and 
Cs NS TOPO fragments
Digest / ligation
PDE11RCs pP{UAST} 
compiled from RCN and 
Cs S TOPO fragments
Digest / ligation
hPDE11A3 pP{UAST} pcDNA3.1  PDE11A3
PCR w/restriction sites 
digeted; ligated
hPDE11A3 pP{YFP UAST} pcDNA3.1  PDE11A3
PCR w/restriction sites 
digeted; ligated
PDE11RBl pAC V5 HIS
ORF from pP{UAST} 
construct
Digest / ligation
PDE11RBs pAC V5 HIS
ORF from pP{UAST} 
construct
Digest / ligation
PDE11RCl pAC V5 HIS
ORF from pP{UAST} 
construct
Digest / ligation
PDE11RBl pAC V5 HIS
ORF from pP{UAST} 
construct
Digest / ligation
pGEX-6P-1 RB N
PDE11RBl pP{YFP 
UAST} 
PCR w/restriction sites 
digeted; ligated
pGEX-6P-1 RC N
PDE11RCl pP{YFP 
UAST} 
PCR w/restriction sites 
digeted; ligated
pGEX-6P-1 PDE11 middle
PDE11RCl pP{YFP 
UAST} 
PCR w/restriction sites 
digeted; ligated
pGEX-6P-1 long C term
PDE11RCl pP{YFP 
UAST} 
PCR w/restriction sites 
digeted; ligated  
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Construct Source Cloning method
pGEX-6P-1 DG1 N DES DG1
PCR w/restriction sites 
digeted; ligated
pGEX-6P-1 DG1 C DES DG1
PCR w/restriction sites 
digeted; ligated
pGEX-6P-1 DG2 P1 N DES DG2 P1
PCR w/restriction sites 
digeted; ligated
pGEX-6P-1 DG2 P1 C DES DG2 P1
PCR w/restriction sites 
digeted; ligated
pGEX-6P-1 DG2 P2 N DES DG2 P2
PCR w/restriction sites 
digeted; ligated
pGEX-6P-1 DG2 P2 C DES DG2 P2
PCR w/restriction sites 
digeted; ligated
pET-28c RB N
PDE11RBl pP{YFP 
UAST} 
PCR w/restriction sites 
digeted; ligated
pET-28c RC N
PDE11RCl pP{YFP 
UAST} 
PCR w/restriction sites 
digeted; ligated
pET-28c PDE 11 middle
PDE11RCl pP{YFP 
UAST} 
PCR w/restriction sites 
digeted; ligated
pET-28c PDE11 long C term
PDE11RCl pP{YFP 
UAST} 
PCR w/restriction sites 
digeted; ligated
pET-28c DG1 N DES DG1
PCR w/restriction sites 
digeted; ligated
pET-28c DG1 C DES DG1
PCR w/restriction sites 
digeted; ligated
pET-28c DG2 P1 N DES DG2 P1
PCR w/restriction sites 
digeted; ligated
pET-28c DG2 P1 C DES DG2 P1
PCR w/restriction sites 
digeted; ligated
pET-28c DG2 P2 N DES DG2 P2
PCR w/restriction sites 
digeted; ligated
pET-28c DG2 P2 C DES DG2 P2
PCR w/restriction sites 
digeted; ligated
DES DG1-TAP DES DG1
PCR; F primer w/ tap tag 
seq
DES DG2P1-TAP DES DG2 P1
PCR; F primer w/ tap tag 
seq
DES DG2P2-TAP DES DG2 P2
PCR; F primer w/ tap tag 
seq
pP{UAST} DG1-TAP DES DG1
PCR; F primer w/ tap tag 
seq
pP{UAST} DG2P1-TAP DES DG2 P1
PCR; F primer w/ tap tag 
seq
pP{UAST} DG2P2-TAP DES DG2 P2
PCR; F primer w/ tap tag 
seq
pACT2 AD DG2 P1 DES DG2 P1 Digested PCR
pACT2 AD DG2 P2 DES DG2 P2 Digested PCR
pACT2 AD PDE11 RA DES PDE 11 RA Digested PCR
pGBK T7 BD DG2 P1 DES DG2 P1 Digested PCR
pGBK T7 BD DG2 P2 DES DG2 P2 Digested PCR
pGBK T7 BD PDE 11 RA DES PDE 11 RA Digested PCR  
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2.4 Schneider 2 (S2) cells 
2.4.1 S2 cell maintenance 
S2 cells were stored in a 28˚C incubator, in complete Schneider‟s Drosophila Medium  
with 10% heat inactivated Foetal Calf Serum (FCS), and were split when they reached a 
density of 6 – 20 x 106 S2 cells/ml. Transfections were performed in a cell culture hood 
using sterile techniques. Stock was split into new flasks for general maintenance; 
transfections and selection were kept in the same flasks or plates. The S2 cells/ml of an S2 
cell stock was calculated using a haemocytometer (Hawksley).  
 
2.4.2 S2 cell transfections 
For each transfection, 3 x 10
6
 S2 cells/transfection were spun down in a 15 ml falcon tube 
at 1000 x g for 3 min, and resuspended in 800 μl of Schneider‟s Drosophila Medium 
(without serum). 800 μl of cells were added to each well of a 6 well plate. For each 
experimental condition, a total of 2 μg plasmid DNA was incubated with 10 μl 
Cellfectin/Cellfectin II (Invitrogen), made up to 200 μl total with Schneider‟s Drosophila 
Medium. This mixture was vortexed briefly, incubated for 30 min, and then added to the 
cells in a dropwise fashion, while swirling the plate. The plate was then incubated 
overnight (for Cellfectin) or for 4 hours (Cellfectin II). Cells were resuspended using a 
transfer pipette, added to a 1.5ml eppendorf, and spun down for 3 min at 1000 x g. The 
supernatant was removed, and the S2 cells were resuspended in 3 ml Schneider‟s 
Drosophila Medium with 10% FCS. Where DES constructs were used these were induced 
with CuSO4 at a final concentration of 0.7 μM. Time of incubation varied depending on 
expression level of the plasmid, which was assessed by ICC or western blot. 
 
2.4.3 Generation of stable S2 cell lines 
Transfections were performed as above, but with the addition of an equimolar amount of 
pCoHygro selection vector. Stable cells were selected for using 300 μg/ml hygromycin-B, 
where the medium was not changed until the cells showed strong resurgence in growth. 
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2.4.4 Generation of an S2 cell frozen stock 
S2 cells were grown to a density of 1 – 2 x 107 S2 cells/ml.  They were centrifuged at 1000 
x g, and resuspended  to a density of 1.1 x 10
7
 S2 cells/ml in Freezing Medium (45% 
conditioned complete Schneider‟s Drosophila Medium containing 10% FBS, with 45% 
fresh complete Schneider‟s Drosophila Medium, and 10% DMSO). 1 ml aliquots in 
cyrovials were placed in an insulated container, then transferred to a -80˚C freezer 
overnight. The vials were then stored in liquid nitrogen. 
 
2.4.5 Initiation of S2 cell frozen stock 
A frozen S2 cell stock was removed from liquid nitrogen, and thawed in a 30˚C water bath. 
The vial was washed with 70% ethanol, and the cells added to 5 ml room temperature 
complete Schneider‟s Drosophila Medium, and stored at 28˚C for 30 min. The cells were 
resuspended, centrifuged at 1000 x g for 3 min, and transferred to a new flask containing 5 
ml Schneider‟s Drosophila Medium with 10% FCS at 28˚C until the cells reached a 
density of 6 x 10
6
.   
 
2.5 Immunoprecipitaions (IP) 
2.5.1 Preparation of S2 cell lysates  
For S2 cell transfections, each transfection was viewed under 20x magnification to assess 
cell membrane integrity (as a measure of survival), and resuspended using a transfer 
pipette. Each transfection was split into two 1.5 ml eppendorfs, and spun down for 4 min at 
1000 x g. The supernatant was removed, and the cell pellets were frozen in a -80°C freezer 
(if there wasn‟t time to pre-clear overnight). When needed, these cell pellets were 
resuspended in a suitable volume of ice cold 3T3 lysis buffer (25mM HEPES pH 7.4, 
50mM NaCl, 10% glycerol, 1% Triton X-100) containing protease inhibitor cocktail. The 
lysate was then sonicated on ice. Where background was apparent the buffer could be 
modified. 3 million S2 cells yielded ~150μg of soluble protein. 
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2.5.2 Preparation of Malpighian tubule lysates  
For each genotype, 200 tubule pairs were dissected, and transferred to a suitable volume of 
ice-cold 3T3 lysis buffer with 1% (v/v) protease inhibitor cocktail. Tubules were lysed on 
ice, using a hand held pestle, then by brief L3 sonication. Insoluble material was pelleted 
by centrifugation at 18,000 x g for 10 min at 4˚C, and the supernatant transferred to a new 
eppendorf tube. Total protein recovered was ~30μg.  
 
2.5.3 Preparation of whole fly lysate 
For each genotype, 10 flies were anesthetized using CO2, and transferred to a suitable 
volume of ice-cold 3T3 lysis buffer with 1% (v/v) protease inhibitor cocktail. Flies were 
lysed on ice, using a hand held pestle, then by three five second bursts of L3 sonication. 
Insoluble material was pelleted by centrifugation at 18,000 x g for 10 min at 4˚C, and the 
supernatant transferred to a new eppendorf tube. Total soluble protein recovered was 
~30μg. 
 
2.5.4 IP with rabbit serum 
Where the IP was performed with a Rabbit polyclonal antibody, 50μl of pre-immune rabbit 
serum per ml (ideally from a pre-immune sample from the immunized rabbit) was added to 
each lysate, and incubated at 4°C on a rotator for ≥30 min. During this preclearing step, 
10-20μl Protein A-Sepharose 4B Fast flow, from Staphylococcus aureus (Sigma)/IP was 
washed 3x in ice cold lysis buffer, and added to each lysate. The samples were incubated at 
4°C on a rotator for ≥1 hour, and then spun down at 8000g. The lysate was removed and 
transferred to a new tube, where 20-50μl serum was added to each sample, and incubated 
at 4°C on a rotator for 1 hour. Pre-washed Protein A beads were added as before, and 
incubated at 4°C on a rotator for 1 hour. The beads were washed 3x in 750μl 3T3 lysis 
buffer with protease inhibitor, with the wash buffer removed as completely as possible 
without disturbing the pellet. The pellet was then used immediately if possible, or frozen at 
-80°C. 
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2.5.5 With Fixed state proteinA beads 
Where the IP was performed with EZview Red αc-Myc Affinity Gel (Sigma), EZ View 
Red Protein A Affinity Gel (Sigma) was used to preclear in place of Protein A-Sepharose 
4B Fast flow; serum was still used because the αc-Myc antibody is Rabbit polyclonal. 
Where αV5 Agarose conjugate (Sigma) was used for the IP, Protein A Agarose conjugate 
(Sigma) was used to preclear as above, but with no addition of serum, as the αV5 antibody 
is a monoclonal.  
 
2.5.6 IP with monoclonal antibodies 
Where monoclonal antibodies were used, amounts used was dictated by the recommended 
concentration in the accompanying protocol. A pool of monoclonal antibodies was used 
wherever possible, and the concentrations of each were lowered as appropriate. Antibody 
was added to each sample, and incubated at 4°C on a rotator for 1 hour. Pre-washed 
Protein A beads were added as before, and incubated at 4°C on a rotator for 1 hour. The 
beads were washed 3x in 750 μl 3T3 lysis buffer with 1:100 protease inhibitor, with the 
wash buffer removed as completely as possible without disturbing the pellet. The pellets 
were then used immediately if possible, or frozen at -80°C. 
 
2.5.7 IP with antibody conjugate 
Where antibody-agarose conjugates were used, the IP was performed as before, except 
there was no antibody incubation before the addition of the antibody-agarose conjugate. 
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2.6 Western blotting 
2.6.1 Preparation of sample 
2.6.1.1 Preparation of S2 cell lysates  
For S2 cell transfections, each transfection was viewed under 20 x magnification to assess 
cell membrane integrity at every stage (as a measure of survival), and resuspended using a 
transfer pipette. Each transfection was split into two 1.5 ml eppendorfs, and spun down 
spun down for 4 min at 2000 rpm in a Thermo Heraeus centrifuge. The supernatant was 
removed, and the cell pellets were frozen in a -80°C freezer. When needed, the pellets were 
resuspended in IGEPAL buffer (150mM NaCl, 50mM Tris, 1% IGEPAL) containing 
protease inhibitor cocktail. The lysate was then sonicated on ice. An equal volume of 
Laemmli 2 x buffer (4% SDS, 5% β-Mercaptoethanol, 20% glycerol, 0.004% bromophenol 
blue, 0.125M Tris-HCl) was then added, and the samples boiled in a boiling water bath for 
3 min.    
 
2.6.2 Bradford assay 
The Bradford assay was performed on a 96 well plate. Standards from 0-5 μg (typically 0 
μg, 0.5 μg, 1 μg, 1.5 μg, 2 μg, 3 μg, 4 μg, 5 μg) were generated in triplicate using Bovine 
Serum Albumin (BSA), Fraction V (Roche) in a volume of 50 μl distilled H20. For each 
protein sample, 1 μl of sample was added to 49 μl H20 in triplicate. To each well, 200μl of 
a well mixed 1 in 5 dilution of Bio-rad protein assay dye reaction concentrate (Biorad) in 
H20 was added. Absorbance at 590 nm was read using a plate reader; Quanta smart 
software was used to generate a standard curve, and from this ascertain the concentration 
of each protein sample. 
 
2.6.3 Sodium Dodecyl Sulfate PolyAcrylamide Gel 
Electrophoresis 
10 or 15 well resolving gels between 6-20% were prepared according to the size of the 
protein of interest, as according to (Joseph Sambrook 2001). Electrophoresis was 
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performed in a Biorad Miniprotean 3 Cell electrophoresis system. Samples were run at 50 
V until the dye front had settled at the bottom of the stacking gel, and then at 130 V for 1 
hour. Prestained Benchmark Ladder (Invitrogen) was used to determine the size of 
proteins. 
 
2.6.4 Coomassie staining of PAGE gels 
PAGE gels were fixed by brief treatment with 40% distilled H20, 10% acetic acid, 50% 
methanol on a horizontal shaker. The gel was then added to the same mix but with the 
addition of 0.25% by weight Coomassie Brilliant Blue R-250, and incubated for 4 hours to 
overnight. The gel was then washed in 67.5% distilled H20, 7.5% acetic acid, 25% 
methanol on a horizontal shaker, the solution changed until excess dye was removed, and 
the protein bands were clear. 
 
2.6.5 Transfer 
Hybond P was incubated in methanol for 5 min, and then rinsed in distilled H20. Western 
blotting was carried out according to Novex Xcell II Blot Module (Invitrogen) instructions. 
Transfer was carried out at 60 V for 1 hour, with ice packs to prevent overheating. 
 
2.6.6 Ponceau S Staining 
To visualise protein on the membrane, the membrane was rinsed in methanol, then washed 
in PBST. The membrane was then incubated for 5 min in PBST-10% (v/v) Ponceau with 
rocking, scanned, rinsed in methanol to remove the stain, and then washed in PBST.   
 
2.6.7 Western blotting 
The membrane was briefly rinsed with PBS with 0.1 % (v/v) Tween 20 (PBST), and 
blocking was performed with PBST containing 5% Marvel Milk (w/v), for three hours, or 
overnight at 4°C. The membrane was then rinsed in PBST. Incubation with a primary 
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antibody was performed in block with a suitable amount of primary antibody, for one hour.  
The membrane was then extensively washed for an hour with frequent changes of PBST. 
The membrane was then incubated with a HRP-conjugated secondary antibody in block for 
one hour. The membrane was then extensively washed for an hour with frequent changes 
of PBST. All steps were performed on a flat bed shaker. 
 
2.6.8 Signal detection 
Chemiluminescence detection was performed using the ECL Western Blotting analysis 
system (Amersham Pharmacia) following manufacturer‟s instructions. Equal volumes of 
reagent 1 and reagent 2 were mixed, and added to a sheet of Saran wrap. The filter was 
added protein side down, and incubated for 1 min. The membrane was then wrapped in 
Saran Wrap, added to a cassette, and exposed to ECL film (Amersham Pharmacia), before 
development in an X-OMAT film processor. 
 
2.7 Antibody design and purification 
2.7.1 Antibody design 
Polyclonal antibody epitopes were designed by analysing protein sequence with Abie Pro 
3.0: Peptide Antibody Design and Macvector software. 14mers showing high antigenicity 
were selected, and a cysteine added at the C terminal to facilitate conjugation. Putative 
sites were blasted against the Drosophila proteome, and any showing 5 consecutive amino 
acids with identity against other proteins were rejected. Antibodies were generated by 
PickCell Laboratories, using the Express Rabbit 28 day protocol, and subjected to ELISA 
testing on peptides attached to Polysorb plates. Serial dilutions of rabbit serum were 
applied for 2 h at rt. Specific IgGs were detected using gamma-chain specific anti-rabbit 
IgG-HPRO conjugate. 
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2.7.2 Isolation of IgG fraction from immune-serum 
Antibody was purified as detailed in Day, 2005. A „HiTrap Protein A HP‟ column 
(Amersham) was flushed with 5 ml 0.1 M glycine pH 2.5, passed through at ~2ml/min, 
then equilibrated with 30 ml of PBS. 5 ml of immune-serum was filtered through a 0.45 
M filter, and then syringed through the column to bind.  The column was washed with 30 
ml of PBS, and the IgG fraction was eluted with 17 ml of 0.1 M glycine, pH 3.0. The first 
2 ml were discarded, and the subsequent 15 ml flow-through was collected in a 50 ml 
Falcon tube containing 1.5 ml 1 M Tris-HCl pH 8.0. The column was then washed with 5 
ml 0.1 M glycine pH 2.5, and stored, sealed, containing ethanol, at 4˚C.  The absorbance at 
280 nm was read to confirm IgG elution, and the IgG eluate was dialysed overnight against 
a large volume of PBS in a Slide-A-Lyzer dialysis cassette (Pierce). 
 
2.7.3 Preparation of affinity columns 
The bottom cap was fitted to a 10 ml polypropylene column (Pierce) and the column filled 
with deionised water. A frit was pushed to the bottom of the column using the plunger 
from a disposable syringe. The water was drained by removing the end cap and 5 ml of 
Sulfolink slurry (Pierce) was added. When the slurry had sedimented, the slurry buffer was 
removed down to the surface of the gel and 2 x 25 ml of 50 mM Tris-HCl, 5 mM Na-
EDTA pH 8.5 was run through the column, with the end cap replaced when the buffer 
reached the slurry. 1 mg of antibody-specific peptide was dissolved in 4 ml of 50 mM Tris-
HCl, 5 mM Na-EDTA, and added to the column. The top cap was added, and the column 
subjected to rotation for 15 min at 4˚C. The column was left upright for 45 min, following 
which the column was drained. 15 ml of 50 mM cysteine in 50 mM Tris-HCl, 5 mM Na-
EDTA was added to the column, and rotated for 15 min at 4˚C. The column was set 
upright and allowed to settle for 45 min.  The top cap was removed and the top frit fitted 
just above the level of the gel.  The end cap was removed and the column drained. 60 ml of 
1 M NaCl was then run through the column, followed by 50 ml of PBS and then 40 ml of 
0.05 % (w/v) sodium azide in PBS keeping the level above the gel. The end caps were 
fitted and the column stored at 4 
o
C until use. 
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2.7.4 Affinity purification of antibodies 
The affinity column was brought to room temperature and the sodium azide was drained. 
The column was equilibrated by passing through 30 ml of PBS and the IgG fraction was 
passed through in 5ml batches.  Next followed a wash with 30 ml of PBS and finally the 
antibody was eluted with 0.1 M glycine, pH 3.0. 12 x 1 ml fractions were collected into 12 
x 1.5 ml Eppendorfs containing 100 l Tris-HCl pH 8.0.  To determine the yield the 
absorbance at 280 nm of each fraction was measured and fractions with readings greater 
than 0.05 were pooled and dialysed overnight against PBS with 0.01 % (w/v) sodium 
azide.  The absorbance at 280 nm was again taken in order to ascertain the final yield using 
the equation: 
 
Antibody concentration (mg/ml) = O.D 280 x 1.35 mg/ml 
 
Aliquots of the antibodies were made and frozen at -20 
o
C until use. 
 
2.7.5 Antibodies generated 
The rabbit polyclonal antibodies generated during the course of this study, the epitope 
chosen, and any additional remarks are listed in table 2.7. 
 
Table 2.7. Antibodies generated during the course of this study, the epitopes used.  
Antibody generated Epitope chosen Remarks
αDG1 PKYEKDFSDKQQIKD
αDG2 FDDYPPDPEGPPPDD Recognises all isoforms
αPDE11 KTKTSQDQEPEEEQQ Recognises all isoforms
αhPDE11Aa QRQTKTKDRRFNDE Recognises Dm PDE11-A3 and -A4
αhPDE11Ab SKGEYDWNIKNHRD PDE11-A1, -A2, -A3, -A4, -006, -202, -203, -204
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2.7.6 Antibodies used in this study 
A list of the antibodies used during the course of this study are shown alongside their 
dilution and use in table 2.8.  
 
Table 2.8: Antibodies used in this study 
Antibody used Dilution and use
PDE11-1 rabbit polyclonal 
(αPQNGHGLPFGSYQH)
1: 500 (IP)
PDE11-2 rabbit polyclonal 
(αPTSTQPSDDDNDAD)
1: 500 (IP)
DG1 rabbit polyclonal 1: 500 (IP)
DG2 rabbit polyclonal 1: 500 (IP)
Anti-V5 (mouse monoclonal, Invitrogen)
1:1000 (immunocytochemistry), 1:5000 
(western)
Anti-cMyc (mouse monoclonal, 
Invitrogen)
1:5000 (western)
Anti-GFP (mouse monoclonal, ZYMED) 1:1000 (western)
Alexa FluorÒ568-labelled anti-rabbit IgG 
H & L (goat polyclonal, Molecular 
Probes)
1:500 (immunocytochemistry)
Alexa FluorÒ568-labelled anti-mouse IgG 
H & L (goat polyclonal, Molecular 
Probes)
1:500 (immunocytochemistry)
HRP labelled anti-rabbit IgG H & L 
(donkey polyclonal, Amersham)
1:5000 (western)
HRP labelled anti-mouse IgG H & L 
(sheep polyclonal, Amersham)
1:5000 (western)
Anti-HIS4 HRP-conjugated 1° antibody 
(mouse monoclonal, Biorad)
1:5000 (peptide array)
 
 
2.8 Immunocytochemistry on tubules 
Protocol from {MacPherson, 2001}. Malpighian tubules from 10 flies were dissected in 
Schneider‟s medium and transferred to a 1.5 ml eppendorf containing 100 l of PBS. This 
was aspirated with care taken not to disturb the tubules. 200 l of fixation solution (4 % 
(w/v) paraformaldehyde in PBS) was then added for 30 min. The fixation solution was 
removed, and the tubules were washed three times in PBS for 30 min each wash, following 
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a single quick wash.  The tubules were then permeabalised for 30 min with PBS, 0.5% 
triton (v/v), 0.15M NaH2PO4, 0.1% Sodium Azide (PBTA) (w/v), changing every 10 min. 
The tubules were then incubated in PBS, 0.3 % (v/v) Triton X-100, 0.5 % (w/v) BSA 
(PAT) for 3 h at RT. Hybridisation in 1° antibody (at an appropriate concentration in PAT) 
was carried out overnight at 4°C. Tubues were then washed 4 x in PAT for 2 h, and then 
blocked with PAT for 3 h. Incubation with 2° antibody was performed in PAT for 1 h to 
overnight. The tubules were washed three times with PBTA for 30 min each wash. Where 
nuclei staining was required, the tubules were incubated with DAPI (500 ng/ml in PBS) for 
2 min, and washed three times with PBTA for 30 min each wash. Finally, the tubules were 
then washed 2 x 10 min in PBS. All solutions were filter sterilised using a 0.22 μm filter. 
 
2.8.1 Mounting 
Tubules were mounted in glycerol mounting medium. The tubules were incubated in 20 % 
glycerol in PBS for 15 min. Around 2mm of a 1ml pipette tip was cut off, and the tubules 
were then pippetted into a dish with 50% glycerol. Slides or glass-bottomed dishes had 
80% glycerol added, and the tubules transferred to these. Where coverslips were required, 
they were sealed with glycerol/gelatin (Sigma). 
 
2.9 Survival assays 
2.9.1 Septic challenge with a needle 
A single pellet of freeze-dried pellet of E. coli (Selectrol freeze-dried pellets, TCS 
biosciences) was added to 5 ml LB-broth, and grown overnight at 37˚C with shaking to 
stationary phase. E. coli was harvested by centrifugation, the LB-broth removed, and the 
pellet resuspended in a small volume of B broth. 5-7 day old flies were separated into vials 
containing 30 flies each. These were anaesthetised on the gas pad. A thin-bore needle (BD 
Microlance ™ 3, 26 G x ⅝) was dipped into the bacterial culture; the flies were stabbed 
just below the first abdominal turgite. Control stabbing with a sterile needle was carried 
out on an equal number of flies to monitor stabbing-induced death. Survival was monitored 
at least daily. Flies were tipped into fresh vials daily. 
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2.9.2 Septic challenge with microinjection 
A single pellet of freeze-dried pellet of E. coli (Selectrol freeze-dried pellets, TCS 
Biosciences) was added to 5 ml LB-broth, and grown at 37˚C with shaking to an OD600 of 
2.0. The E. coli was harvested by centrifugation, and resuspended in an equal volume of 
PBS. Flies were injected with 69 nl bacteria using a Nanoject II (Drummond Scientific) 
mounted to a micromanipulator. Microinjection needles (N-51-A glass capillaries) were 
pulled using a moving coil microelectrode puller (Campden Instruments limited). The tip 
of the needle was broken by touching to the flat plane of a pair of forceps, and the needle 
was backfilled with mineral oil prior to the uptake of bacteria. Where possible, the same 
needle was used for every fly. The site of injection was just below the first abdominal 
turgite. 30 flies/genotype were used, and transferred daily to fresh vials. 
 
2.10 Enzymatic assays 
2.10.1 [Ca
2+
]i measurements in aequorin expressing tubules 
Measurement of [Ca
2+
]i in the Malpighian tubules was performed using transgenically 
expressed aequorin, following the method detailed in {Rosay, 1997}. To reconstitute 
intracellular aequorin, 30 tubules from 5-7 day old adults were dissected in Schneider's 
medium and placed in 160 l of Schneider‟s solution with coelenterazine added to a final 
concentration of 2.5 M.  Samples were then incubated in a rack wrapped in tin foil for 3 
h. Bioluminescence recordings were carried out using an LB9507 luminometer (Berthold 
Wallace).  To monitor tubule condition and control for transients initiated by the injection 
process itself, samples were 'mock' injected with 25 l of Schneider's, before injection with 
the appropriate agonist at the desired concentration, and bioluminescence recorded for 20 
min.  Tubules were then disrupted with 300 l lysis solution (1% (v/v) Triton X-100, 100 
mM CaCl2); integration of total counts allowed the calculation of total aequorin levels. 
Ca
2+
 concentrations for each time point in an experiment were calculated by backward 
integration, using a program written in Perl based on work previously described by 
{Button, 1996}, and plotted using Excel or GraphPad prism. 
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2.10.2 PDE assays 
PDE assays were performed as per the protocol detailed in {Day, 2005}.Samples were 
prepared as above, in KHEM buffer (50 mM KCl, 10 mM EGTA, 1.92 mM MgCl2, and 50 
mM HEPES), containing protease inhibitor cocktail (Sigma) at a 1:100 dilution. Protein 
samples were added at equal concentrations to 1.5 ml eppendorfs in a total of 50 μl on ice, 
with two control tubes containing 50 μl KHEM buffer for each substrate concentration. A 
2 x stock solution was generated by adding the appropriate amount of 3‟, 5‟-cyclic 
adenosine monophosphate, or 3‟, 5‟-cyclic guanosine monophosphate (sigma) to 20 mM 
Tris-Hcl, 10 mM MgCl2 pH 7.4. To this solution, [
3
H] cGMP or [
3
H] cAMP was added at 
3 μCi/ml. 50 μl of substrate was added to the protein samples, and mixed by flicking the 
tubes. Phosphodiesterase activity was stimulated by incubation in a 30˚C water bath for 20 
min. Samples were transferred to a boiling water bath for 2 min to denature the enzyme, 
and were then cooled on ice. 25 μl of snake venom (diluted 1:10 from a 10 mg/ml stock 
solution (Sigma)) was added to each sample, the tubes flicked to mix, and transferred to 
the 30˚C water bath for a further 10 minutes, to remove phosphate groups from AMP or 
GMP. Dowex ion exchange resin (Sigma) diluted 1:1 in water was further diluted 1:2 with 
ethanol, and 400 μl was added to each sample. Tubes were vortexed, incubated on ice for 
15 min, and vortexed again. Tubes were then subjected to centrifugation at 13,000 x g, 4˚C 
for 2 min, and 150 μl of supernatant was removed from each sample, and added to a fresh 
eppendorf containing 1 ml Ecoscint ORIGINAL scintillation fluid (National Diagnostics), 
with a further two “substrate” eppendorfs generated by adding 50μl substrate. Each tube 
was vortexed to homogeneity, and added to a beta scintillation counter set to record 
3
H 
counts for 1 min / sample. Counts should not exceed 18,000 counts / min after subtraction 
of blanks to represent less than 20% of substrate hydrolysed. 
 
2.10.3 Calculation of PDE activity and kinetic parameters 
Specific PDE activity was calculated using the following formula: 
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Where  
A = specific PDE activity (pmol cGMP or cAMP/mg/min) 
C = sample value (CPM) 
B = blank value (CPM) 
S = substrate value (CPM) 
N = cAMP or cGMP in substrate (moles) 
P = protein (g) 
t = time (min) 
 
2.24 Cyclic GMP-dependent protein kinase assay 
 
The cyclic GMP-dependent protein kinase activity of Malpighian tubules was determined 
by direct measurement of radiolabelled phospho-transfer to a short peptide sequence 
substrate, homologous to sequence of a bovine PDE 5 cGK phosphorylation site, as 
detailed in {MacPherson, 2004}.  Approximately 400 tubules per sample were dissected 
and homogenised on ice in 20 l of homogenisation buffer (20 mM Tris (pH 7.5), 250 mM 
sucrose, 2 mM EDTA, 100 mM NaCl, 50 mM -mercaptoethanol, 1:100 dilution of 
protease inhibitor cocktail (Sigma)). The protein concentration of each sample was 
measured by Bradford assay, and standardised by addition of homogenisation buffer.  Two 
stock solutions of kinase assay buffer were prepared fresh, with and without 1 M cGMP. 
This comprised 20 mM Tris-HCl, pH 7.5, 1 mM EDTA, 2 mM EGTA, 10 mM magnesium 
acetate, 1 nM PKA inhibitor (TYADFIASGRTGRRNAI-NH2), 20 M ATP, 1 mM 
zaprinast, 1 M sildenafil, 1 mM DTT, 0.2 g/ml GLASS-tide (RKRSRAE, Calbiochem), 
0.5-2 l of [-32P] ATP (370 MBq/ml, to an approximate specific activity of 4000 
cpm/pmol ATP). 
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Reaction samples were generated by the addition of 40 l kinase assay buffer to 5 l 
(approximately 30 mg of protein) homogenised tubule sample in 500 μl eppendorfs. Two 
sets were generated, one with and one without cGMP in the reaction buffer. Sample blanks 
consisted of 40 μl reaction buffer and 5 μl homogenisation buffer.  Kinase activity was 
stimulated by incubation for 30 min in a 30˚C block, after which 35 μl of each sample was 
spotted onto individual squares of P81 paper (Whatman, Maidstone, Kent) labelled with 
pencil, and allowed to dry on a tray with benchtop paper, facing absorbent side up under a 
plastic shield for 45 min. To calculate specific activity of the radiolabelled ATP at the end 
of the reaction, 5 μl of several random samples (representative of 1/9 total count) were 
spotted onto individual squares of P81 paper („total count‟), and allowed to dry as above. 
 
The reaction samples were washed for 3 x 5 min in 75 mM phosphoric acid, then washed 
once for 15-20 s in ethanol and allowed to dry.  All squares of paper, including the total 
count samples, were then transferred to scintillation vials, with the addition of 3 ml 
scintillation fluid and counted in a scintillation counter (Beckman, High Wycombe, UK) 
set to record 
32
P for 60 s. 
 
Specific activity of [-32P] ATP was calculated (9 x mean c.p.m. of total count 
squares/[ATP] in reaction) and used to calculate protein kinase activity (pmol ATP min
-1
 
g-1 protein) as follows: 
kinase activity = γ-32P cpm (total) x 45/5)  (45 initial radiation mix put in; 5 amount of                                     
                  (usually 20) μM moles ATP            radiation mix added to substrate paper)                         
0.37 mBq usually used. 
= 1μL / ml 
 ½ life 14 days; double this amount/14 days 
Activity =           (γ-32P cpm – blank cpm x 35) 
               Specific activity x total protein x time x 45 (assay buffer amount)  
 
Where  
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C = sample counts per minute 
B = blank counts per minute 
V = sample volume on filter  
R = reaction time in minutes 
P = protein amount in g 
S = specific activity  
 
2.11 Peptide arrays 
The peptide array protocol given is based upon {Bolger, 2006}. 
2.11.1 SPOT synthesis of peptides 
Peptide libraries comprising amino acid 25mers were generated on a Whatman 50 cellulose 
membrane support by automatic SPOT synthesis using Fmoc (9-
fluorenylmethyloxycorbonyl) chemistry with the Autospot Robot ASS 222 (Intavis 
Bioanalytical Instuments).  
 
2.11.2 Expression of HIS6 tagged proteins 
HIS6 tagged proteins were generated by transfection of the expression vector pET-28c 
(cloned with appropriate ORF) into BL21 (DE3) pLysS competent cells following 
manufacturer‟s instructions. Cells were thawed on ice, mixed, and 100 μl aliquots were 
generated in pre-chilled 1.5 ml culture tubes. To each tube, 1.7 μl of β-mercaptoethanol 
was added and mixed. 50ng of DNA was then added to each tube, and flicked to mix. 
Tubes were stored on ice for 10 min, and heat-shocked in a 42°C water bath for 45–50 s in 
a water bath. Tubes were then transferred to ice for 2 min. 900μl of (4°C) SOC medium 
was added to each transformation reaction, and the tubes were incubated for 60 minutes at 
37°C on a horizontal shaker at 225rpm. Cells were plated on antibiotic plates, and left, 
inverted, at 37˚C overnight. 
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2.11.3 Analytical-scale growth 
 Individual cultures were added to 3 ml  L. Broth, and grown to an OD600 of ≥0.6 – ≤1.0. 
From this 3 ml, 1 ml was removed, from which 100 μl was centrifuged at 18,000 g for 3 
min and the pellet used as a non-induced control, and 900 μl were used to generate a 
glycerol stock as detailed in materials and methods. The remaining 2 ml culture was 
induced by the addition of IPTG (typically 0.1 mM) and incubated for a further 2 h with 
shaking at 37˚C. Two 1 ml aliquots were centrifuged at 18,000 g. One of these pelltets was 
lysed in IEPAL lysis buffer, and one lysed in native lysis buffer using L3 sonication, both 
with protease inhibitor, and lysed on ice. These were run alongside the non induced control 
(also lysed in IGEPAL with an identical dilution factor) on an SDS page gel, and western 
blotting was performed with the appropriate antibody. All conditions were individually 
optimised for each fusion protein. 
2.11.4 Purification-scale growth 
Following optimisation of the growth and induction protocol, growth was performed on a 
large scale to facilitate protein purification. Growth was performed as above, except the 3 
ml culture was used a starter culture. From this, 100 μl was added to 50 ml L. Broth 
containing the appropriate antibiotic, and was incubated at 37˚C with shaking to an OD600 
of ≥0.6 – ≤1.0. The culture was induced by the addition of IPTG (typically 0.1 mM) and 
incubated for a further 2 h with shaking at 37˚C. Cells were harvested by centrifugation at 
3,000 x g for 5 min at 4˚C. 
 
2.11.5 Native cell lysis 
The 50 ml cell pellet was resuspended in 8 ml native lysis buffer. 8 mg lysozyme was 
added to the cell pellet, and incubated on ice for 30 min. Cells were lysed by L3 sonication 
on ice. To reduce viscosity, 10 μg/ml RNase A and 5 μg/ml DNase I (Invitrogen) were 
added, and mixed. Insoluble material was pelleted by centrifugation at 3,000 x g for 15 
min, at 4˚C, and the supernatant used for protein purification. 
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2.11.6 Preparation of Ni2+/NTA columns 
HIS6 tagged peptides were purified using 2 ml Ni
2+
/NTA agarose (Invitrogen) immobilised 
in a disposable chromatography column, under native conditions, following manufacturer‟s 
instructions. 10 ml Ni
2+
//NTA Columns were prepared by pipetting 1.5 ml of well-mixed 
resin into a 10-ml Purification Column with a frit at the bottom. The resin was allowed to 
settle, and the supernatant was aspirated.  6 ml distilled water was added to the column, 
and the resin resuspended by tapping the column. The resin was allowed to settle, and the 
supernatant again removed. 6 ml Native Binding Buffer (50 mM NaH2PO4, pH 8.0, 0.5 M 
NaCl) was then added to the column, and the resin resuspended by tapping the column. 
When the resin had settled, the supernatant was removed and the column stored at 4˚C 
until use.  
 
2.11.7 Purification of HIS6 tagged peptides 
8 ml lysate was added. The column was rotated at 4˚C for 30–60 min. The resin was 
allowed to settle, and the supernatant aspirated, and stored for SDS-PAGE analysis. The 
resin was then washed with 8 ml Native Wash Buffer (50 mM NaH2PO4, pH 8.0, 0.5 M 
NaCl, 10 mM Imidazole), and allowed to settle. The supernatant was aspirated and again 
saved for SDS-PAGE analysis. This wash was repeated three times. The column was then 
clamped in a vertical position, and the bottom cap of the column was removed. The protein 
was eluted with 8–12 ml Native Elution Buffer (50 mM NaH2PO4, pH 8.0, 0.5 M NaCl, 
250 mM Imidazole), which was collected in 1 ml fractions. These were analysed by SDS-
PAGE, and stored at 4˚C with protease inhibitors until use. 
 
2.11.8 Overlay experiments 
The array was bathed in ethanol for 5-10 min, and equilibrated in TBST (50mM Tris, 150 
mM NaCl 0.1% Tween-20 (v/v),pH 7.5) in a 10 min wash on a flat bed shaker. The array 
was then blocked in 5% Marvel-TBST (w/v), 0.1% Tween-20 (v/v) for two hours. After a 
brief rinse with TBST, recombinant HIS6 tagged proteins were diluted at 10 μg/ml in 1% 
Marvel-TBST (w/v) 0.1% Tween-20 (v/v), applied to the array in a sealed bag, and 
incubated overnight with shaking at 4°C. Following 3 x 15 min washes with TBST, an 
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anti-HIS4 HRP-conjugated 1° antibody (Biorad) was applied to the array, diluted 1:5000 in 
1% block. This was incubated in a sealed bag at 4°C for two hours. Following 3x15 min 
washes in TBST, the array was treated with ECL as in an Immunoblot, and several 
different exposures were obtained.  
 
2.11.9 Stripping arrays 
Stripping buffer (0.31g DTT 2g SDS 0.75g Tris-HCl in 100ml H20, pH 6.8) was pre-heated 
to 70°C and applied to the array, face up in a hybridisation tube.  The arrays were bathed 
with rotation in a hybridisation oven set to 70°C for 30 min. The stripping buffer was 
removed, and the array was briefly rinsed twice, then for 2 x 10 min, in TBST. The array 
was then removed, dried on blue roll on the non-protein side, and stored, sealed, at 4°C; 
arrays were stripped and reused a maximum of 4 times. When needed for reuse, the 
membranes were bathed in ethanol and incubated in TBST as before. 
 
2.12 Phylogenetic analysis 
Phlogentic analysis was performed using ClustalW alignment in MacVector, using a 
Gonnet matrix with the default settings (open gap penalty = 10, extend gap penalty 0.1, 
delay divergent 40%, using end gap separation, residue specific penalties and hydrophilic 
penalties). A best tree phylogram was generated using neighbour joining tree building, and 
uncorrected “p” distance calculation. As a control bootstrap analysis (1000 repetitions) was 
performed. 
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3.1 Summary 
This chapter describes the work done on the Drosophila melanogaster dual specificity 
phosphodiesterase PDE11RA. The PDE11 family was discovered in 2000. It is a dual 
specificity phosphodiesterase, but the in vivo function of the enzyme is currently not well 
understood. Drosophila melanogaster utilises cAMP and cGMP signalling to control 
numerous vital processes, which are well studied in the organism. As such, Drosophila 
should prove a useful tool to reveal the function in vivo function of PDE11. 
Difficulties were encountered in proving that DmPDE11RA was in fact a bona fide PDE, 
which was likely explained by Flybase release 5.2 (http://flybase.org/), which replaced the 
RA transcript with two newly predicted transcripts, RB and RC, as detailed in chapter four. 
The aims of my PhD when this enzyme was shown to be falsely predicted did not change, 
save the need to clone the newly predicted RB and RC isoforms, and from these repeat any 
necessary subcloning in order to perform subsequent experiments. As such this chapter 
essentially serves as a blueprint for the work done on the RB and RC transcripts, although 
limited time dictated that some experiments be prioritised, and other experiments were 
replaced because they did not appear to work, or had been superseded by alternative 
techniques. 
3.2 Introduction  
Phosphodiesterases are the only known enzyme responsible for cyclic nucleotide 
hydrolysis, and as such are of great importance in the modulation of cyclic nucleotide 
signalling. The PDE11 phosphodiesterase family is the most recently discovered of the 
PDEs. Discovered in 2000 (Fawcett et al., 2000a; Hetman et al., 2000; Yuasa et al., 
2000b), its function is not well understood. It is a dual specificity enzyme, with four 
isoforms in human, and one in Drosophila melanogaster.  
Drosophila has been used to great effect in the study of PDE4, known as dunce in 
Drosophila. Furthermore, many phenotypes in Drosophila have been linked to both 
cAMP-, and cGMP-dependent processes and enzymes. Yet until 2005, only two PDEs had 
been identified in Drosophila, PDE1, a Ca
2+
/Calmodulin sensitive, dual specificity PDE 
(Walter and Kiger, 1984), and PDE 4, dunce, a cA-PDE (Davis et al., 1989). Work 
undertaken in the Dow/Davies lab revealed that Drosophila expresses six of the PDE 
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families; PDE 1, PDE 4, PDE6 (cG-PDE), PDE 8 (predicted cA-PDE), PDE 9 (predicted 
cG-PDE), and PDE11 (dual specificity PDE) (Day et al., 2005). These genes showed high 
sequence similarity with their mammalian counterparts, with amino acid identity ranging 
from 26 – 47% (34 – 66% similarity). However sequence identity in the catalytic domain 
was higher at 51 – 77% sequence identity (69 – 96% similarity). The lower number of PDE 
genes in Drosophila should result in lower redundancy than mammalian systems, and thus 
make the elucidation of function easier. These genes show widespread expression 
(http://www.flyatlas.org/), underlying their importance (table 3.1). 
Table 3.1: Tissue expression profiles of the Drosophila phosphodiesterases. Data from 
(Chintapalli et al., 2007)   
PDE1 dunce PDE6 PDE8 PDE9 PDE11
Tissue Enrichment
Brain 0 4.1 7.3 5.4 8.9 2.5
Head 0.4 1.3 2.5 1.9 4.6 1.2
Eye 0.23 1.83 0.91 1.79 6.55 3.09
Thoracicoabdominal ganglion 0 3.3 8.9 3.3 13 1.5
Salivary gland 0.06 6.07 2.23 1.45 2.96 2.53
Crop 0 0.9 0.8 2.4 2.9 1.7
Midgut 6 0.8 0.5 1.9 0.6 1.8
Tubule 1 1.5 2.1 3.7 2 1.5
Hindgut 1.8 0.7 2.1 3.5 0.8 2.7
Heart 0.9 2.37 1.34 2.36 6.21 3.14
Fat body 1.36 0.79 3.08 2.2 5.15 0.92
Ovary 0 1 0.1 0.5 0.4 1.8
Testis 0 0.2 0.1 2.9 1.8 0.4
Male accessory glands 0.5 0.8 1.4 1.5 1.6 0.7
Virgin spermatheca 1.56 0.79 4.55 0.69 7.17 0.99
Mated spermatheca 1.49 0.9 3.9 0.75 4 1.04
Adult carcass 0.6 1.6 1.3 2.3 3.9 1
Larval CNS 0.01 1.87 1.82 2.46 2.43 0.75
Larval Salivary gland 1.12 0.8 0.28 0.47 4.21 1.66
Larval midgut 6.81 0.86 0.11 1.79 2.4 0.86
Larval tubule 1.1 0.7 0.3 3.1 3.8 1.7
Larval hindgut 2.15 0.89 0.49 2.31 1.89 1.63
Larval fat body 0.2 0.5 0.3 1.1 4.5 0.7
Larval trachea 0.05 1.75 0.14 3.48 5.35 1.48
Larval carcass 0.01 3.49 2.58 3.25 0.99 0.73
S2 cells (growing) 0 1.05 0.01 6.78 3.67 2.31
Whole fly 1 1 1 1 1 1  
The number of cG-PDEs represented above is reflected in the numerous processes that are 
modulated by cGMP in Drosophila. These include fluid secretion of the Malpighian tubule 
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(Davies et al., 1995), feeding behaviour (Osborne et al., 1997), immunity (McGettigan et 
al., 2005), hypoxia (Dijkers and O'Farrell, 2009), and nervous system signalling (Bicker, 
1998). 
3.3 DmPDE11RA 
CG34341 encodes DmPDE11RA, a gene spanning 9kb at position 37A1 on chromosome 2 
(Figure 3.1).  
Figure 3.1: Ensemble CG34341/DmPDE11RA gene model. 
http://www.ensembl.org/Drosophila_melanogaster/geneview?gene=CG34341. Accessed 
04.03.2008.  
 
The expression profile of DmPDE11 is shown in table 3.2. 
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Table 3.2: PDE11 expression in Drosophila melanogaster. Table showing enrichment of 
DmPDE11 expression in each tissue when compared to whole fly (Chintapalli et al., 2007). 
PDE11
Tissue
Brain 2.5
Head 1.2
Eye 3.09
Thoracicoabdominal ganglion 1.5
Salivary gland 2.53
Crop 1.7
Midgut 1.8
Tubule 1.5
Hindgut 2.7
Heart 3.14
Fat body 0.92
Ovary 1.8
Testis 0.4
Male accessory glands 0.7
Virgin spermatheca 0.99
Mated spermatheca 1.04
Adult carcass 1
Larval CNS 0.75
Larval Salivary gland 1.66
Larval midgut 0.86
Larval tubule 1.7
Larval hindgut 1.63
Larval fat body 0.7
Larval trachea 1.48
Larval carcass 0.73
S2 cells (growing) 2.31
Whole fly 1  
 
Drosophila PDE11 shows widespread expression in the fly, with enrichment in brain, eye, 
salivary gland, heart, gut tissues, and Malpighian tubules (Chintapalli et al., 2007). 
Likewise, H. sapiens PDE11 shows widespread expression, and is enriched in the pituitary 
gland, the salivary gland, testis, liver and kidney (D'Andrea et al., 2005; Fawcett et al., 
2000b). 
 
3.3.1 The Expressed Sequence Tag SD13096 encodes the entire 
PDE11RA ORF 
When attempts to clone the full length ORF of PDE11RA were undertaken (Day, 2005), 
two incomplete Expressed Sequence Tags (ESTs) were available that included sequence 
extending from approximately half way through the ORF through to the poly-A tail and 
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3‟UTR. Attempts to clone the 5‟ end of the gene using Reverse Transcriptase-Polymerase 
Chain Reaction (RT-PCR) and Rapid amplification of 5' complementary DNA ends (5‟ 
RACE) on the available ESTs failed. The EST SD 10396 was released by the BDGP EST 
sequencing program concurrently with these efforts. SD 10396 is a 5.8Kb EST, containing 
sequence present in the previously released, incomplete DmPDE11RA ESTs, but also 
incorporating a 5‟ UTR, and an in-frame start codon within two novel 5‟ exons. A 
Northern blot of PDE11RA produced one band of approximately 5.8kb; as the sizes 
matched it was accepted that SD13096 encodes the entire DmPDE11RA ORF. However, 
expression of full-length protein in S2 cells was not achieved (Day et al., 2005).  
 
3.3.2 DmPDE11RA encodes a protein of the predicted size 
DmPDE11RA was sub-cloned from the full length EST SD13096 into Drosophila 
Expression System (DES) pMT/V5-His-TOPO vector in-frame with the C-terminal V5 and 
His tags (primers used listed in materials and methods table 2.5). Two constructs were 
generated; one full length and one N terminal construct extending to the end of the 
catalytic domain. These constructs were expressed in Drosophila S2 cells to verify 
expression (figure 3.2).  
 
Figure 3.2: Western analysis of pMT/V5-His DmPDE11RA transfected S2 cells. Lanes 
1 + 2: N terminal half of DmPDE11RA-V5 (expected size 95kDa) Lanes 3 + 4: Full length 
DmPDE11RA-V5 (expected size: 173kDa). Antibody used anti-V-5 mouse monoclonal.  
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When S2 cell lysate was subjected to western analysis, the full length protein (lanes three 
and four), predicted to be 173kDa, showed one faint band at approximately the correct 
size, and an equally faint band around 60KDa, which potentially represents a breakdown 
product. The faintness of the band can be attributed to an extremely low transfection 
efficiency of less than 5%, determined by immunocytochemistry of anti-V5 antibody-
probed transiently transfected S2 cells, where ≥95% of DAPI-stained cells showed no 
fluorescence. The N terminal construct was predicted to yield a protein of 95kDa. One 
band was produced at approximately this size, with two additional bands, one over 100kDa 
and one around 80kDa. The larger band may be explained by post translational 
modification, such as phosphorylation. The smaller band may be explained by an 
alternative in-frame start codon, 267bp into the ORF. Alternatively, as PDEs usually run to 
a larger size than that predicted under SDS-PAGE analysis, bands other that the largest 
may again represent breakdown products.  
 
3.3.3 DmPDE11RA shows cytoplasmic localisation 
Full length DmPDE11RA tagged with a V5 epitope tag was transiently transfected into S2 
cells. These were subjected to immunocytochemistry in order to determine protein 
localisation (figure 3.3).  
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Figure 3.3: Subcellular localisation of DmPDE11A-V5 in S2 cells. S2 cells were 
transiently transfected with pMT/V5-His DmPDE11RA. Subcellular localisation of the 
protein was ascertained by staining with anti-V5 monoclonal antibody, TRITC secondary 
(Red). Nuclei were stained with DAPI (blue). Two examples of transfected cells are shown 
(A and B), and an untransfected cell is shown in C, where immunocytochemical techniques 
used were identical. 
A 
 
B 
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C 
 
 
 
The protein showed cytosolic localisation in S2 cells. Levels of expression were judged to 
be low, both in terms of cellular protein level, and transfection efficiency. Untransfected 
cells showed no visible background expression; one such example is shown in figure 3.3C. 
 
3.3.4 Analysis of full length DmPDE11RA 
Previous attempts to express full length DmPDE11RA in S2 cells had not produced protein 
on western blots (Day et al., 2005). The catalytic domain of DmPDE11 was expressed in 
S2 cells, and showed no cG-PDE activity above basal, and cA-PDE activity at 1, 2, and 
4μM of substrate, but this activity fell at higher concentrations (Day, 2005). Following 
this, DmPDE11 was verified as a bona fide dual specificity PDE by cA- and cG-PDE 
assays performed on immunoprecipitated DmPDE11 from head lysate, using specific 
antisera (Day et al., 2005). This data is summarised in appendix 2. As shown above, in my 
hands the construct yielded expressed protein in western blots and ICC. As such, cAMP 
and cGMP PDE assays were performed on transiently transfected S2 cells with the full 
length pMT/V5-His DmPDE11RA construct. Initial experiments to ascertain an effective 
concentration of cAMP and cGMP for use in PDE assays on DmPDE11RA, and a 
construct expressing a truncation of DmPDE11RA, from the N terminus to the end of the 
catalytic domain, were performed. When compared to control, DmPDE11RA 
overexpressing S2 cells showed no significant increase in either cA-, or cG-PDE activity 
(data not shown). 
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Following this, I surmised that S2 cells may lack factors required for either the activation 
or stabilisation of DmPDE11RA. DmPDE11RA contains 4 putative cGK phosphorylation 
motifs. To identify whether DG2P1 or DG2P2 would either phosphorylate, thereby 
modulating DmPDE11 function, or stabilise DmPDE11 by association, I co-expressed 
these with DmPDE11 in S2 cells, and performed cA- and cG-PDE assays (figure 3.4). 
 
Figure 3.4: DmPDE11A does not show cG- or cA-PDE activity when transiently 
transfected in S2 cells, and is not stimulated by DG2. cG- (A) and cA- (B) PDE assay 
on transiently transfected S2 cell lysate using 1μM substrate in each case. In order to aid 
comparison, data is expressed as % cN-PDE activity of mock transfected S2 cell, where 
(A) mock = 23.8 pmol cGMP/mg/min, and (B) mock = 32.4 pmol cAMP/mg/min. N=1 
       A                                                             B 
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When compared to control, DmPDE11RA overexpressing S2 cells showed no significant 
increase in either cA-, or cG-PDE activity, as found previously. Co-expression of either 
DG2P1 or DG2P2 with DmPDE11 drastically reduced both cA- and cG-PDE activity. This 
data should be considered preliminary, as only one replicate was performed in either 
experiment, and cGK-only transfected S2 cells were not assayed. As these were only 
transient transfections, a large number of cells would have unaltered PDE activity. This 
suggests that in those cells which do express cGK, endogenous PDE activity is massively 
reduced, in turn suggesting that the over-expressed cGK modulates phosphodiesterase 
activity or protein levels. The experiment was not repeated, as it mirrors a finding in flies 
overexpressing DG2P1 and DG2P2 in tubule principal cells, which show a drastic 
reduction in endogenous PDE activity (Macpherson and Day, 2004). 
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3.4 C42 driven DmPDE11 RNAi does not significantly 
affect cA-PDE activity in tubule  
In order to measure the effect on cA-PDE activity in the tubule, DmUAS-PDE11 RNAi 
(line 9), c 42, and DmUAS-PDE11 RNAi (line 9)/c42 progeny were aged upon eclosion to 
5-7 days, and the tubules were excised and homogenised. A cA-PDE assay was performed 
with 3 biological replicates, using 2 uM cAMP, and 3 μCi/ml [3H] cAMP (figure 3.5).  
 
Figure 3.5: C42 driven DmPDE11 RNAi does not significantly affect cA-PDE activity 
in the tubule. 50 Malpighian tubules from DmUAS-PDE11 RNAi (line 9), c42, and 
c42/DmUAS-PDE11 RNAi (line 9) progeny were assayed for cA-PDE activity at 2M 
cAMP in biological triplicate. Specific cA-PDE activity given in pmol cAMP/mg 
protein/min. 
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There was no significant change in cA-PDE activity between parents and progeny. 
Reasons for this are unknown, although 2μM is below the Km of 18.5 ± 5.5M ascertained 
from IP of head lysate. However the catalytic domain, expressed in S2 cells, only yielded 
cAMP-specific PDE activity at concentrations of between 1 M and 4 M of cAMP, hence 
the use of 2M. Counts were around 15000, close to the 18000 maximum acceptable in 
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this assay. Repeat with higher substrate concentration (with a shorter 30
◦
C incubation 
period to reduce activity and thus counts) may yield different results, and would be 
desirable. The complementary cG-PDE assays were not performed, as replicates of the cA-
PDE assay were carried out instead with available tissue lysate. 
A PDE11 deletion line (DmPDE11∆121) in our possession also gave no significant change 
in cA-PDE activity when midgut was excised and assayed. However cG-PDE assays 
revealed a large reduction when head lysate was assayed (Sebastian, 2009).  
 
3.4.1 Transgenic tools for the study of DmPDE11 
3.4.1.1 Q-PCR to validate the knockdown of DmPDE11 by RNAi 
Two DmPDE11 RNAi stocks were generated by Day, 2005, labelled DmPDE11 RNAi line 
1 and DmPDE11 RNAi line 9. These were targeted against the same sequence, but differed 
in the insertion point of the pWIZ PDE11 transgene. When DmPDE11 RNAi were crossed 
to the ubiquitous driver line Act5cGAL4, crosses were ~90% lethal at room temperature. 
As such knock down was validated by crossing DmPDE11 RNAi with the principal cell 
driver c42. c42/DmPDE11 RNAi line 1 progeny tubule cDNA and parental strains were 
subjected to Q-PCR analysis. Progeny showed a knockdown of 69% compared to parental 
controls (Aitcheson, 2006). However, the melting curve showed two distinct peaks, and 
thus two products were produced. New primers were designed, and Q-PCR was performed 
using c42/PDE11 RNAi (line 9) and parental strain tubule cDNA; this Q-PCR showed a 
knockdown of 34%, and gave a single product of the predicted size (figure 3.6 A and B). 
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Figure 3.6: Q-PCR to determine knock down of PDE11 RNAi (line 9). (A) Q-PCR 
performed on cDNA from excised tubules, using primers specific to the C-terminal of 
DmPDE11. cDNA biological triplicate from PDE11 RNAi (line 9) parent, c42 GAL4 
parent (drives expression in the principal cell of the Malpighian tubule,) and c42/PDE11 
RNAi (line 9) progeny. Significance to a P value of <0.01. Analysis performed using 1-
way ANOVA. (B) Melting curve for a single well/product for PDE11RNAi q-PCR: Upper 
melting curve (Aitcheson) shows two distinct peaks; lower melting curve relating to this 
Q-PCR shows a single peak and thus a single product. 
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Q-PCR using the new primers for line 1 has yet to be repeated. c42 drives GAL4 
expression in principal cells, yet Q-PCR of tubule cDNA will amplify DmPDE11 
transcripts from all cell types in the tubule. In order to determine total knockdown, Q-PCR 
would have to be performed on cDNA using a high level ubiquitous driver crossed to 
DmPDE11 RNAi. 
 
3.4.2 Phenotype screen 
As mentioned above, ubiquitous knock down of DmPDE11 using the pWIZ RNAi line 9 
results in ~90% lethality at the larval stage when crossed to the ubiquitous driver Actin 
GAL4, consistent with widespread expression pattern of DmPDE11. Additionally, the 
larvae show delayed eclosion by a day. Upon eclosion males display a green abdomen 
usually present in 10 day plus males. However upon dissection organs appeared normal in 
colour. 
 
Following this result, PDE11 RNAi (line 9) was crossed to several tissue-specific GAL4 
drivers, in order to screen for phenotypes (table 3.3). 
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Table 3.3: Screen for phenotypes in the progeny of PDE11 RNAi (line 9) crossed to 
various GAL4 driver lines. All tissue-specific Gal4 crosses did not show any obvious 
phenotypes  
 
Driver Expression pattern Phenotype?
Ato Gal4 paired DC neurons x
D42 Gal4 embryogenesis: broad, larvae: motorneurons, x
interneurons, adult: nervous system
 Appl Gal4 neuron specific x
Repo Gal4 glial cell expression x
Sgs3 Gal4 salivary gland expression x  
 
None of these crosses yielded visible phenotypes, and all eclosed normally.  
 
3.5 DmPDE11 doesn’t affect osmoregulation 
DmUAS-PDE11 RNAi (line 9) flies were crossed with c42 GAL4, and Malpighian tubules 
from DmUAS-PDE11 RNAi (line 9) parents, and c42/DmUAS-PDE11 RNAi (line 9) 
progeny were assayed for secretion induced by a final concentration of 10
-5
 M exogenous 
cGMP, as detailed in materials and methods. No change was seen between either the basal 
or stimulated fluid secretion rate of Malpighian tubules from c42 and c42/DmUAS-
PDE11RNAi (line 9) flies (figure 3.7). The data represents the pooling of three datasets. 
 
 
 
 
 
 
118 
Figure 3.7: Fluid secretion assay. The basal fluid secretion rate of intact Malpighian 
tubules was measured for 30 minutes, whereupon the tubules were stimulated with 10
-5
 
cGMP (final concentration, time point of addition represented by arrow), and the secretion 
rate measured for a further 30 minutes. Tubules from DmUAS-PDE11 RNAi (line 9) 
parental line, and from c42/DmUAS-PDE11 RNAi (line 9) progeny showed no difference 
in fluid secretion. Error bars represent SEM. 
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3.6 Calcium signalling 
The Malpighian tubule utilises cGMP, cAMP and calcium signalling, (Davies and Day, 
2006) and there is cross talk between these signalling pathways (Arnold et al., 1977; 
Valeyev et al., 2009; Walter and Kiger, 1984). The nitrigergic peptide capa-1 induces a rise 
in [Ca
2+
]i, and stimulates NO production and thus cGMP production in the Malpighian 
tubule, when applied exogenously (Kean et al., 2002). To determine whether DmPDE11 
affects this process in the tubule, DmUAS-PDE11 RNAi flies were crossed with c42 
GAL4-aequorin flies, which express a luminescent calcium reporting transgene in tubule 
principal cells. The Malpighian tubules of these flies were excised, and the calcium 
transients induced by capa-1 peptide were measured in a luminometer (figure 3.8), as 
described in materials and methods.  
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Figure 3.8: Capa-1 induced [Ca
2+]
i transients are not affected by a reduction in 
DmPDE11 levels. A: In order to measure capa-1-induced [Ca
2+]
i transients, 30 tubule pairs 
from c42 aequorin (c42 aeq) and c42 aequorin/DmPDE11 RNAi (line 9) (c42 
aeq/DmUAS-PDE11 RNAi (line 9) flies were treated with 10
-7
 M capa-1 peptide (arrow). 
Each trace represents the average of four replicates. B: Basal [Ca
2+
] levels for each 
genotype were calculated from the data point 1 min pre-stimulation with capa-1. 
Measurement of the secondary peak was taken from the data point four min post-
stimulation with capa-1. Results expressed as mean nM [Ca
2+
]i, where N=4 for each 
genotype. Basal [Ca
2+
]i, the primary response peak, and the secondary response peak were 
not significantly different when analysed with an unpaired T-Test. 
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The basal [Ca
2+
]i, primary response peak, and secondary response peak of c42 aequorin 
and c42 aequorin/DmPDE11 RNAi (line 9) Malpighian tubules were compared using an 
unpaired T-test. There was no significant difference between any of these. This suggests 
that DmPDE11 does not modulate capa-1 induced [Ca
2+
]i transients in the Malpighian 
tubule. 
3.7 DmPDE11A and DG2 colocalise in S2 cells 
3.7.1 Individual transfections 
In order to determine subcellular localisation, S2 cells were transiently transfected with 
DmPDE11RA tagged with a V5 epitope, or one of the cGKs DG2P1 or DG2P2, tagged 
with a c-Myc epitope. Subcellular localisation was determined for DmPDE11RA with an 
anti-V5 antibody (red) (figure 3.9), and for DG2P1 and DG2P2, where anti-c-Myc 
antibody was used (green) (figure 3.10). Nuclei were stained with DAPI (blue). 
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Figure 3.9: Confocal image of S2 cells transfected with V5-DmPDE11 (red). 
Subcellular localisation ascertained by staining with anti-V5 monoclonal antibody, TRITC 
secondary Nuclei were stained with DAPI (blue). 
 
Figure 3.10: Confocal images of S2 cells transfected with c-Myc-DG2P1 (green), and 
c-Myc-DG2P2 (green). Subcellular localisation ascertained by staining with anti-c-Myc 
monoclonal antibody, TRITC secondary (green). Nuclei were stained with DAPI (blue). 
Untransfected cells showed no background immunofluorescence; nuclei of untransfected 
cells are visible in both pictures. 
                   c-Myc-DG2P1                               c-Myc-DG2P2 
 
            
In agreement with published data  (MacPherson et al., 2004b), c-Myc-DG2P1 localised 
predominantly to the membrane in S2 cells. Published images of DG2P2 are of V5-tagged 
DG2P2, stained with anti-V5 monoclonal antibody and also a vertebrate anti-cGK 
antibody, anti-cGKI, from (Markert et al., 1995). Images with anti-V5 antibody show 
solely localisation to the membrane, while those stained with anti-cGKI rabbit polyclonal 
antibody also showed localisation within the cytosol, stronger towards the membrane. The 
DG2P2 construct in my possession was tagged with c-Myc. Staining with an anti-c-Myc 
antibody produced similar staining to the published anti-cGKI stained images, 
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predominantly showing localisation to the membrane, with staining in the cytosol, stronger 
towards the membrane. This may be a characteristic of the antibody; however, 
untransfected cells show no background staining. The c-Myc tag may alter protein 
localisation; however the tag is one amino acid smaller than the V5 tag used in 
Macpherson et al, 2004, and so this is doubtful. A third alternative, and perhaps the most 
likely, is that conditions in those images using anti-c-Myc and anti-cGKI antibodies were 
more sensitive, and so fluorescence was detected that was not detected in anti-V5 images. 
Polyclonal antibodies designed against a novel epitope were unfortunately not delivered on 
time to test untagged DG2P2. 
 
3.7.2 Co-transfections 
It was reasoned that as DmPDE11 will affect cGK activity, the proteins may colocalise so 
that DmPDE11 samples the same pools of cGMP. S2 cells were transiently co-transfected 
with DmPDE11RA tagged with a V5 epitope, and either DG2P1 or DG2P2, tagged with a 
c-Myc epitope. 
 
3.7.2.1 PDE11RA and DG2P1 colocalise in S2 cells 
In order to screen for co-localisation, V5-DmPDE11RA and c-Myc-DG2P1 were 
transiently transfected in S2 cells, and the subcellular localisation of the proteins 
determined by immunohistochemistry (figure 3.11).  
 
 
 
 
 
123 
Figure 3.11: An S2 cell expressing c-Myc-DG2P1 and V5-DmPDE11A. Confocal 
images of V5-DmPDE11A (red) co-transfected with c-Myc-DG2P1 (green). V5-
DmPDE11A subcellular localisation ascertained by staining with anti-V5 monoclonal 
antibody, TRITC secondary. c-Myc-DG2P1 subcellular localisation ascertained with anti-
c-Myc monoclonal antibody, FITC secondary (green). Nuclei were stained with DAPI 
(blue) 
           c-Myc-DG2P1           V5-DmPDE11RA                    Merge 
 
 
 
 
 
 
 
When co-transfected, V5-DmPDE11RA and c-Myc-DG2P1 show a large degree of co-
localisation in S2 cells. The distribution of each changes; V5-DmPDE11A shows an 
association with the membrane, and c-Myc-DG2P1 shows an increase in cytoplasmic 
localisation compared to the single transfections in figure 3.12. 
3.7.2.2 DmPDE11A and DG2P2 colocalise in S2 cells 
In order to screen for co-localisation, V5-DmPDE11RA and c-Myc-DG2P2 were 
transiently transfected in S2 cells, and the subcellular localisation of the proteins 
determined by immunohistochemistry (figure 3.12).  
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Figure 3.12: An S2 cell expressing c-Myc-DG2P2 and V5-DmPDE11A. Confocal 
images of V5-DmPDE11A (red) co-transfected with c-Myc-DG2P2 (green). V5-
DmPDE11A subcellular localisation ascertained by staining with anti-V5 monoclonal 
antibody, TRITC secondary. c-Myc-DG2P2 subcellular localisation ascertained with anti-
c-Myc monoclonal antibody, FITC secondary (green). Nuclei were stained with DAPI 
(blue). Merge shows two additional nuclei from untransfected cells. 
      c-Myc-DG2P2               V5-DmPDE11RA                   Merge 
 
 
 
 
 
Figure 3.14 shows that V5-DmPDE11RA and c-Myc-DG2P2 show a large degree of co-
localisation in S2 cells. There are multiple areas in the cytosol where both proteins are 
excluded. These could be an unknown form of vesicle, or endosomes. As both proteins 
show a cytoplasmic localisation, however, this does not suggest that either protein 
modulates the localisation of the other. 
 
3.8 Projects undertaken that were halted when the new 
DmPDE11 sequence predictions were released 
As the DmPDE11RA gene model was replaced with two newly predicted isoforms in 
Flybase release 5.2, several constructs and projects were postponed until the gene model 
could be investigated and postponed. Subsequently, the data presented in chapter 4 led to 
the verification of the new gene model, and the cancelation of these projects. Details of 
these are found in appendix 1.  
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3.9 Generation of transgenic DmPDE11RA flies 
In order to generate DmPDE11RA overexpressing Drosophila, the ORF was sub-cloned 
into the pP{UAST} vector. Two constructs were generated, one with a stop codon, and one 
with without, in order to fuse DmPDE11RA in-frame with YFP. The inserts were 
sequenced for fidelity (data not shown); generation of the flies was postponed until 
DmPDE11RA could be validated as a bona fide PDE. In the same week Flybase 5.2 was 
released; as above, the data presented in chapter 4 verified the new gene model and 
rendered the constructs invalid. 
 
3.10 Discussion 
The 5.8 kb expressed sequence tag (EST) SD13096 had previously been shown to contain 
sequence present in the incomplete PDE11RA ESTs previously released by Flybase, but 
also incorporating a 5‟ UTR, and an in-frame start codon within two novel 5‟ exons. A 
Northern blot of DmPDE11RA produced one band of approximately 5.8kb; as this matches 
the size of the DmPDE11RA ORF, was accepted that SD13096 encodes the entire 
PDE11RA ORF (Day). Expression of this EST in S2 cells revealed that the construct 
produced a protein of the accepted size, and that the protein localised to the cytoplasm, as 
is the case for several cA- and cG-PDEs (Omori and Kotera, 2007).  
 
A screen for phenotypes, whereby UAS-DmPDE11 RNAi (line 9) flies were crossed to 
various GAL4 driver lines, and the progeny screened for phenotypes. Eclosed flies 
appeared normal, other than flies crossed to Act-5c GAL4, which had a green tint to their 
abdomen. The flies were dissected, but the tissue responsible was not identified. 
Calcium signalling is modulated by cGMP (Schlossmann et al., 2000), and in Malpighian 
tubules capa-1 and capa-2 stimulate fluid transport via calcium and cGMP signalling 
pathways (Davies et al., 1995; Kean et al., 2002), where the entry of extracellular calcium 
is permitted by the activation of a cyclic nucleotide gated channel, cng, where cGMP 
enhances cytosolic calcium and increases fluid transport (MacPherson et al., 2001). cAMP 
and calcium signalling networks display extensive crosstalk in non-excitable cells, where 
each modulates the spatiotemporal dynamics of the other (Bruce et al., 2003; Valeyev et 
al., 2009). As DmPDE11 is a dual specificity PDE, it was hypothesised that the protein 
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may exert a modulatory effect on tubule calcium signalling in response to capa-1. Thus, the 
protein‟s role in calcium signalling was investigated by stimulating aequorin expressing 
Malpighian tubules from c42 aequorin, and c42 aequorin/DmUAS-PDE11 RNAi (line 9) 
flies with capa-1, and measuring the calcium response to the neuropeptide. The basal 
[Ca
2+
]i, primary response peak, and secondary response peak were compared between the 
two genotypes using an unpaired T-test, where neither were found to be significantly 
different. This suggests that DmPDE11 does not modulate the [Ca
2+
]i response to capa-1 in 
the Malpighian tubule. 
PDEs are responsible for the hydrolysis of cyclic nucleotides, which subsequently affects 
the activity of cyclic nucleotide-responsive effector proteins (Beavo et al., 2007). cGKs, in 
turn, have been shown to modulate the catalytic activity of PDE11A4 and PDE5A, two 
PDEs capable of hydrolysing cGMP, through phosphorylation (Corbin et al., 2000; Gross-
Langenhoff et al., 2008; Turko et al., 1998; Yuasa et al., 2000a), thus providing a feedback 
loop facilitating a reduction in the activity of the activated cGKs. The co-localisation of 
PDE5 and PKG1β has previously been shown to play an important physiological role, 
where PDE5 has been shown to localise to the ER in a PKG1β signalling complex 
responsible for the cGMP mediated inhibition of IP3R dependent Ca
2+
 release in platelets, 
where PKG1β phosphorylates and activates PDE5, thus initiating a negative feedback loop. 
This co-localisation appears to result from both proteins interacting with IP3R and not a 
direct interaction (Wilson et al., 2008). Thus, the subcellular localisation of DmPDE11 and 
DG2 were characterised and compared in S2 cells. Co-expression of V5 tagged DmPDE11, 
and c-Myc tagged DG2 P1 and P2 showed that the two co-localise. DG2P1 shows a 
stronger presence in the cytosol when co-expressed with DmPDE11A, which shows an 
association with the membrane in doubly transfected cells. 
Attempts to identify DmPDE11RA as a bona-fide PDE were made using two methods; cA- 
and cG-PDE assays on S2 cell transiently transfected with DmPDE11RA, and a cA-PDE 
assay of the parents and progeny of a DmUAS-PDE11 RNAi (line 9) x c42 cross, as 
DmPDE11 is upregulated in the Malpighian tubule 1.5 times (http://www.flyatlas.org/). 
DmPDE11A did not yield any cA- or cG-PDE activity when expressed in S2 cells. With 
the rationale that DG2 has been shown to modulate cG-PDE activity in the tubule 
(MacPherson et al., 2004a), and that DG2 may therefore modulate DmPDE11 activity, 
DmPDE11 was co-expressed in S2 cells with DG2P1 or DG2P2, and the lysate use to 
perform cA- and cG-PDE assays. Although these were only performed as N=1, again, no 
increase in cA- or cG-PDE activity was seen in DmPDE11 transfected cells. Furthermore, 
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where DmPDE11 was co-transfected with DG2P1 and DG2P2, a reduction in PDE activity 
was seen. This mirrors an unpublished observation by MacPherson and Day.  
In order to determine if a knock-down in DmPDE11 transcript levels and therefore protein 
levels affected PDE activity in the tubule, DmUAS-PDE11 RNAi (line 9) were crossed to 
c42, and the Malpighian tubules of parent and progeny subjected to a cA-PDE assay. No 
difference in cA-PDE activity was seen. However, it may be that the concentration of 
cAMP used was such that other cA-PDEs expressed in the tubule may have dwarfed the 
contribution of DmPDE11 to total PDE activity, and so no difference was seen. As such, it 
is desirable that this assay be repeated at higher cAMP concentration, and also that the 
assay be performed for cG-PDE activity. 
The significance of the Flybase 5.2 release is discussed in chapter four. 
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Chapter 4 
Identification and cloning of DmPDE11RB long, 
DmPDE11RB short, DmPDE11RC long, and 
DmPDE11RC short 
4 Chapter 4 
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4.1 Summary 
The DmPDE11RA isoform was replaced in the Flybase 5.2 release by two newly predicted 
isoforms; DmPDE11RB and DmPDE11RC 
(http://fb2007_01.flybase.org/reports/FBgn0085370.html). Both are similar, but not 
identical isoforms to the RA transcript. There are two key differences between 
DmPDE11RA and the two newly predicted isoforms. Firstly, the first two exons of 
DmPDE11RA were predicted to be incorrect, and these exons were newly predicted to be 
5‟ UTR within the DmPDE11RB transcript. DmPDE11 RB and RC each have novel N 
termini encoded by alternate first exons, and share a second exon not present in 
DmPDE11RA. Secondly, exon 11 within the DmPDE11RA transcript was also predicted 
as false, and is not present in the DmPDE11RB or DmPDE11RC isoforms. Analysis of 
transiently transfected S2 cells expressing V5-tagged DmPDE11RA had shown that the 
protein displayed no discernable cA- or c-PDE activity, and showed low levels of 
expression. As such, it was probable that DmPDE11RA was not a bona fide PDE.   
The evidence rank supporting DmPDE11 RB and RC on Flybase is “weakly supported”; 
i.e., they are predictions backed by sequencing of end sequenced cDNA clones (or ESTs) 
around 500 bases long, and computational prediction. The length of supporting ESTs 
prohibit their use in cloning. As both DmPDE11 RB and RC were still rated as “weakly 
predicted”, updating the RA ORF by cloning the novel N-termini, and the region around 
exon 11, and sub-cloning these into the DmPDE11RA transcript using endogenous 
restriction sites was not pursued, as only PCR of the entire ORF would guarantee that the 
isoforms were bona fide, and the Flybase predictions correct. Prior to cloning these 
isoforms, they were confirmed as being transcribed by three methods; comparison of 
predicted exons with a head and Malpighian tubule EST database not used in the Flybase 
sequence analysis, sequencing of RT-PCRs from cDNA from multiple tissues, and 
diagnostic RT-PCRs, where multiple exons were amplified, and analysed by agarose gel 
electrophoresis and sequencing. 
Each isoform was amplified in fragments using a high-fidelity DNA polymerase from 
brain or hindgut cDNA, sequenced for fidelity, and ligated together utilising endogenous 
restriction sites to yield a full length open reading frame. Sequencing of RT-PCR amplified 
ORF fragments revealed a novel exon/exon splice site in the C-terminus not predicted by 
Flybase; the novel exon encodes 4 amino acids followed by a stop codon 1kb from the stop 
codon of the “long” C terminus, and thus a truncated protein. RT-PCR analysis revealed 
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that both the B and C isoforms have both a long and a short isoform, thus yielding two 
additional novel ORFs. Polyclonal antibodies previously raised against sequence from 
DmPDE11RA target the long isoforms only, in an area with no sequence changes. The 
pWIZ RNAi construct targeted against DmPDE11RA utilises sequence from an unchanged 
region, shared by all four isoforms.  
Transgenic Drosophila expressing the four DmPDE11 isoforms were generated, and the 
proteins verified by western blotting. The B and C isoforms showed differential subcellular 
localisation in the Malpighian tubule, where the long and short isoforms of DmPDE11B 
localised to the apical and basolateral membranes, and the long and short isoforms of 
DmPDE11C localised to unidentified organelles or vesicles. 
Over-expression of DmPDE11 C long or short in S2 cells failed to yield an increase in cA- 
or cG-PDE activity. However, when ubiquitously overexpressed in fly, 
immunoprecipitated, and subjected to PDE assays, YFP tagged DmPDE11B long and short 
and C long and short display cA- and cG-PDE activity, and thus are bona fide dual 
specificity phosphodiesterases. 
 
4.2 Introduction 
Previous attempts to transiently transfect S2 cells with DmPDE11RA failed to generate 
expressed protein (Day). Although further attempts to express V5 tagged DmPDE11RA 
yielded expression of a protein of the expected size, the protein was expressed at low 
levels, and displayed unusually low transfection efficiency. Attempts to verify that 
DmPDE11RA was a bona fide phosphodiesterase through PDE assays yielded no cA- or 
cG-PDE activity above background (as detailed in chapter 3). Previously, PDE assays on 
the sub-cloned catalytic domain yielded slight cA-PDE activity (Day).  
It was thought that perhaps DmPDE11 needed some unknown binding partner to facilitate 
PDE activity; thus S2 cells co-transfected with PDE11 and DG2 were subjected to PDE 
assays; again, these yielded no significant activity, and indeed cGK/PDE11RA co-
transfected S2 cell lysate demonstrated lower PDE activity than untransfected cells 
(summarised in chapter three).  
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4.2.1 Flybase 5.2 replaces DmPDE11RA with DmPDE11RB and 
DmPDE11RC 
In the Flybase 5.2 genome annotation release of August of 2007, DmPDE11RA was 
replaced with two newly predicted transcripts, DmPDE11 RB and RC (figure 4.1). 
Ensemble was updated accordingly in March 2008. 
 
Figure 4.1: DmPDE11 RB and RC. Diagram representing the initial transcript, mRNA, 
and cDNAs of the DmPDE11 isoforms. From 
http://flybase.bio.indiana.edu/reports/FBgn0085370.html. 
 
 
The Flybase 5.2 predictions for DmPDE11 RB and RC were still based on computational 
prediction, and a number of incomplete cDNAs (or ESTs). The prediction was still classed 
as “very weak”. This may explain why Ensemble kept their prediction as RA until March 
2008. However, several aspects of the research detailed in chapter 3 led me to believe that 
DmPDE11RA was incorrectly predicted. The enzyme provided no PDE activity above 
baseline when expressed in S2 cells. Whereas transient expression of the N terminus of 
PDE11RA in S2 cells gave robust expression, expression levels of transiently transfected 
full length protein were much lower. Furthermore, the protein showed a classical “non-
specific” cytoplasmic localisation. Thus, validation of the newly predicted isoforms was 
undertaken. The 5639 bp DmPDE11RB transcript contains 17 exons, and encodes a protein 
product of 1451 residues. The 5238 bp DmPDE11RC transcript contains 17 exons, and 
encodes a protein product of 1407 residues. Both encode similar, but not identical protein 
products to the RA transcript. 
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4.2.2 Comparison between DmPDE11RB and DmPDE11RA 
The predicted first two exons of DmPDE11RA were predicted to be incorrect, and replaced 
in the RB transcript, which contains two alternate exons at the 5‟ end (figure 4.2).  
 
Figure 4.2: Transcript structure of DmPDE11RA and DmPDE11RB. Kb figure refers 
to the breadth of sequence localisation within chromosome 2L. White = UTR, Red = exon. 
RA 
 
RB  
 
 
A further difference between RB and RA is the omission of the 78 bp exon 11 of RA from 
the RB transcript. The RB ORF remains in-frame so that 26 amino acids are removed from 
this site but the amino acids following this are unaffected (figure 4.3).  
 
Figure 4.3: ClustalW alignment of DmPDE11RA and DmPDE11RB. Sequences of 
DmPDE11RA and DmPDE11RB were aligned using ClustalW, which revealed a 78bp 
deletion within the RB ORF present in the predicted RA ORF.  
 
 
This deletion corresponds to exon 11 of RA. This sequence is located between the GAF 
domains and the catalytic domain. This deletion aside, the C termini of the two isoforms 
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are identical. As such, DmPDE11B still contains twin GAF domains, and a dual specificity 
PDase domain. 
 
4.2.3 Comparison between DmPDE11RC and DmPDE11RA 
DmPDE11RC has a unique N-terminus, consisting of two novel exons not present in 
DmPDE11RA, the second of which is shared with DmPDE11RB (figure 4.4).  
 
Figure 4.4: Transcript structure of DmPDE11RA and DmPDE11RC. Kb figure refers 
to the breadth of sequence localisation within chromosome 2L. White = UTR, Red = exon. 
RA 
 
RC 
 
Exon 11 of DmPDE11RA is also not present in DmPDE11RC. As such, the only difference 
between DmPDE11RB and DmPDE11RC is the first exon.   
 
4.2.4 Verification of the newly predicted isoforms 
4.2.4.1 Analysis of Expressed Sequence Tag traces 
The RB and RC transcripts were predicted through a combination of EST sequencing and 
computational prediction. I analysed Solexa Illumina EST sequencing runs from poly-A 
primed mRNA generated from head and Malpighian tubule RNA (Dow and Wang, 2009), 
using a CLC genomics workbench suite (CLC Genomics Workbench 3.7., CLC Bio) 
which allowed the further screening of predicted exons in the EST library. These ESTs 
were not used in the Flybase sequence analysis. EST sequencing traces of 50 base pairs, 
unless representative of repeat genomic sequence over-represented in the genome, should 
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only be found in one genomic location. The genomic region of CG34341 was “overlaid” 
with the EST traces using a CLC genomics workbench suite, and the putative start sites 
and exons of the transcripts were validated by comparison with EST coverage. Tubule EST 
reads are shown. 
The sequence originally designated as RA exons 1 and 2 and is now designated as RB 5‟ 
UTR. Within this region there are four ESTs, and significant areas are not represented 
(figure 4.5).  
 
Figure 4.5: 50bp reads representing the 5’ UTR of the PDE11 transcript 
DmPDE11RB. Yellow band represents translated region. Green band represents UTR.  
Purple highlighted sequence shows previously predicted start site for DmPDE11RA. 
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Of prime importance was the verification of the newly predicted DmPDE11RB and 
DmPDE11RC N termini. These are represented in the ESTs gathered (figure 4.6 and 4.7). 
 
Figure 4.6: 50bp read representing first exon of DmPDE11RB with start codon 
(ATGGGCCAAGCGGCA...). Yellow band represents translated region. Green band 
represents 5‟ UTR.   
 
 
Figure 4.7: 50bp read representing first exon of DmPDE11RC with start codon 
(ATGGCATCATCCCCA...). Yellow band represents translated region. Green band 
represents 5‟ UTR.   
 
 
The presence of these novel N termini in these sequencing runs supports the Flybase 
prediction. The second, shared exon is also represented within the EST database (figure 
4.8). 
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Figure 4.8: 50bp read representing second exon of DmPDE11RB and RC. Yellow 
band represents translated region. 
 
 
The coverage of these exons in the Solexa Illumina EST sequencing runs, as well as those 
used in the Flybase prediction, suggests strongly that the newly predicted N termini of the 
RB and RC isoforms are correct. 
 
4.3 Amplification and further verification of DmPDE11 RB 
and RC 
4.3.1 Amplifying DmPDE11 RB and RC from cDNA 
Flyatlas, a database of whole fly and tissue specific expression levels of every known 
Drosophila gene (Chintapalli et al., 2007), shows the highest enrichment for DmPDE11 
transcript compared to whole fly in brain and hindgut (table 4.1) 
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Table 4.1: Tissue expression profile of DmPDE11. mRNA signal: abundance of 
transcript in each tissue. Enrichment: compared to whole fly (Chintapalli et al., 2007). 
Tissue mRNA Signal Enrichment
Brain 268 ± 9 2.5
Head 132 ± 10 1.2
Eye 327 ± 37 3.09
Thoracicoabdominal ganglion 154 ± 11 1.5
Salivary gland 268 ± 1 2.53
Crop 176 ± 7 1.7
Midgut 188 ± 8 1.8
Tubule 161 ± 7 1.5
Hindgut 285 ± 11 2.7
Heart 332 ± 13 3.14
Fat body 98 ± 7 0.92
Ovary 192 ± 2 1.8
Testis 39 ± 2 0.4
Male accessory glands 77 ± 4 0.7
Virgin spermatheca 105 ± 10 0.99
Mated spermatheca 110 ± 7 1.04
Adult carcass 102 ± 8 1
Larval CNS 79 ± 2 0.75
Larval Salivary gland 176 ± 13 1.66
Larval midgut 91 ± 8 0.86
Larval tubule 180 ± 7 1.7
Larval hindgut 172 ± 9 1.63
Larval fat body 73 ± 4 0.7
Larval trachea 156 ± 16 1.48
Larval carcass 77 ± 9 0.73
S2 cells (growing) 245 ± 9 2.31
Whole fly 106 ± 11  
The probes used in the Drosophila Fly Atlas did not differentiate between RB and RC. It 
was shown by Day and Sebastian that both isoforms are expressed in hindgut and head, as 
shown in appendix 3. As both isoforms are expressed in these tissues, cDNA was 
generated from dissected brain (as this showed enrichment over head) and hindgut, and this 
cDNA used to clone the ORFs, as full length ESTs were not available. 
 
4.4 Cloning of DmPDE11RB and RC 
4.4.1 PCR of full length ORFs 
The newly predicted DmPDE11 RB and RC mRNA coding regions (ORFs) are 4365bp 
and 4224bp in size respectively. Attempts to clone the entire ORFs failed, despite attempts 
138 
with non-proofreading DNA polymerase, and with Platinum Taq DNA polymerase high 
fidelity (Invitrogen), an enzyme supposedly capable of amplifying up to 20kb, adding 
weight to Sambrook‟s description of manufacturer‟s claims towards their proprietary Taq 
polymerases as “indefatigably optimistic” (Sambrook and Russell, 2001). As with all 
cloning from cDNA in this chapter, a gradient PCR, with a wide spread of annealing 
temperatures, was used. Every variable; primer concentration, MgCl
2+
 concentration, 
cDNA type and concentration, and cycle number, were altered, but to no avail.  
 
4.4.2 Fusion PCR 
Fusion PCR is a method of amplifying two or more fragments of DNA, and subsequently 
fusing these fragments into one long DNA molecule (Shevchuk et al., 2004). This involves 
three PCR steps. The first amplifies the fragments, using primers that result in two (or 
more) products with a 21 bp “overlap” homologous region; these fragments are gel 
purified. The subsequent two steps fuse these fragments. An initial 13 cycles are performed 
without primers, during which the region of homology essentially acts as a primer, and 
generates a full length dsDNA template from the newly fused fragments. Following this, 
the product of the previous fusion step is DNA purified and used as a template; a PCR with 
primers for the extreme 5‟ and 3‟ ends of the gene, (PCRs were performed with two sets of 
primers, either with incorporated restriction sites to facilitate cloning, or without), and an 
extended extension step (to reflect the increase in size of the template) should yield full-
length fusion product. 
 
The N termini of RB and RC, and the conserved C terminus, were amplified with a 21bp 
overlap, as one clean band in each case. Equimolar amounts of these were used in the 
fusion PCR. When the products were separated by gel electrophoresis, strong, non-specific 
bands were obtained, and when a combined annealing/extension PCR program still yielded 
these bands the approach was abandoned (data not shown).   
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4.4.3 Sub cloning of DmPDE11 using endogenous restriction 
sites 
As amplification of the full length ORF failed, a multi-step cloning strategy was planned. 
Analysis of DmPDE11 RB and RC sequence for endogenous restriction sites showed a 
BglII site around midway through the two ORFs.  
This pointed towards a two stage cloning strategy; amplify the two unique N termini of RB 
and RC, and the single shared C terminus with these incorporating the endogenous BglII 
site, adding unique restriction sites at the N and C terminals, and clone these sequentially 
into a compatible multiple cloning site. As RB and RC have unique N termini, differing 
forward primers were designed to amplify these. Reverse primers for the common C 
terminal were designed with and without a stop codon. These fragments could then be 
ligated together to yield a full-length ORF, both YFP-tagged and untagged, following 
verification by sequencing (figure 4.9). 
Figure 4.9: Cloning strategy for DmPDE11 
Step 1: Primers are designed to amplify the N and C terminal halves of RB and RC, 
extending just past the endogenous BglII site. The C terminal half of RB and RC are 
identical. Restriction sites, not present within the ORF, corresponding to sites in pUAST 
MCS are incorporated at the N and C terminal ends of RB and RC. The C terminal was 
amplified with and without a stop codon to facilitate in frame fusion with a YFP tag. 
 
Step 2: TOPO clone the fragments, and sequence them to screen for fidelity 
 
 
 
    C terminal     N terminal 
pCR 2.1 TOPO pCR 2.1 TOPO 
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Step 3: Digest the N and C terminal ends, and ligate sequentially into digested, MCS-
modified pUAST 
 
 
 
Step 4: Screen colonies for full length PDE11 RB and RC inserted into pUAST and 
pUAST-YFP. 
 
All PCRs were performed with Herculase II DNA polymerase, following manufacturer‟s 
instructions. For all PCRs at least three TOPO cloned inserts were sent for sequencing.  
 
4.4.3.1 Amplification of DmPDE11RB N terminus 
The BglII site is 2654bp into the RB ORF. Although the fragment would amplify with 
standard DNA polymerase, using proofreading DNA polymerase, the N terminus of RB 
did not amplify despite extensive attempts to optimise the protocol, including primer 
redesign without a 5‟ EcoRI addition. Fortuitously, a Xho I site exists half way through 
this N terminal fragment, and so the N terminus was amplified in two fragments. These 
fragments overlapped so that the primers did not contain a Xho I site, as a control. The 
EcoRI – XhoI fragment, and the XhoI to BglII fragment were amplified, sub-cloned into 
pCR TOPO 2.1 vector, and verified by PCR and restriction analysis. They were then 
sequenced for fidelity.  
 
    C terminal     N terminal 
       pP{UAST} / pP{YFP UAST} 
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4.4.3.2 Amplification of DmPDE11RC N terminus 
Using proofreading DNA polymerase, the N terminus of DmPDE11RC amplified as a 
single clean band of the predicted size. This band was sub cloned into the TOPO 2.1 
vector, verified by PCR and restriction analysis, and sequenced for fidelity.  
 
4.4.3.3 Amplification of the conserved DmPDE11 C terminus 
The C terminus was amplified using two different reverse primers, one with a stop codon, 
incorporating a KpnI restriction site, and one without a stop codon, with a NotI restriction 
site, to facilitate in-frame fusion to a YFP tag. With either reverse primer, PCR of the C 
terminus of DmPDE11 yielded two fragments, one of the predicted size, and one that ran 
approximately 50bp smaller (figure 4.10). Both were gel purified, TOPO-cloned using 
pCR TOPO 2.1 vector, verified by PCR and restriction analysis, and sent for sequencing. 
 
Figure 4.10: The DmPDE11 C terminus amplifies as a doublet. Two PCR fragments of 
the DmPDE11 C terminus, produced using proofreading PCR polymerase, BglII C term 
forward and KpnI reverse primers, and tubule cDNA. Fragments were separated by 
agarose gel electrophoresis. Band size identified using 1kb ladder.  
 
 
 
 
 
 
 
 
 
 
3 Kb 
1.6 Kb 
1 Kb 
DmPDE11 C terminus     
2 Kb 
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Sequencing of these fragments showed that the smaller band contained a novel exon/exon 
boundary, not predicted by Flybase, which results in 4 novel amino acids followed by a 
novel stop codon 1kb from the C-terminus, and thus a truncated protein (figure 4.11). 
Figure 4.11: Truncated DmPDE11 transcript. Sequencing of two DmPDE11 C terminal 
PCRs from cDNA, showing a novel intron/exon boundary. * denotes matching sequence 
 
When the C terminal, amplified with no stop codon, was TOPO cloned in-frame with a V5 
tag, and expressed in S2 cells, western blot of cell lysate gave bands of the predicted size. 
The transfer was “dirty,” and so although bands were visible on the exposed film, when 
scanned the bands were no longer visible, and so the data is not shown. 
4.4.4 RT-PCR to verify long and short isoforms 
With two possible N termini, and two C termini, the question of how many isoforms exist 
in vivo arose. RT-PCR was performed in order to determine which combinations of N 
termini and C termini were represented in transcripts. Primers were designed in the unique 
B and C termini, as close to the novel exon/exon boundary as possible. Two reverse 
primers were generated, one within the originally predicted exon/exon boundary, and one 
within the novel exon/exon boundary within the short C terminus (figure 4.12). These 
primers were designed to generate products of ~3.5 kb. 
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Figure 4.12: DmPDE11 transcript verification strategy. Primers were designed to 
confirm the presence of long and short full length isoforms. Forward primers were 
designed in regions of sequence specific to the B and C isoforms, and reverse primers were 
designed to either represent the originally predicted exon/exon boundary of the long 
isoform, or to represent the newly discovered exon/exon boundary of the short isoform. 
 
These primers were used in PCRs of hindgut cDNA, and the PCRs run on an agarose gel 
(figure 4.13). 
Figure 4.13: Verification of DmPDE11RB and RC. Forward primers specific to the N-
termini of DmPDE11-RB and –RC isoforms (RBF and RCF respectively) were used 
alongside reverse primers designed to amplify the originally predicted exon/exon boundary 
of the long isoform (REV), or to amplify the newly discovered exon/exon boundary of the 
short isoform (GAP) from hindgut cDNA. Band size identified using 1kb ladder. 
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Bands of the expected size (~3.5kb) were produced for both DmPDE11 RB and RC using 
both the reverse primer within the originally predicted exon/exon boundary, and one within 
the novel exon/exon boundary within the short C terminus. Thus, both DmPDE11-RB and 
-RC were found to have a full length and a truncated isoform, and as such these were 
designated DmPDE11RB long, DmPDE11RB short, DmPDE11RC long, and 
DmPDE11RC short. The features of these proteins are summarised in figure 4.14.  
Figure 4.14: The four DmPDE11 isoforms. Antibody epitope refers to the polyclonal 
rabbit antibody generated for DmPDE11RA. 
PKA/PKG 
Phosphorylation 
motif
GAF: cGMP-binding phosphodiesterase, Anabaena adenylyl cyclase,
and Escherichia coli FhlA domain
GAF GAF Catalytic domain
GAF GAF Catalytic domain
GAF GAF Catalytic domain
GAF GAF Catalytic domain
RNAi target
Antibody Epitope
Unique N-terminus
DmPDE11 RC long
DmPDE11 RB short
DmPDE11 RB long
DmPDE11 RC short
Coiled coil motif
 
These isoforms share a “core” area containing twin GAF domains, and a dual specificity 
PDEase domain (Attwood et al., 2003; Bateman et al., 2004; Letunic et al., 2006). The 
novel N termini are of low homology when compared to HsPDE11A, as is the long C 
terminus. The novel N terminus of DmPDE11B is predicted to contain a coiled coil motif 
when analysed with the COILS program (Lupas, 1997; Lupas et al., 1991). 
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4.5 Generation of DmPDE11 transgenic flies 
Due to time constraints, it was reasoned that I should generate the four verified DmPDE11 
transgenic flies while concurrently assaying for cA- or cG-PDE activity in S2 cells. As 
PDE assays on S2 cell over-expressed PDE11RA and catalytic domain had shown no 
significant PDE activity, but anti-DmPDE11 immunoprecipitate of whole fly lysate yields 
significant cA- and cG-PDE activity, it was reasoned that expression in whole fly may be 
needed to verify one way or the other, as the catalytic domain remains unchanged in terms 
of sequence. As such, if the S2 cell PDE assays were unsuccessful, PDE assays on 
DmPDE11 overexpressing whole fly could be performed. 
4.5.1 Cloning of DmPDE11 ORFs into pUAST 
4.5.1.1 Cloning of DmPDE11RC long and short 
Attempts to ligate the N and C termini of RC into pUAST simultaneously failed, and as 
such these were cloned sequentially. The long and short C terminals (with a stop codon) 
were cloned into pUAST first. pUAST-YFP was a kind gift from John Day; the long and 
short C terminals (without a stop codon) were cloned into this construct in frame with the 
C-terminal YFP tag.  The N terminus of RC was then cloned into these constructs in order 
to generate full length ORFs. pUAST-DmPDE11RC-YFP long and short, and pUAST-
DmPDE11RC short were generated, however, despite numerous attempts, the N terminus 
did not sub-clone into pUAST-Cterm long, and so pUAST-DmPDE11RC long could not 
be generated. Were untagged DmPDE11RC long required, it could be generated by PCR 
using pUAST-DmPDE11-YFP long as a template, with a stop codon incorporated into the 
reverse primer. 
4.5.1.2 Generation of modpUAST 
The order of restriction sites of DmPDE11RB, 5‟  3‟, is EcoRI-XhoI-BglII-NotI/KpnI. 
Numerous vectors were checked for an EcoRI-XhoI-BglII order in the MCS to facilitate 
sequential cloning, but none were found. The multiple cloning site of pUAST has 
restriction sites in the order of EcoRI-BglII-NotI-EagI-XhoI-KpnI-XbaI. As this would not 
permit sequential sub-cloning of the EcoRI-XhoI, XhoI-BglII, and BglII–KpnI/NotI TOPO 
cloned fragments, the MCS of pUAST was modified. This was achieved by the generation 
of two overlapping primers representing the sequence of the desired MCS; the overlap 
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facilitated the formation of “sticky ends” when then two were incubated together, and 
ligated into doubly digested pUAST (materials and methods 1.3.19). The forward primer 
was coupled to a reverse primer 500bp into pP{UAST}, and this primer set was used to 
screen for successful recombinants (figure 4.15).  
Figure 4.15: Screen for successful mod pP{UAST} recombinants. PCR screening of 
modified pP{UAST} yielded a successful recombinant (lane 10, indicated by an arrow). 
                     1     2     3     4     5     6      7     8     9    10 
 
 
 
When this recombinant pP{UAST} was identified (lane 10), DmPDE11RB was subcloned 
into it in the order BglII–KpnI/NotI, XhoI-BglII, then EcoRI-XhoI. However, the EcoRI 
site was found to be mutated, and so the EcoRI-XhoI fragment was sub-cloned into the N 
terminus of pP{UAST} PDE11RC. However, frustratingly the EcoRI-XhoI fragment 
would not ligate into the untagged PDE11 RC long or short constructs, and so only 
DmPDE11RB long-YFP and DmPDE11RB short-YFP could be generated. Were untagged 
constructs required, these could be generated by PCR of the entire ORF, with a stop codon 
incorporated into the reverse primer. 
4.5.2 Cloning of ORFs into pAc5.1/V5-HIS C 
The above ORFs were sub-cloned into pAc5.1/V5-HIS C, an S2 expression system that 
does not require induction with CuSO4, as it was considered a possibility that CuSO4 may 
displace the Zn ion at the active site of the PDE, rendering it catalytically null, or resulting 
in the mis-folding of the protein. An experiment to check this, where untransfected S2 
cells, one treated with the concentration of CuSO4 used to induce expression using DES 
vectors, and an “uninduced” control,  showed a marked reduction (~13%) in PDE activity 
where the cells were exposed to CuSO4 , although this was N=1 and would need to be 
repeated at N=3 to verify the finding. 
400bp 
500bp 
1000bp 
1600bp 
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4.6 Verification of protein size 
YFP tagged DmPDE11 flies were crossed to the GAL4 driver line heat shock GAL4 
(HSG4), which drives GAL4 expression ubiquitously in response to a 37˚C heat shock. Fly 
lysate was subjected to western blot analysis. Protein size was verified by western blotting 
using an anti-GFP antibody which recognised YFP. YFP tagged DmPDE11B long and B 
short were immunoprecipitated from whole fly lysate alongside HSG4 control, and 
subjected to western blot analysis (figure 4.16). 
                            
Figure 4.16: Analysis of YFP-tagged DmPDE11B. YFP-DmPDE11B long and YFP-
DmPDE11B short flies were crossed to the ubiquitous driver line heat shock GAL4 
(HSG4), and gene expression induced by 3 x 20 min heat shocks. Protein sizes were 
identified by western blot analysis, where YFP-tagged proteins were identified using αGFP 
monoclonal (that recognises YFP) primary, αmouse Cy3-coupled secondary, and band size 
was calculated using ImageQuantTL software (GE Healthcare).shown is the. Lane 1. Fly 
lysate HSG4 2: Fly lysate YFP-DmPDE11RBL/HSG4 3. Fly lysate YFP-
DmPDE11RBS/HSG4. Expected sizes YFP-DmPDE11B long: 187.9, YFP-DmPDE11B 
short: 157.0 kDa.          
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Expected band sizes for YFP-tagged DmPDE11B long and short are 187.9 kDa and 157.0 
kDa respectively. Analysis of band sizes for YFP-tagged DmPDE11B long using 
ImageQuantTL software identifies a novel band at 186.2 kDa, in close agreement with the 
predicted protein size of 187.9 kDa, and a band at 164.6 kDa. Analysis of band sizes for 
YFP-tagged DmPDE11B short identifies a novel band at 159.2 kDa, again in close 
agreement with the predicted protein size of 157.0 kDa, and two further novel bands at 
121.0 kDa and 55 kDa.  Three bands were present in the HSG4 negative control lane (one 
~85 kDa and two ≤30kDa), and so were identified as non-specific bands. 
Fly lysate from YFP tagged DmPDE11C long and Canton S control were subjected to 
western blot analysis (figure 4.17). 
 
Figure 4.17: Analysis of YFP-tagged DmPDE11C long. YFP-DmPDE11C long and 
YFP-DmPDE11C short flies were crossed to the ubiquitous driver line heat shock GAL4 
(HSG4), and gene expression induced by 3 x 20 min heat shocks. Protein sizes were 
identified by western blot analysis, where YFP-tagged proteins were identified using αGFP 
monoclonal (that recognises YFP) primary, αmouse HRP-coupled secondary, and band 
size was calculated by comparison with Benchmark prestained protein ladder. Intervening 
lanes deleted in Paint program, and lanes moved together. Lane 1. Fly lysate Canton S 2: 
Fly lysate YFP-DmPDE11RCL/HSG4. Expected protein size YFP-DmPDE11C long: 
182.6 kDa. 
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YFP-tagged DmPDE11C long is predicted to be 182.6 kDa. When expressed in fly, the 
protein runs to ~180 kDa, in close agreement with the predicted protein size of 182.6 kDa. 
A band of ~70 kDa was present in the Canton S negative control lane, and so was 
identified as a non-specific band. 
YFP tagged DmPDE11C short was immunoprecipitated from whole fly lysate alongside 
HSG4 control, and subjected to western blot analysis (figure 4.18). 
 
Figure 4.18: Analysis of YFP-tagged DmPDE11C short. YFP-DmPDE11C long and 
YFP-DmPDE11C short flies were crossed to the ubiquitous driver line heat shock GAL4 
(HSG4), and gene expression induced by 3 x 20 min heat shocks. Protein sizes were 
identified by western blot analysis, where YFP-tagged proteins were identified using αGFP 
monoclonal (that recognises YFP), and band size was calculated using ImageQuantTL 
software (GE Healthcare). Lane 1. Fly lysate HSG4 2: Fly lysate YFP-
DmPDE11RBL/HSG4 3. Fly lysate YFP-DmPDE11RBS/HSG4. Expected protein size                                
DmPDE11C short 151.7 kDa. 
 
 
 
 
 
 
 
 
YFP-tagged DmPDE11C short is predicted to be 151.7 kDa. Analysis of the two novel 
bands in the DmPDE11C short lane identifies one band of 149.0 kDa, in close agreement 
with the predicted protein size, and two further bands of 112.7 kDa and 54.2 kDa. Two 
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bands were present in the HSG4 negative control lane of ≤30kDa, and so were identified as 
non-specific bands. 
 
4.7 Verification of phosphodiesterase activity 
S2 cells were transfected with DmPDE11RC long (untagged and YFP tagged) and RC 
short (untagged, V5 tagged, and YFP tagged). cA-PDE assays were performed on S2 cell 
lysate, with concentrations of 5 μM  and 10 μM cAMP. None of these constructs gave a 
significant increase in PDE activity at either concentration (figure 4.19). 
 
Figure 4.19: DmPDE11RC does not yield cA-PDE activity when expressed in S2 cells.  
cA-PDE assay on transiently transfected S2 cell lysate using 5 μM substrate (A) and 10 
μM substrate (B). In order to aid comparison, data is expressed as % cA-PDE activity of 
mock transfected S2 cell, where for A, mock = 142.1 pmol cAMP/mg/min (SEM ±14.61), 
and for B mock = 90.23 pmol cAMP/mg/min (SEM ±10.12). N=≤3 biological replicates, 
except for DmPDE11RCs V5 and DmPDE11RCs stop, where N=2 biological replicates. 
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Indeed, where DmPDE11RC constructs were transfected this resulted in a significantly 
(analysis with one-way anova) lower level of cA-PDE activity compared to untransfected 
control. Reasons for this are unknown; perhaps the protein acts as a catalytically null 
dominant negative in S2 cells. A smaller cAMP/min/mg value for the 10μM assay mock 
control may have been due to unusually high blank readings. PDE assays using 
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immunoprecipitate (IP) with an anti-DmPDE11 polyclonal antibody against whole-fly 
yields a Km of 6±2μM for cGMP, and 18.5±5.5μM for cAMP, as published in Day et al, 
2005. Thus, DmPDE11 is a dual specificity cAMP- and cGMP-PDE. It is notable that 
DmPDE8, when transiently expressed in S2 cells and subjected to PDE assays, also fails to 
yield measurable PDE activity (Day, 2005). Furthermore, when aligned with the catalytic 
domain of other Drosophila PDEs, the sequence showed a very high sequence similarity, 
with only one amino acid change within this region, with the same change in DmPDE6 
catalytic domain (figure 4.20). A cG-PDE, this has been shown to display cG-PDE activity 
in S2 cells. 
 
Figure 4.20: ClustalW alignment of Drosophila PDE catalytic domains with their 
human homologues. This region is invariant between the RA, and RB/RC isoforms of 
DmPDE 11 (From Day et al, 2005) 
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As such it was decided to send the pP{UAST} constructs for injection, and with the 
generated transgenic flies to perform PDE assays on fly lysate. Indeed, analysis of the 
protein by western blot does suggest that the enzyme may be subjected to a post-
translational modification when expressed in fly, which may affect its activity. As such, 
YFP-tagged DmPDE11RB and RC expressing flies were crossed to heat shock GAL4 flies 
to ubiquitously induce expression of the transgene. The protein was immunoprecipitated, 
and the immunoprecipitate used to assay cA- and cG-PDE activity of the protein (figures 
4.21 and 4.22). 
Figure 4.21: YFP tagged DmPDE11RB long, RB short, RC long, and RC short yield 
significant cA-PDE activity when transgenically expressed in Drosophila. cA-PDE 
assay on αYFP immunoprecipitated PDE from transgenic whole fly lysate using 10 μM 
substrate. Data expressed as pmol cAMP hydrolysed/IP/min. Assay performed in 
biological triplicate. Data statistically significant between parental control and PDE-
expressing progeny to P<0.0001 (Student‟s unpaired T test). Error bars show SEM. 
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Figure 4.22: YFP tagged DmPDE11RB long, RB short, RC long, and RC short yield 
cG-PDE activity when transgenically expressed in Drosophila. cG-PDE assay on αYFP 
immunoprecipitated PDE from transgenic whole fly lysate using 10 μM substrate. Data 
expressed as pmol cGMP hydrolysed/IP/min. Assay performed in biological duplicate. 
Error bars show SEM. 
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Each YFP tagged PDE11 isoform showed a significant increase in cAMP-PDE activity 
compared to heat shock GAL4 parental control (figure 4.21). As the cGMP-PDE assays 
were performed in biological duplicate, statistics cannot be performed, however B long, B 
short, and C short gave an increase in cGMP-PDE activity compared to heat shock GAL4 
control. 
 
4.8 Implications of the DmPDE11 sequence change 
A concern was that tools designed around the sequence of DmPDE11RA would become 
redundant with the prediction of the RB and RC isoforms. The epitope used to raise anti-
DmPDE11 polyclonal rabbit antibodies is unchanged in the long isoforms, but is not 
present in the short isoforms. The published western blot shows one clear band (Day, 
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2005); it may be that the RB and RC long isoforms run so close together as to be 
indistinguishable on a western blot. 
The RNAi (pWIZ) construct was targeted against an area conserved between all 4 
isoforms, which remains unchanged between RA, and RB and RC. Thus it should knock-
down all four isoforms. Furthermore the primers used in the PDE11RA Q-PCR also 
amplified a region present in all 4 isoforms, and as such, remains valid, as no single region 
would allow Q-PCR against a single isoform, as Q-PCR with primers designed against 
sequence specific to DmPDE11RB or RC would amplify sequence from both long and 
short isoforms. 
Flyatlas was produced using the Drosophila genome 2 array, which contains 14 probes 
against DmPDE11-RA (Affymetrix nettafx analysis center). These probes hybridised 
between 4529 and 5049bp of the ORF. Again, this range of sequence remains unchanged 
between DmPDE11RA and both RB and RC transcripts, and thus these probes hybridise 
to, but do not differentiate between, RB long, RB short, RC long and RC short.  
 
4.9 Confocal microscopy of DmPDE11 
Transgenic Drosophila were crossed to heat shock GAL4 flies, the tubules dissected and 
fixed, and images obtained by immunocytochemistry (figures 4.23-4.27).  
  
Figure 4.23: RB long YFP single plane. Tubules from DmPDE11RB long/HSG4 flies 
were fixed and visualised by confocal microscopy. 
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Figure 4.24: RB short YFP single plane. Tubules from DmPDE11RB short/HSG4 flies 
were fixed and visualised by confocal microscopy. 
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Figure 4.25: DmPDE11 B long YFP projection. Tubules from DmPDE11 B long/HSG4 
flies were fixed, and a Z-stack obtained by confocal microscopy. Shown is a projection of 
this Z-stack. 
 
 
Confocal images of both DmPDE11B long and short show that both proteins show similar 
localisation, both localising primarily to the apical and basolateral membranes of the 
Malpighian tubule, with lesser staining in the cytosol. 
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Figure 4.26: DmPDE11 C long YFP single plane. Tubules from DmPDE11 C 
long/HSG4 flies were fixed, DAPI stained, and visualised by confocal microscopy. Shown 
is a single cell from the main segment. DmPDE11 C long YFP = green, DAPI = blue. 
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Figure 4.27: DmPDE11 C short YFP single plane. Tubules from DmPDE11 C 
short/HSG4 flies were fixed, DAPI stained, and visualised by confocal microscopy. 
DmPDE11 C long YFP = green, DAPI = blue. 
 
 
RC long and short isoforms showed indistinguishable localisation to an unidentified 
organelle, or perhaps vesicles. It shows no nuclear localisation.  
 
4.10 Discussion 
DmPDE11RA was replaced in the Flybase 5.2 release with two novel isoforms, 
DmPDE11RB and RC. In this chapter, these isoforms were verified as being expressed. 
The ORFs of these genes were cloned into S2 cell expression vectors, and pP{UAST}. 
Overexpression of YFP tagged DmPDE11 in fly yielded proteins of the predicted size. cA-
PDE assays on S2 cells transfected with DmPDE11RC at 5 μM and 10 μM did not yield 
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cA-PDE activity above that of untransfected S2 cell control, and indeed, as PDE activity 
was reduced compared to control, it may be that in S2 cells transgenically expressed YFP 
tagged DmPDE11 acts as a dominant negative, reducing endogenous PDE activity. 
However, when transgenically overexpressed in fly, the enzymes yield cA- and cG-PDE 
activity, and are thus bona fide dual specificity PDEs. No direct comparison can be made 
with PDE assays performed on αPDE11 IPs from head lysate published in (Day et al., 
2005), where values were ~2.5 pmol/min/IP for cGMP, and ~6 pmol/min/IP, as the 
protocols of that paper and this work differ markedly; Day used 20 heads instead of 10 
whole flies as starting lysate, and used the αPDE11 polyclonal antibody which targets an 
epitope shared by all 4 isoforms of PDE11 referred to in chapter 3 to pull down 
endogenous (untagged) PDE11, instead of αGFP monoclonal antibody to pull down YFP 
tagged overexpressors. As PDE assays on immunoprecipitate cannot give specific 
activity/min/mg protein, the data of figures 4.21 and 4.22 do not show whether the 
isoforms differ in affinity for their substrates. A dose response curve would need to be 
generated using overexpressed protein, in a format that allowed quantification of protein. 
As for the reasons that the enzymes displayed no cAMP- or cGMP-PDE activity in S2 
cells, while these same enzymes displayed cAMP- and cGMP activity when transgenically 
overexpressed in Drosophila, they are unknown. It may be that a post translational 
modification occurs in Drosophila but not in S2 cells, which may be necessary to confer 
enzymatic activity on the protein. cNMP-PDE assays were previously performed in S2 
cells on transiently transfected full length PDE1 and PDE8 (transcript A), and the catalytic 
domain of PDE6, 9, and 11 (Day, 2005). Of these, PDE 6 showed cGMP-PDE activity, and 
the catalytic domain of PDE11 showed cAMP-PDE activity, but only at substrate 
concentrations of between 1 - 4 μM, and did not show cGMP-PDE activity, as was the case 
for IP from fly head lysate. Thus, S2 cells do not appear to be a good cell choice for the 
heterologous study of PDE catalytic function. 
The subcellular localisation of each isoform was determined by immunocytochemistry on 
fixed YFP tagged-DmPDE11 expressing Malpighian tubules. The long and short isoforms 
of YFP-DmPDE11B localised to the apical and basolateral membranes, with lower levels 
of protein in the cytosol. The unique N-terminus of DmPDE11B is 64 amino acids in 
length, and is not predicted to be a transmembrane domain when analysed with Argos or 
von Heijne tests using MacVector software. It contains a polyglutamine region that falls 
within a region predicted to form a coiled coil structure when analysed with the Ncoils test 
of the protein analysis toolkit (Lupas, 1997). Coiled coils are known to reversibly mediate 
homo- and heteromeric protein-protein interaction (Strauss and Keller, 2008), and can 
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facilitate the formation of protein complexes (Langosch and Heringa, 1998). Therefore this 
region may facilitate the interaction of DmPDE11B with an unidentified protein that 
tethers the PDE to the membrane. PDEs from several other families have been shown to 
localise to the membrane due to interaction with other proteins. PDE3 contains N-terminal 
hydrophobic membrane association domain, which either mediate localisation by 
interaction with unidentified proteins, or by functioning as a transmembrane domain 
(Wechsler et al., 2002). PDE4 isoforms contain differing N-termini that encode unique 
subcellular targeting motifs and direct novel protein-protein interactions that tether the 
enzymes to particular subcellular localisations. PDE4A1 contains a motif called tryptophan 
anchoring phosphatidic acid selective-binding domain (TAPAS-1), which permits a Ca
2+
 
sensitive association with the membrane via phosphatidic acid binding (Baillie et al., 
2002). PDE4D5 is recruited to the membrane due to the presence of a β-arrestin binding 
site in the N terminus (Bolger et al., 2006). PDE6 localises to the membrane due to its 
interaction with glutamic acid-rich proteins (GARPs) (Körschen et al., 1999), as well as 
lipid modifications to the C terminus of the catalytic subunits (Anant et al., 1992). 
 The long and short isoforms of YFP-DmPDE11C localised to foci within the cytosol, 
likely within unidentified organelles, or to vesicles. As DmPDE11B and C show markedly 
different localisation, and the only difference between these isoforms is the first exon, this 
sequence must encode a targeting motif. As the long and short isoforms of DmPDE11B or 
C do not show any discernable differences in localisation, the long C terminal must have 
some other, unknown function, perhaps pertaining to the predicted PKA/PKG consensus 
phosphorylation site. The C terminus is of low homology to that of HsPDE11A. As 
DmPDE11C is YFP tagged, the identification of the unknown organelle could be identified 
by either co-staining of each organelle using specific antibodies, or by the crossing of these 
flies to proteins tagged with a different marker such as Venus or GFP that are known to 
localise to a particular organelle, and screening for co-localisation. YFP-DmPDE11C 
localise to organelles similar in appearance to peroxisomes in S2 cells as reported in (Ally 
et al., 2009), a pattern that does not match that reported in (Southall et al., 2006) where the 
peroxisomes are fewer in number and larger. Regardless, the number of peroxisomes per 
cell in the Malpighian tubule is clearly far higher than the number of organelles per cell 
containing DmPDE11C in the tubule, thus discounting the peroxisomes as a candidate 
organelle. The localisation is distinct to the staining pattern seen in Malpighian tubules 
when using antibodies against proteins localised to the sarcoplasmic reticulum, endoplamic 
reticulum, Golgi (Southall et al., 2006), and vesicles (Evans et al., 2008), and is distinct to 
that of lysosomes in S2 cells (Tsruya et al., 2002). Thus a survey of the literature does not 
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identify a candidate organelle. The localisation of other PDEs to organelles is dictated by 
association with anchoring proteins. PDE4A localises to numerous organella via 
interaction with AKAPs, for example AKAP95 (perinucleus), AKAP149 (mitochondria), 
AKAP 450 (Golgi) (Dodge-Kafka et al., 2008), and myeloid translocation gene (Golgi), 
which also confers Golgi localisation to PDE7A (Asirvatham et al., 2004). PDE4D 
localises to the Golgi via association with Myomegalin (Verde et al., 2001). PDE5A is 
localised to vesicles and also the centrosome in human myometrical cells (Dolci et al., 
2006) 
That the N termini of DmPDE11B and C affect subcellular localisation, likely by affecting 
the interaction of these proteins with the proteasome, immunoprecipitation of each isoform 
(i.e., using specific antisera or pulling down tagged PDE) and identification of interacting 
proteins using mass spectrometry specific to each isoform, and subsequent characterisation 
of these would perhaps identify proteins showing overlapping subcellular localisation that 
were worthy of investigation as putative anchoring proteins.  
 As the short and long isoforms of DmPDE11 B and C show identical subcellular 
localisation, the extended C-terminal of the protein does not contain a subcellular 
localisation sequence. 
The subcellular localisation of Drosophila PDEs has not been widely studied. GFP tagged 
DmPDE6 localises predominantly to the apical membrane of the Malpighian tubule, with 
lower intensity fluorescence at the basolateral membrane (Day et al., 2006). When bovine 
PDE5, a close homologue of DmPDE6, is transgenically overexpressed in tubule, it too 
predominantly localises to the apical membrane (Broderick et al., 2004). DmPDE11B 
localises to the basolateral and apical membranes. The presence of two DmPDEs capable 
of hydrolysing cGMP to the membranes suggests that cGMP signalling is under tight 
control in the Malpighian tubule, befitting the prominent role of cGMP signalling in the 
tubule. 
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Chapter 5 
A study of DmPDE11/cGK interaction 
5 Chapter 5 
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5.1 Summary 
Previously obtained data (Day and Sebastian) suggested that DmPDE11, and other 
DmPDEs capable of hydrolysing cGMP, interact directly or indirectly with cGKs. The Dm 
cG-PDEs PDE1, PDE6, and PDE11 co-immunoprecipitate with significant amounts of 
cGK activity when immunoprecipitated using specific antisera from Drosophila head 
lysate. Likewise, the cGKs DG1 and DG2 co-immunoprecipitate with significant amounts 
of cG-PDE activity when immunoprecipitated using specific antisera from Drosophila 
head lysate. 
Co-transfection in S2 cells of DmPDE11 RB long and the cGKs shows that DmPDE11B 
long shows a high degree of co-localisation with DG1, DG2P1, and DG2P2. Furthermore, 
DG1 appears to mediate DmPDE11B long internalisation from the membrane. DmPDE11 
long appears to internalise membrane-tethered DG2P1, so that DG2P1 shows increased 
cytosolic localisation, and localises to foci within the cytosol, mostly coinciding with those 
of PDE11B long.  
Co-immunoprecipitation experiments were performed in S2 cells, between the long and 
short isoforms of DmPDE11, tagged with YFP, and the cGKs, tagged with c-Myc, where 
cGK was immunoprecipitated with anti-c-Myc-conjugated beads, the immunoprecipitate 
resolved by SDS-PAGE, and immunoblotted with anti-GFP antibody which recognised 
YFP. YFP-tagged DmPDE11C long and short was shown to co-immunoprecipitate with c-
Myc tagged DG1, DG2P1, and DG2P2, where bands of the expected size were present in 
doubly transfected anti-c-Myc immunoprecipitates, but not for anti-c-Myc 
immunoprecipitates of singly-transfected YFP-tagged DmPDE11C long or short, or mock 
transfected S2 cell lysate. No data is presented for DmPDE11B-cGK interactions, as 
negative controls showed background staining, although this was of lower intensity that 
doubly-transfected S2 cells. This provides direct evidence of DmPDE11 interacting with 
each of the cGKs, directly or indirectly, and suggests the prospect of potential cGMP 
signalling compartmentalisation in Drosophila. 
5.2 Introduction 
Previously obtained data summarised in appendix 4 (Day and Sebastian, unpublished data) 
suggested that DmPDE11, and other DmPDEs capable of hydrolysing cGMP, interact 
directly or indirectly with cGKs. This demands further investigation, as interactions 
between numerous cA-PDEs and PKA isoforms (mediated by AKAPs) have been shown to 
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dictate the specificity of cAMP signalling events, and facilitate the formation of a feedback 
loop where each protein may modulate the function of the other (Wong and Scott, 2004), 
as detailed in the introduction. Differential localisation of cGK and PDE proteins, 
facilitated by gene and isoform multiplicity, permits the transmission of multiple, 
simultaneous signalling events. Interaction of cGKs and cG-PDEs would allow cG-PDEs 
to modulate interacting cGK function by affecting local cGMP concentration. It has 
previously been shown that DG2 modulates cG-PDE activity in the Malpighian tubule 
(MacPherson et al., 2004a). This modulation may occur by one of several methods; by 
modulation of cG-PDE function through phosphorylation, by direct, non catalytic binding, 
either of which would be facilitated by protein-protein interaction, or by reduction of PDE 
transcription.  Furthermore, association of cG-PDEs with the main effectors of the cGMP 
signalling pathway could modulate PDE and cGK localisation, thus facilitating the 
formation of cGMP microdomains, and altering cGK substrate specificity. 
5.3 DmPDE11B long and cGK co-localise in S2 cells 
DmPDE11 RA and DG2 displayed a large degree of co-localisation when co-transfected in 
S2 cells and visualised by staining with anti-tag antibodies and subsequent confocal 
microscopy, as detailed in chapter 3. The above immunoprecipitation data suggests that the 
two proteins interact, directly or indirectly. However, to interact, proteins must 
demonstrate subcellular localisations that at least partially overlap. Thus, S2 cells were 
transiently transfected with DmPDE11 RB long tagged with C-terminal YFP, and one of 
the cGKs DG1, DG2P1, or DG2P2, each tagged with C-terminal c-Myc, and 
immunocytochemistry performed to ascertain subcellular localisation. To assay whether 
the localisation of cGK or DmPDE11 is affected by the presence or absence of the other, 
each construct was also transfected individually. 
5.3.1 Individually transfected constructs 
Constructs were transfected individually to ascertain the subcellular localisation of each 
protein. An S2 cell expressing YFP tagged DmPDE11B long is shown in figure 5.1. 
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Figure 5.1: Confocal image of S2 cells transfected with YFP-DmPDE11 RB long 
(green). Nuclei were stained with DAPI (blue).  
 
YFP tagged DmPDE11B long predominantly localises to the membrane, with foci-like 
regions within the cytosol showing strong fluorescence, and lighter fluorescence 
throughout the cytosol.  
Individual S2 cells expressing c-Myc tagged DG1, DG2P1, and DG2P1 are shown in 
figure 5.2. 
Figure 5.2: Confocal images of individual S2 cells transiently transfected with c-Myc-
DG1 (A), c-Myc-DG2P1 (B), and c-Myc-DG2P2 (C). Subcellular localisation was 
ascertained by staining with anti-c-Myc monoclonal antibody, TRITC secondary (red). 
Nuclei were stained with DAPI (blue). Untransfected cells showed no background 
fluorescence (example cell visible in C).  
 
DG1 localises to the cytosol, with stronger staining towards the membrane. Published 
images show staining adjacent to the membrane, in common with the image above, 
although did not display quite as strong cytosolic staining (MacPherson et al., 2004b). The 
localisation of individually transfected DG2 P1 and P2 are discussed in chapter 3, but shall 
be repeated here. In agreement with published data (MacPherson et al., 2004b), DG2P1 
localised predominantly to the membrane in S2 cells. Published images of DG2P2 are of 
166 
V5-tagged DG2P2, stained with anti-V5 monoclonal antibody and also a vertebrate anti-
cGK rabbit polyclonal antibody, anti-cGKI, from (Markert et al., 1995). Images with anti-
V5 antibody show solely localisation to the membrane, while those stained with anti-cGKI 
antibody also showed localisation within the cytosol, stronger towards the membrane. The 
DG2P2 construct in my possession was tagged with c-Myc. Staining with an anti-c-Myc 
antibody produced similar staining to the published anti-cGKI stained images, 
predominantly showing localisation to the membrane, with staining in the cytosol, stronger 
towards the membrane. This may be a characteristic of the antibody; however, 
untransfected cells show no background staining. The c-Myc tag may alter protein 
localisation; however the tag is one amino acid smaller than the V5 tag used in 
Macpherson et al, 2004, and so this is doubtful. A third alternative, and perhaps the most 
likely, is that conditions in those images using anti-c-Myc and anti-cGKI antibodies were 
more sensitive, and so fluorescence was detected that was not detected in anti-V5 images. 
Polyclonal antibodies designed against a novel epitope were unfortunately not delivered on 
time to test untagged DG2P2. 
5.3.2 Co-transfection of c-Myc-cGK and YFP-DmPDE11 RB long in 
S2 cells 
In order to screen for co-localisation, S2 cells were co-transfected with YFP-DmPDE11 
RB long and c-Myc-DG1, and the subcellular localisation of the proteins was ascertained 
by confocal microscopy (figure 5.3). 
Figure 5.3: Confocal images of S2 cells co-transfected with YFP-DmPDE11 RB long 
(green) and c-Myc-DG1. Subcellular localisation of c-Myc-DG1 was ascertained by 
staining with anti-c-Myc monoclonal antibody, TRITC secondary (red). Nuclei were 
stained with DAPI (blue).  
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Shown are two examples of doubly transfected S2 cells; two images are shown because in 
some cells, YFP-DmPDEB long showed lower levels of membrane localisation when 
compared to S2 cells expressing YFP-B long only, suggesting that DG1 may mediate the 
internalisation of the protein (figure 5.5 A). This is interesting, as DG1 is not endogenously 
expressed in S2 cells (Chintapalli et al., 2007). In either case, the two proteins show a large 
degree of co-localisation within the cytosol. DG1 localisation does not appear to alter when 
co-expressed with DmPDE11RB long. It appears that within the cytosol, 
(immuno)fluorescence of both proteins increases around what appear to be vacuoles, or 
some other organelle (figure 5.5 B, white arrows).  
In order to screen for co-localisation, S2 cells were co-transfected with YFP-DmPDE11 
RB long and c-Myc-DG2P1, and the subcellular localisation of the proteins was 
ascertained by confocal microscopy (figure 5.4). 
Figure 5.4: Confocal image of an S2 cell co-transfected with YFP-DmPDE11 RB long 
(green) and c-Myc-DG2P1. Subcellular localisation of c-Myc-DG2P1 was ascertained by 
staining with anti-c-Myc monoclonal antibody, TRITC secondary (red).  Nuclei were 
stained with DAPI (blue).  
 
In YFP-DmPDE11 RB long and c-Myc-DG2P1 co-transfected S2 cells, the proteins show 
a large degree of co-localisation. Localisation of DG2P1 is altered when compared to 
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individually transfected S2 cells, as the protein shows increased cytosolic localisation, and 
localises to foci within the cytosol similar to those of by PDE11B long. This finding was 
observed in several doubly transfected cells. The two proteins co-localise within these foci 
(white arrows), although DG2P1 shows localisation to additional foci that PDE11B long 
does not localise to. The two proteins co-localise to the membrane, where each protein has 
regions of increased intensity, and furthermore this variation in intensity shows a very 
similar pattern for the two proteins.  
In order to screen for co-localisation, S2 cells were co-transfected with YFP-DmPDE11 
RB long and c-Myc-DG2P2, and the subcellular localisation of the proteins was 
ascertained by confocal microscopy (figure 5.5). 
Figure 5.5: Confocal image of an S2 cell co-transfected with YFP-DmPDE11 RB long 
(green) and c-Myc-DG2P2. Subcellular localisation of c-Myc-DG2P1 was ascertained by 
staining with anti-c-Myc monoclonal antibody, TRITC secondary (red). Nuclei were 
stained with DAPI (blue).  
 
An overlay of PDE11B long and DG2P2 shows that the proteins show a large degree of co-
localisation, predominantly at the membrane, although also in the cytosol. Both proteins 
are excluded from what appear to be vacuoles or some other organelle (white arrows). The 
subcellular localisation of each protein does not noticeably change between co-transfected 
cells and individually transfected cells. 
5.4 Kinase assay from DG2 immunoprecipitate 
As DmPDE11 was shown to co-localise with DG2, it was reasoned that DmPDE11 may 
affect cGK activity, and that a reduction in DmPDE11 transcript levels and therefore 
protein levels might lead to an increase in cGK activity, due to an increase in localised 
[cGMP] concentration. In order to test this hypothesis, DG2 was immunoprecipitated from 
Malpighian tubule lysate of UAS-PDE11 RNAi (line 9), and c42/UAS-PDE11 RNAi (line 
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9) progeny using specific anti--DG2 antisera, and the immunoprecipitate was subjected to 
a kinase assay, which uses a bovine PDE5 substrate (“glasstide”) to measure ATP transfer 
and thus levels of total kinase activity, as detailed in materials and methods (figure 5.6).  
Figure 5.6: Malpighian tubules display a qualitative increase in kinase activity when 
PDE 11 expression is reduced in tubule principle cells via expression of a UAS-PDE11 
RNAi transgene with the GAL4 driver c42.  N=3 for each genotype, error bars show 
standard error of the mean. Statistical significance was not achieved, as determined by a 
two-way T-test. 
 
 
 
 
 
 
 
 
 
 
When DmPDE 11 expression was reduced in Malpighian tubule principal cells, total 
cGMP-dependant protein kinase activity of the whole tubule was qualitatively increased, 
but no significant difference was seen. However, the qualitative increase suggests that 
further analysis would be worthwhile; kinase assays at various concentrations of cGMP for 
each genotype would generate two response curves, which would show whether cGK 
activity was affected by DmPDE11 expression levels. 
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5.5 DmPDE11 C long and short co-immunoprecipitate 
with DG1, DG2P1, and DG2P2 
Appendix 4 shows data obtained by Day and Sebastian that provide evidence of an 
interaction between DmPDE11 and the cGKs, although only DG2P2 has been directly 
identified as co-immunoprecipiting, where it was shown to associate with DmPDE11 by 
MALDI-TOF MS analysis of DmPDE11 immunoprecipitate. The interaction of these 
proteins was investigated using co-immunoprecipitation, where immunoprecipitation was 
performed of c-Myc tagged cGK, and V5- and YFP-tagged DmPDE11, and the potential 
binding partner screened by immunoblot using anti-tag antibodies. Direct capture 
immunoprecipitation was employed for c-Myc and V5 tags, and indirect capture in the case 
of the YFP tag. That is, anti-c-Myc and –V5 antibodies were coupled to solid-state support, 
whereas anti-GFP (which recognise YFP) antibodies were captured using Protein-A 
conjugated sepharose beads. These methods are detailed in materials and methods. 
5.6 Immunoprecipitation of V5-tagged DmPDE11B, 
immunoblot of c-Myc-tagged cGK  
In order to determine which cGKs interact with DmPDE11B, coimmunoprecipitations 
were performed from the lysate of 3 x 10
6
 S2 cells co-transfected with one of YFP-tagged 
DmPDE11 RB and RC long and short, and one of c-Myc tagged DG1, DG2P1, or DG2P2. 
Additionally, 3 x 10
6
 S2 cells were singly-transfected with YFP-tagged DmPDE11 RB 
long and short, and with c-Myc tagged DG1, DG2P1, or DG2P2, and the lysate from these 
used as negative controls (Figure 5.7). 
 
 
 
 
 
 
 
171 
Figure 5.7: Immunoprecipitation of V5-PDE11B is enhanced when co-expressed with 
c-Myc-cGK.  S2 cells were transfected with V5-DmPDE11RB long (lane 1), V5-
DmPDE11RB short (lane 2), V5-DmPDE11RB long + c-Myc-DG1 (lane 3), V5-
DmPDE11RB short + c-Myc-DG1 (lane 4), V5-DmPDE11RB long + c-Myc-DG2P1 (lane 
5), V5-DmPDE11RB short + c-Myc-DG2)1 (lane 6), V5-DmPDE11RB long + c-Myc-
DG2P2 (lane 7), V5-DmPDE11RB short + c-Myc-DG2P2 (lane 8), c-Myc-DG1 (lane 9), 
c-Myc-DG2P1 (lane 10), c-Myc-DG2P2 (lane 11). Anti V5 immunoprecipitation 
performed with anti-V5 affinity gel (Invitrogen), blot probed with Anti c-Myc monoclonal. 
The predicted sizes of these (c-Myc tag included) are:  DG1 89 kDa, DG2P1 123kDa, 
DG2P2 85 kDa 
 
 
 
 
 
 
 
 
 
 
While a qualitative increase was seen in all double-transfected immunoprecipitations above 
negative controls (i.e., singly transfected immunoprecipitations), background was still 
apparent in cGK-only controls, and so the interaction could not be verified. This result was 
obtained several times. 
5.7 c-Myc cGK immunoprecipitation, anti-YFP DmPDE11 
immunoblot 
As a preliminary experiment to gauge conditions, without negative controls other than 
mock transfected S2 cells, S2 cells were co-transfected with one of c-Myc tagged DG1, 
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DG2P1, or P2, and one of YFP-tagged DmPDE11RC long or short. Lysates were 
precleared by incubation with rabbit serum (as EZview™ Red protein A affinity gel uses 
affinity purified anti-c-Myc rabbit polyclonal antibody), then incubated with EZview™ 
Red protein A affinity gel (Sigma). Supernatant was then incubated with EZview
™
 Red 
Anti-c-Myc Affinity Gel, then washed 3 x in 3T3 lysis buffer, and processed for SDS-page 
and immunoblotting. The figure is shown with a cropped, zoomed view of the DmPDE11C 
long bands for clarity (figure 5.8). 
 
Figure 5.8: YFP-DmPDE11C long co-IPs with DG2.  anti-YFP immunoblot of anti-c-
Myc immunoprecipitated DmPDE11-YFP/cGK-c-Myc overexpressing S2 cell lysate. 
Sample precleared in protein A beads, pulled down using 10μl anti-c-Myc proteinA beads, 
immunoblotted with a pool of anti-GFP monoclonal antibodies. The predicted sizes of 
these (tag included) are:  YFP-DmPDE11C long: 182 kDa, YFP-DmPDE11C short: 152 
kDa. 
 
 
 
 
 
 
 
 
 
 
 
Bands of the predicted size were obtained of YFP-DmPDE11C long in c-Myc DG2P1 and 
DG2P2/YFP-DmPDE11 RC long co-transfected S2 cell immunoprecipitate. No other 
bands of the predicted size are visible for the other experimental conditions.  
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Thus, the experiment was repeated, with an aim to reduce background, while boosting the 
signal of those interactions not confirmed by this experiment, and including DmPDE11 
transfected S2 cells as further controls. To boost the signal, the concentration of S2 cell 
lysate used was doubled, an increased amount of antibody used, and an increased 
incubation time in immunoblotting were used. To reduce background binding, the amount 
of beads used for antibody/protein capture was halved, the % Triton-X 100 in the lysis 
buffer used was increased from 1% to 1.5%, and more extensive washing was performed, 
where the amount of wash buffer was doubled, and the three wash steps were extended to 
10 min rotation at 4°C. For the immunoblot, block and wash steps were extended. The blot 
is shown in figure 5.9. 
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Figure 5.9: YFP-DmPDE11C long and short co-IP with DG1 and DG2. (A) S2 cells 
were transiently transfected with YFP tagged DmPDE11 RC long and short, both 
individually and in combination with c-Myc tagged DG1, DG2P1, and DG2P2. cGK was 
immunoprecipitated using c-Myc affinity gel, and the immunoblot was probed with αGFP 
antibody that recognises YFP in order to screen for co-immunoprecipitation of 
DmPDE11C and cGK. Expected band sizes: DmPDE11 RC long: 182 kDa, DmPDE11 RC 
short: 152kDa. (B) Control αc-Myc immunoblot of c-Myc-cGK immunoprecipitations, 
where an equal amount of beads were analysed by western blotting. Expected band sizes: 
c-Myc-DG1: 88.0 c-Myc-DG2P1: 122.5 kDa c-Myc-DG2P2: 84.5 kDa (C) Control αGFP 
immunoblot of equal amounts of S2 cell lysate prior to immunoprecipitation with c-Myc 
affinity gel. Expected band sizes: DmPDE11 RC long: 182 kDa, DmPDE11 RC short: 
152kDa. 
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This experiment yielded bands of the predicted size for all experimental conditions, bar the 
negative controls, and the DmPDE11C long/DG2P2 immunoprecipitation which gave a 
band in the prior experiment. An aliquot of each cell lysate was analysed by western 
blotting, to ensure equal DmPDE11C expression in each lysate, which was confirmed (data 
not shown).. The experiment should be repeated two more times, and repeated with YFP 
tagged DmPDE11 RB long and short. 
5.8 Discussion 
cGMP signalling is known to be highly compartmentalised, and so the subcellular 
localisation of DmPDE11A and DG2 were investigated in chapter 3, where DmPDE11A 
was shown to colocalise with DG2P1 and P2 in S2 cells. As CG34341 was now known to 
encode four isoforms that differ in sequence from the originally predicted DmPDE11A, the 
c-Myc tagged cGKs DG1, DG2P1, and DG2P2 were co-expressed with YFP-
DmPDE11RB long in S2 cells, to see if the proteins still showed co-localisation in light of 
DmPDE11B localising predominantly to the cell membrane, as opposed to the cytoplasmic 
localisation of DmPDE11A. Each cGK displayed strong co-localisation with YFP-
DmPDE11B long. DG1 is not endogenously expressed in S2 cells (Chintapalli et al., 
2007). Co-transfection of S2 cells with c-Myc-DG1 and YFP-DmPDE11RB long yielded 
some S2 cells in which YFP-DmPDE11B long showed a lower degree of membrane 
localisation. This could be mediated by a number of factors; direct association with the 
protein and sequestration to the cytosol, or modulation of localisation by phosphorylation, 
either of the PDE or some other substrate that then interacts with the PDE. While PKA has 
been shown to modulate the subcellular localisation of PDE10A by phosphorylation 
(Kotera et al., 2004), no examples have been shown where cGK alters the subcellular 
localisation of a PDE. 
YFP-DmPDE11B long also co-localises with c-Myc tagged DG2 P1 and P2, where the 
localisation of c-Myc-DG2P1 is altered, with increased cytosolic expression, in which the 
protein localises to foci. This increases co-localisation, as DmPDE11B long also localises 
to the cytosol, and foci within the cytosol, although these foci do not necessarily contain 
both proteins. 
When this experiment was performed, anti-DG1, anti-DG2, and anti-PDE11 antibodies had 
been designed against new epitopes, with the intention of apply these to 
immunocytochemistry of Malpighian tubules and other tissues to screen for co-localisation 
between the four DmPDE11 isoforms and the cGKs in vivo. However, the antibodies were 
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produced behind the anticipated schedule, by which time my time in the laboratory had 
finished. 
YFP tagged DmPDE11B long and short isoforms in tubule localise to the apical and 
basolateral membranes, which overlaps with the localisation of the cGKs in tubule. DG1 
localises to the basolateral membrane and the cytosol, DG2P1 localises to the apical and 
basolateral membranes, and DG2P2 localises to the apical membrane (MacPherson et al., 
2004b). In S2 cells, DmPDE11B long was shown to co-localise with DG1, DG2P1, and 
DG2P2. The DmPDE11C isoforms localise to some unidentified organelle or vesicle, 
which does not overlap with the subcellular localisation of any of the cGKs in the 
Malpighian tubule (other than perhaps DG1, which localises to the cytosol but 
predominantly to the basolateral membrane). Although the co-immunoprecipitation data 
reported in this chapter relates to both DmPDE11B and DmPDE11C isoforms, if co-
localisation is mediated by domains common to the B and C isoforms, it is possible that 
although both isoforms can potentially interact, that the in vivo localisation of these 
isoforms may dictate whether or not any interaction with the cGKs actually occur. To 
confirm this, immunocytochemistry of Malpighian tubules co-staining for cGK and each 
DmPDE11 isoform would demonstrate if in vitro demonstrations of interactions are 
potentially relevant in vivo. Clearly, the generation of tagged cGK expressing flies would 
allow co-immunoprecipitation to be applied to fly. Alternatively, the availability of 
specific anti-cGK and anti-DmPDE11 antisera would allow these to be used in 
immunoprecipitation; use of specific antisera against organisms and not cell systems is 
considered the gold standard for co-immunoprecipitation. The tubule would be a 
physiologically relevant tissue to use, as the cGKs have been shown to play roles in fluid 
secretion (MacPherson et al., 2004b), and cG-PDE function also modulates the process 
(MacPherson et al., 2004a). Furthermore, DG1 has a limited expression pattern, with high 
expression in the tubule and hindgut, and slight expression in head (and the tissues within). 
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Chapter 6 
Investigation of the DmPDE11/cGK interaction using 
peptide arrays 
6 Chapter 6 
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6.1 Summary 
In this chapter, peptide arrays were used to investigate if the interaction between 
DmPDE11 and the cGMP-dependent kinases is direct, and if so, identify the peptide 
sequence within these proteins responsible for these interactions. Peptide arrays 
representing the sequences of DmPDE11, DG1, and DG2 were generated using an autospot 
robot. The open reading frames of the genes encoding of these proteins were fused in-
frame into either pGEX-6P-1 or pET-28-c expression vectors in fragments to generate 
Glutathione-S-Transferase- (GST) or HIS6-tagged proteins respectively. These were 
transformed into BL21 (DE3) cells, and expression was analysed in terms of protein size, 
non-proteolysis, and solubility by western blotting. In all cases, HIS6 tagged fusion 
proteins were found to yield protein with more desirable characteristics, and so these were 
used to overlay the peptide arrays. Large scale purification was undertaken, and purified 
protein was then overlaid on the arrays, which were probed with HRP conjugated anti-HIS5 
antibody. These arrays were compared to negative controls, which were probed with a 
HIS6 protein derived from empty pET-28-c vector, then with antibody as above. Putative 
direct interactions were found between DG1 and DmPDE11, where three regions were 
identified on a DG1 peptide array that were immunoreactive when probed with a HIS6-
fused truncate of DmPDE incorporating the second GAF domain and the catalytic domain. 
Likewise when the PDE11 array was probed with a HIS6-fused DG1 C terminal truncate, 
two putative regions of interaction were found. Taken alongside the co-
immunoprecipitation data presented in chapter five, this provides evidence of a direct 
interaction that should be verified by alanine substitution arrays, or in vivo work.  Attempts 
to affinity purify DG1N-HIS6 failed, and so the DmPDE11 array was not probed with this 
fragment. Peptide array experiments to determine whether the interaction between DG2 
and DmPDE11 presented in chapter 5 is direct did not yield conclusive data, and so should 
be researched further. 
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6.2 Introduction 
Chapter six describes the use of peptide arrays to investigate the interactions between the 
four isoforms of PDE11, and the cGKs DG1, and DG2 presented in chapter 5. Spot 
synthesis, the technique of synthesising multiple peptides or peptide chains simultaneously 
onto a membrane, was first described in 1992 (Frank, 1992). The screening of these 
peptide libraries with overlaid protein, metal and DNA was described the next year 
(Kramer et al., 1993). The process of mapping protein-protein interaction sites was 
validated in a paper that forms the basis for current peptide array techniques (Reineke et 
al., 1996). The process sees the entire sequence of a protein of interest arrayed onto a 
membrane by an autospot robot using F-moc chemistry in spots of 25 amino acids, 25mers, 
which overlap by 20 amino acids. Thus each subsequent spot represents a 5 amino acid 
frameshift within the sequence. These peptide arrays are probed with soluble, recombinant 
protein, which is tagged with a protein tag. This tag acts both as an affinity tag, which 
permits the affinity purification of the protein, and as an epitope tag, which allows the use 
of an anti-tag antibody to identify those 25mer spots which have bound, interacting 
protein. A primary, “antibody only” experiment identifies spots that are present as 
background, i.e., they are immunoreactive in the absence of overlaid protein of interest. 
Tagged protein of interest is then overlaid on the array, and the array probed with anti-tag 
antibody; immunoreactive spots not present in the initial control experiment are considered 
as putative sites of interaction. 
In the course of this study, Glutathione-S-Transferase (GST) and HIS6 tagged proteins 
were generated. The HIS6 tag is highly suitable for use in peptide arrays, due to the 
availability of specific monoclonal antibodies, the small size of the tag, and thus minimal 
disruption of protein structure, and its reversible affinity for metal matrices, which aids in 
protein purification. The GST tag is larger, and so may compromise overall protein levels 
and structure, but acts as a solubilisation tag, which aids in the solubilisation of the protein, 
and thus may prevent the formation of inclusion bodies. Its affinity for glutathione allows 
its affinity purification, and again there are specific antibodies available. For HIS6, 
negative controls are performed by overlaying an array with purified HIS6 peptide, then 
immunoblotting with anti-HIS5-HRP coupled mouse monoclonal antibody (Qiagen). GST 
negative controls are performed with a monoclonal anti-Glutathione-S-Transferase 
antibody (Sigma-Aldrich).  
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Like yeast two-hybrid, false positives and false negatives can occur. Expressing a fusion 
protein transgenically in E. coli can yield proteins that do not behave as they would in 
mammalian systems. Misfolding may occur, the protein may be unavoidably degraded 
during cell lysis and subsequent protein purification, or inclusion bodies may form, 
rendering the protein insoluble. As the tertiary structure of an individual domain may be 
influenced by other domains within the protein, a truncated, transgeneically expressed 
protein may adopt a novel structure, which may alter the protein‟s binding properties, 
which in turn may result in false positive or false negative interactions. The conformation 
of the spotted peptide may not be suitable to facilitate binding, or the spot may be 
immunoreactive in negative controls, thus masking the interaction site. The array may 
present epitopes that do not reside on the surface of the protein in vivo, which may result in 
false positive interactions. Despite this, the system offers an unparalleled opportunity to 
not only detect if a protein-protein interaction is direct, but to identify those amino acids 
responsible for the interaction. 
Ideally, the generation of both peptide arrays and tagged recombinant protein for two 
potential interactors should yield reciprocal binding sites. This data can be confirmed by 
alanine substitution arrays, which sequentially replace each amino acid within the stretch 
of sequence positive for an interaction with an alanine residue, which renders the 
interaction null if that residue was vital for the interaction (Gibbs and Zoller, 1991; 
Uttamchandani et al., 2003); in this case, it is the non-immunoreactive spots that are 
informative.  
Taken together, it is clear that any positives are considered putative, but where an array is 
confirmed by an alanine array, which identifies individual amino acids essential for the 
interaction, this knowledge can then be used to screen for any resultant phenotypes when 
this interaction is disrupted. This can be achieved through the generation of a protein 
mutated at this site, or via the generation of peptides representing this sequence, which will 
act as a dominant-negative when present in excess, or by generating protein mutant at this 
site. This can be used in co-immunoprecipitation to confirm that an interaction has been 
rendered null, or a transgenic animal or cell can then be subjected to a functional assay in 
which the mutant protein has been implicated.  
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6.3 Generation of peptide arrays 
Peptide arrays representing the sequence of DmPDE11 RB and RC, and DG1 were 
produced in collaboration with Dr. Alan Dunlop of the Houslay laboratory. Two arrays 
representing the sequence of DG2 were produced by Dr George Baillie as part of a 
previous collaboration with Dr Matt Macpherson. 
 
6.4 Design of truncate fusion protein 
The E. coli pET and pGEX expression systems will facilitate a maximum of 2kb of ORF 
sequence. As the DmPDE11 and cGK ORFs are significantly larger than this, it was 
necessary to generate tagged truncates which would still incorporate entire functional 
domains, as protein-protein interactions can occur at the level of domain-domain 
interactions (DDIs) (Pawson and Nash, 2003). The amino acid sequences were analysed 
using InterProScan (Zdobnov and Apweiler, 2001). InterProScan uses a total of ten 
databases including PFAM, SMART, and PROFILE to define each functional domain 
within the protein (Quevillon et al., 2005). As each database gives a different prediction as 
to the extent of each domain, the region of truncation was determined by selecting regions 
that are not designated as domains by any of the tools, with the rationale that domains will 
not be truncated with this approach. 
 
6.4.1 Consideration of Drosophila cGK literature 
DG1 and DG2 were isolated in 1989 (Kalderon and Rubin, 1989). Phylogenetic analysis 
suggested that DG1 is most closely related to mammalian type II cGK, and DG2 is most 
closely related to mammalian type I cGK (Jarchau et al., 1994). As well as this work there 
are of course a number of papers focusing on these important Drosophila enzymes. As 
such there is further information pertaining to the location of domains within DG1 and 
DG2; indeed, the InterProScan database uses some of these domains in its analysis. A 
dimerisation domain is believed to reside within the amino terminal of both DG1 and DG2, 
but amino acid similarity with the dimerisation domain of mammalian cGK is so low that 
InterProScan does not predict the domain. The exact size and location is unknown in both 
enzymes and is thus not shown. Likewise, a regulatory domain is believed to be present in 
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each enzyme, but low homology prevents computational prediction of its localisation (Heil 
et al., 1987; Monken and Gill, 1985; Takio et al., 1984). It is believed to be directly N-
terminal of the CNB domains. The bovine regulatory domain acts as a substrate analogue 
and binds to the catalytic domain at a lower affinity than cGMP, and thus impairs function 
in the absence of cGMP. However, Kalderon and Rubin believe that homology of this 
regulatory domain is low enough in both DG1 and DG2 that the mode of regulation may 
differ in Drosophila.  
 
6.4.2 DG1 
The amino acid sequence of DG1 was analysed using Interproscan (table 6.1). 
 
Table 6.1: Interproscan analysis of DG1 
Domain Program Site
Cyclic nucleotide binding domain PFAM 203-285 322-415
SMART 185-299 304-428
PROFILE 185-301 304-427
Protein kinase, core PROFILE 457-717
AGC Kinase, C terminal SMART 718-768
PROFILE 718 - 768  
 
InterProScan analysis revealed a length of sequence between the twin cyclic nucleotide 
binding domains and the kinase domain around halfway through the protein which was not 
designated as a domain, and so the constructs were generated using this as the boundary. 
DG1 is 768 amino acids in length. The N terminal truncate is 427 amino acids in length 
and extends to the end of the second of the cyclic nucleotide binding (CNB) domains, and 
incorporates the dimerisation and regulatory domains. The C terminal truncate extends 
from the end of the second CNB domain to the end of the protein, thus incorporating the 
kinase, ATP binding domains, and the AGC (cAMP-dependent, cGMP-dependent and 
protein kinase C) kinase C-terminal domain, a regulatory domain conserved between a 
diverse range of kinases (Kannan et al., 2007; Newton, 2003) and consists of 341 amino 
acids (figure 6.1).  
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Figure 6.1: Primary structure of DG1, showing regions used to generate fusion 
proteins. Shaded cylinders represent domains. Drawn to scale. 
 
 
 
 
 
                      N terminal truncate                                  C terminal truncate 
 
 
6.4.3 DG2  
The amino acid sequence of DG2 was analysed using Interproscan (table 6.2). 
 
Table 6.2: Interproscan analysis of DG2 
Domain Program Site
Cyclic nucleotide binding domain PFAM 538-623 656-749
SMART 520-636 656-749
PROFILE 520-635 638-761
Protein kinase, core PROFILE 777-1036
AGC Kinase, C terminal SMART 1037-1088
PROFILE 1037-1088  
 
DG2 P1 is 1088 amino acids in length; DG2 P2, the other active DG2 isoform in 
Drosophila (MacPherson et al., 2004), is a truncate of this and is represented entirely 
within the DG2 P1 sequence (http://flybase.org/reports/FBgn0000721.html). InterProScan 
analysis shows that the CNB domain starts at amino acid 520, and so this was picked as the 
boundary. The N terminal truncate is 519 amino acids long, and incorporates the 
CNB1 CNB2 Catalytic domain 
AGC kinase 
C terminal 
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dimerisation and regulatory domains. The C terminal truncate is 569 amino acids long and 
incorporates the ATP binding, twin CNB, protein kinase, and the AGC kinase C terminal 
domains (figure 6.2). 
 
Figure 6.2: Primary structure of DG2 (P1), showing regions used to generate fusion 
proteins. Shaded cylinders represent domains. Drawn to scale. 
 
 
 
  
                 N terminal truncate                                     C terminal truncate 
 
6.5 DmPDE11 
The amino acid sequence of DmPDE11 was analysed using Interproscan (table 6.3). 
 
Table 6.3: Interproscan analysis of DmPDE11. Amino acids refer to those of 
DmPDE11B long. 
Domain Program Residues
3'5'-cyclic nucleotide phosphodiesterase PFAM 859-1097
PROSITE 900-911
GAF PFAM 419 - 572 604 - 754
SMART 419 - 582 604 - 764 
 
As a size of 2kb was the maximum size of insert that the E. coli expression vectors could 
facilitate, the ~4.5kb DmPDE11 ORF was cloned as three fusion protein truncates. 
CNB1 CNB2  
 
AGC kinase 
C terminal 
Kinase domain 
186 
InterProScan analysis dictated that the best three-way split would be two N terminal 
truncates, incorporating sequence from the unique B or C isoform N termini, until the end 
of the first GAF domains, and thus the B isoform N terminal fragment incorporates 582 
amino acids, and the C isoform N terminal fragment incorporates 538 amino acids. The 
“Middle” truncate incorporates sequence ranging from the start of the second GAF domain 
until the end of the catalytic PDEase domain, and consists of 515 amino acids. The “End” 
C terminal truncate extends from the end of the catalytic domain to the end of the long C-
terminus, and consists of 354 amino acids (figure 6.3).  
 
Figure 6.3: Primary structure of DmPDE11, showing regions used to generate fusion 
proteins. Shaded cylinders represent domains. Drawn to scale. 
 
 
 
                  N terminal truncate                       “Middle” truncate                 “End” truncate   
 
The unique sequence within the short C terminal is represented in the PDE11 peptide 
array; as the sequence is so short, and co-immunoprecipitations show an interaction with 
both the long and short isoforms, it was assumed that it would not mediate the interaction. 
6.6 Cloning of ORFs into expression vectors 
Primers were designed to generate E. coli expression constructs for all of the above 
truncates, using pET-28-c, a gene fusion vector with an N terminal HIS6-thrombin-T7 tag, 
and pGEX-6P-1, a gene fusion vector with an N terminal Glutathione S-Transferase (GST) 
tag. All ORFs were amplified using proofreading DNA polymerase from previously 
verified plasmid DNA, with primers designed to incorporate restriction sites not present in 
 
GAF1   GAF2  Long C terminus 
Catalytic 
 domain 
 
Unique B/C  
 N-termini 
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the ORF, but present in the multiple cloning site to permit direction cloning of the inserts. 
These PCR fragments were digested with the appropriate restriction enzymes, and ligated 
into digested expression vector. These were transformed into Stratagene Gold 
ultracompetent cells, and plasmid DNA was recovered from multiple colonies by miniprep 
and screened using both digestion and PCR analysis.  
 
6.7 Expression of constructs 
As pET and pGEX constructs were generated for each gene, it was sought to determine 
which of these, in each case, provided the greater amount of pure, non-degraded protein by 
performing small scale growth and induction to analyse by western blot. In each case, 
BL21 (DE3) pLysS competent cells were transformed with plasmid DNA, and a colony 
used to generate a 3ml culture, which was grown to an OD600 of ≥0.6 – ≤1.0 at 37˚C with 
shaking. Of 1 ml, 100μl was spun down, the pellet used as a non-induced control, and 
900μl to make a glycerol stock. The remaining 2ml was induced with 0.4mM IPTG 
(pGEX) or 0.1mM IPTG (pET) for two hours. Two 1 ml aliquots were spun down and 
lysed, one in IGEPAL lysis buffer to completely solubilise the cellular protein, the other in 
the appropriate native lysis buffer using L3 sonication, both with protease inhibitor and 
lysed on ice. These were run alongside the non induced control (also lysed in IGEPAL 
with an identical dilution factor) on an SDS page gel, and western blotting was performed 
with the appropriate antibody. 
Comparison between HIS6- and GST-tagged protein lysate showed HIS6 tagged protein 
showed higher levels of immunoreactivity, and lower levels of background, for which most 
of the GST lysates displayed high levels (data not shown). The HIS6 protein also displayed 
lower levels of degradation. Although this may have been down to a poor anti-GST 
antibody, the HIS6 tagged protein expression did not appear to need any modification of 
protocol (with the exception of the DmPDE11 End fragment, which gave an equally poor 
yield when tagged with GST), and thus these were affinity purified using Ni-NTA columns 
for use with the arrays, as detailed in materials and methods. 
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6.8 Purification of HIS6 protein 
HIS6 protein was purified using a Ni-NTA column as described in materials and methods. 
5 μl aliquots of lysate (following application to column), wash fraction, and the 1 ml HIS6 
eluates were analysed by western blotting. 
6.8.1 HIS6 
HIS6 protein was generated by the transformation of pET-28-c vector into BL21 (DE3) 
pLysS competent cells, for use as a negative control. The HIS6 protein has an expected size 
of ~3 kDa. Affinity purified fractions were analysed by western blotting (figure 6.4). 
 
Figure 6.4: HIS6 purified peptide. HIS6 peptide, from pET-28-c vector. 14% SDS-PAGE 
gel. Lane 1: run-through lysate applied to column, lane 2: wash fraction, lanes 3 – 11: 
purified fractions. 1
◦
 antibody anti-HIS6 mouse monoclonal HRP conjugated.  
 
 
 
 
 
 
 
Western analysis of HIS6 purified protein yielded a band of the predicted size, and showed 
no unspecific bands. The protein purified to a high concentration. 
 
6.8.2 DmPDE11BN-HIS6 
DmPDE11BN-HIS6 protein (BN-HIS6) was generated by the transformation of 
DmPDE11RBN-pET-28-c vector into BL21 (DE3) pLysS competent cells. BN-HIS6 
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protein has an expected size of ~67 kDa. Affinity purified fractions were analysed by 
western blotting (figure 6.5). 
 
Figure 6.5: BN-HIS6 purified protein. 10% SDS-PAGE gel. Lane 1: run-through lysate 
applied to column, lane 2: wash fraction, lanes 3-10: purified fractions, lanes 11 and 12: 
fractions purified at a higher imidazole concentration. 
 
 
 
 
 
BN-HIS6 purified protein was of the predicted size, recovered at a high concentration, 
higher in those fractions containing a high concentration of imidazole, and showed little 
degradation, increased in the higher imidazole elates; as such these were not used.  
 
6.8.3 DmPDE11CN-HIS6 
DmPDE11CN-HIS6 (CN-HIS6) protein was generated by the transformation of 
DmPDE11RCN-pET-28-c vector into BL21 (DE3) pLysS competent cells. CN-HIS6 
protein has an expected size of ~61 kDa. Affinity purified fractions were analysed by 
western blotting (figure 6.6) 
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Figure 6.6: CN-HIS6 purified protein. 10% SDS-PAGE gel. Lane 1: soluble lysate, lane 
2: wash fraction, lanes 3-9: purified fractions, lanes 10 and 11: fractions purified at a 
higher imidazole concentration. 
 
 
 
 
 
 
CN-HIS6 purified protein was of the expected size (lane 9), was recovered at a low 
concentration only from those fractions eluted using a high concentration of imidazole, and 
showed no appreciable degradation. 
 
6.8.4 DmPDE11 Middle-HIS6 
DmPDE11 Middle-HIS6 protein was generated by the transformation of Middle-pET-28-c 
vector into BL21 (DE3) pLysS competent cells. Middle-HIS6 protein has an expected size 
of ~62 kDa. Affinity purified fractions were analysed by western blotting (figure 6.7). 
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Figure 6.7: Middle-HIS6 purified protein. 10% SDS-PAGE gel. Lane 1: soluble lysate, 
lane 2: wash fraction, lanes 3-9 purified fractions: lanes 10 and 11: fractions purified at a 
higher imidazole concentration.  
 
 
 
 
 
Middle-HIS6 purified protein was of the expected size, and was recovered at a reasonable 
concentration. The protein showed no appreciable degradation.  
6.8.5 End-HIS6 
DmPDE11 End-HIS6 protein was generated by the transformation of End-pET-28-c vector 
into BL21 (DE3) pLysS competent cells. End-HIS6 protein has an expected size of 41 kDa. 
Affinity purified fractions were analysed by western blotting (figure 6.8). 
Figure 6.8: End-HIS6 purified protein. 10% SDS-PAGE gel. Lane 1: soluble lysate, lane 
2: wash fraction, lanes 3-9: purified fractions, lanes 10 and 11: fractions purified at a 
higher imidazole concentration. 
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Although protein of the predicted size purified at high concentration, the protein showed 
high levels of degradation. Furthermore a non-specific band of ~64 kDa co-purified with 
the fusion protein. Subsequent to this attempt, incubation with MgSO4 for 30 min prior to 
application to the column prevented the 64 kDa protein, which the literature suggests is the 
common contaminant DnaK, from co-purifying, although the immunoblot of the 
subsequent western blot was “dirty”; although the bands were clearly visible, the blot 
would not scan clearly, and so is not shown. In lanes with a higher concentration of 
protein, immunoreactive protein that had not migrated from the wells was present, which 
suggests that the protein forms inclusion bodies at high concentrations. The gel shown has 
two lanes with protein of the correct size, with little degradation (lanes 7 and 9); the 
compromised transfer showed bands equally pure without DnaK, and so these eluates were 
applied to the array. 
6.8.6 DG1N-HIS6 
DG1N-HIS6 protein was generated by the transformation of DG1N-pET-28-c vector into 
BL21 (DE3) pLysS competent cells. DG1N-HIS6 yielded soluble protein of ~50 kDa at the 
analytical stage, yet no protein was observed in western blots of Ni-Nta column purified 
protein. This was despite attempts to optimise the purification protocol, by excluding 
imidizole from the binding buffer, using a reduced-strength wash buffer, varying the length 
of the binding step, and performing the purification as quickly as possible to minimise 
degradation (data not shown). 
 
6.8.7 DG1C-HIS6 
DG1C-HIS6 protein was generated by the transformation of DG1C-pET-28-c vector into 
BL21 (DE3) pLysS competent cells. DG1C-HIS6 protein has an expected size of ~42 kDa. 
Purified fractions were analysed by western blotting (figure 6.9). 
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Figure 6.9: DG1C-HIS6 purified protein. 10% SDS-PAGE gel. Lane 1: soluble lysate, 
lane 2: wash fraction, lanes 3-9: purified fractions, lanes 10 and 11: fractions purified at a 
higher imidazole concentration. 
 
 
 
 
 
Protein of the predicted size purified at high concentration under elution conditions of high 
levels of imidazole (lanes 10 and 11). The protein showed mild levels of degradation, but 
these bands were less strong than the desired size of band. Subsequent to this first attempt, 
incubation with MgSO4 for 30 min prior to application to the column prevented co-
purification with the ~64 kDa protein, identified as DnaK, from co-purifying, although the 
transfer of this gel was compromised as above and so is not shown.  
6.8.8 DG2N-HIS6 
DG2N-HIS6 protein was generated by the transformation of DG2N-pET-28-c vector into 
BL21 (DE3) pLysS competent cells. DG2N-HIS6 protein has an expected size of ~60 kDa. 
Purified fractions were analysed by western blotting (figure 6.10). 
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Figure 6.10: DG2N-HIS6 purified protein. 10% SDS-PAGE gel.  Lane 1: soluble lysate, 
lane 2: wash fraction, lanes 3-9: purified fractions, lanes 10 and 11: fractions purified at a 
higher imidazole concentration. 
 
 
 
 
DG2N-HIS6 purified protein ran as two bands, one of the expected size, and one ~5 kDa 
larger. Reasons for this are unknown; perhaps the protein was subjected to a post 
translational modification. Protein was recovered at a reasonable concentration where an 
increased concentration of imidazole was used, and showed no degradation, in lanes 
outside of the lysate and wash. 
6.8.9 DG2C-HIS6 
DG2C-HIS6 protein was generated by the transformation of DG2C-pET-28-c vector into 
BL21 (DE3) pLysS competent cells. DG2C-HIS6 protein has an expected size of ~67 kDa. 
Purified fractions were analysed by western blotting (figure 6.11). 
 
Figure 6.11: DG2C-HIS6 purified protein. 10% SDS-PAGE gel.  Lane 1: soluble lysate, 
lane 2: wash fraction, lanes 3-9: purified fractions, lanes 10 and 11: fractions purified at a 
higher imidazole concentration. 
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DG2C-HIS6 purified protein was of the expected size, highly pure, recovered at a low 
concentration from elution conditions of increased imidazole concentration, and showed no 
discernable degradation outside of the wash fraction. 
 
6.9 Screening of peptide libraries for direct interactions 
In order to identify non-specific immunoreactive spots, each array was probed with 
purified HIS6 protein at a concentration approximately equimolar to that of the purified 
gene – HIS6 fusion protein subsequently applied, and detected with an anti-HIS5 HRP 
conjugated monoclonal antibody, using several lengths of exposure. Arrays were then 
probed with a protein of interest fused to HIS6 at 10 μg/ml, and probed with an anti-HIS5 
HRP conjugated monoclonal antibody as before. Putative direct interactions were 
identified by comparing control arrays with gene-HIS6 probed arrays; where a spot is 
immunoreactive on the array probed with the gene-HIS6 that is not immunoreactive on the 
control array, it is considered a putative interaction site. Arrays were stripped between 
probes. The technique is described in detail in materials and methods. 
6.10 PDE11 Array 
A peptide array representing the sequence of DmPDE11, including sequence of the unique 
N-termini of the B and C isoforms, and the unique sequence of the short isoform C 
terminus, was produced in collaboration with Dr Allan Dunlop, and was probed with cGK 
fusion protein in order to detect putative interaction sites. 
6.10.1 PDE11 array probed with HIS6 
As a control, the PDE11 array was probed with a control peptide, HIS6, at a concentration 
approximately equimolar to that of the gene – HIS6 fusion proteins that were subsequently 
applied, and non-specific spots were identified with an anti-HIS5 HRP conjugated 
monoclonal antibody (figure 6.12). 
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Figure 6.12: PDE11 array probed with HIS6. The DG2 array was probed with HIS6 
protein. Non-specific spots were identified by staining with an anti-HIS5 HRP conjugated 
monoclonal antibody. Arrays exposed to film for 10 minutes. 
 
 
There is a large degree of background. Rows of immunoreactive spots contain either 
HIS5mers, which matches the specificity of the αHIS5 antibody used, or contain HIS5mers 
with a single amino acid substitution (such as HHHNH, in the case of the two rows near 
the top left of the array), suggesting that conditions permit antibody binding to epitopes 
that are not 100% specific. The C terminal region of PDE11 has two histidine rich regions, 
which are represented in two strips of spots, 864-871, and 882-888.  
 
6.10.2 PDE11 array probed with DG1C-HIS6 
The PDE11 array was probed with DG1C-HIS6 protein. Specific interacting spots were 
identified by staining with an anti-HIS5 HRP conjugated monoclonal antibody, and 
comparing these to a control exposed for 10 minutes (figure 6.13). 
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Figure 6.13: PDE11 array probed with DG1C-HIS6, shown alongside HIS6 control. 
The PDE11 array was probed with DG1C-HIS6 protein. Interacting spots were identified 
by staining with an anti-HIS5 HRP conjugated monoclonal antibody. Putative interaction 
sites are highlighted with a solid or dashed line. Array exposed to film for 1 minute. 
 
 
PDE11 array probed with HIS6. Array exposed to film for 10 minutes. 
 
 
Spots 729 – 732 (highlighted with a solid line) and spot 763 (highlighted with a dashed 
line) are immunoreactive after a mere 30 seconds of exposure on the PDE11 array 
challenged with DG1C-HIS6 and are negative on both HIS6 controls, suggesting that these 
regions interact with the sequence of DG1 represented by DG1C-HIS6, which consists of 
the final 341 amino acids of the protein, thus incorporating the kinase, and ATP binding 
domains. These spots correspond the sequence 
VHEADKGSFSRVFDFEANDLSEEEATSRTSPYESRFPINI (amino acids 630-669), and 
VHFRLHDFKFDDIHFEDDDTLKACL (amino acids 800 - 824) within DmPDE11, using 
DmPDE11 B long as a reference. These residues fall within the second GAF domain, and 
the region between the second GAF domain and the catalytic domain respectively, and as 
such both are found in the region of PDE11 shared by all four isoforms, and are included in 
Middle-HIS6 (figure 6.14).  
198 
Figure 6.14: PDE 11, with putative regions of interaction with the C terminus of DG1. 
Exposures of equal time (5 minutes) shown. Top array control, bottom array probed with 
DG1C-HIS6. 
 
 
 
 
 
 
 
 
 
Analysis of both regions with NetPhosK predicts no putative cGK phosphorylation sites in 
either region of putative interaction. However, NetPhosK predicts serine 798 (of 
DmPDE11B long) to be phosphorylated by cGK with a score of 0.68 (Blom et al., 2004), 
two amino acids immediately proximal to the 25mer of spot 763 showing strong 
immunoreactivity. Indeed this spot is immunoreactive in the DG1C-HIS6 probed PDE11 
array compared to control, but not to a convincing extent. 
 
6.10.3 PDE11 array probed with DG2N-HIS6 
The DmPDE11 peptide array was probed with DG2N-HIS6 in order to detect any putative 
interaction sites. Specific interacting spots were identified by staining with an anti-HIS5 
HRP conjugated monoclonal antibody, and comparing these to a control exposed for 10 
minutes, as this has similar background (figure 6.15). 
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Figure 6.15: PDE11 array probed with DG2N-HIS6, shown alongside HIS6 control. 
The PDE11 array was probed with DG2N-HIS6 protein. Interacting spots were identified 
by staining with an anti-HIS5 HRP conjugated monoclonal antibody. Array exposed to film 
for 1 min. 
 
 
PDE11 array probed with HIS6. Array exposed to film for 10 min. 
 
 
Compared to the HIS6-probed control PDE11 array, the DG2N-HIS6 probed PDE11 array 
showed a stronger average signal for each length of exposure, and as such the DG2N-HIS6 
probed array exposed for 1 min is compared to a HIS6 control PDE11 array of ten minutes. 
Curiously, there are a number of spots positive in control blots that were not strongly 
immunoreactive in the DG2N-HIS6 probed array even after a 20 min exposure. The reason 
for this is unknown. Comparison of the DG2N-HIS6 probed PDE11 array with control does 
not show any novel spots. As such, there is no evidence of interaction. It does, however, 
merit further investigation. Use of a different anti-(poly)HIS antibody may reduce the non-
specific immunoreactivity of non-specific immunoreactive spots, which would allow the 
array to be re-probed with DG2N-HIS6. Alternatively, probing the array with GST-fused 
DG2N would give a different set of non-specific immunoreactive spots, and thus perhaps 
be more informative.  
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6.10.4 PDE11 array probed with DG2C-HIS6 
The DmPDE11 peptide array was probed with DG2C-HIS6 in order to detect any putative 
interaction sites. Specific interacting spots were identified by staining with an anti-HIS5 
HRP conjugated monoclonal antibody, and comparing these to a control exposed for 10 
minutes, as this has similar background (figure 6.16). 
Figure 6.16: PDE11 array probed with DG2C-HIS6, shown alongside HIS6 control. 
The DG2 array was probed with HIS6 protein. Interacting spots were identified by staining 
with an anti-HIS5 HRP conjugated monoclonal antibody. Array exposed to film for 5 min. 
 
PDE11 array probed with HIS6. Array exposed to film for 10 min. 
 
 
When the PDE11 array is probed with DG2C-HIS6, spots 729-730, represented by a solid 
black line (VHEADKGSFSRVFDFEANDLSEEEATSRTS, amino acids 630-659) and 
763, represented by a dashed line (VHFRLHDFKFDDIHFEDDDTLKACL, amino acids 
800 - 824) are immunoreactive when compared to the HIS6 probed control. These spots 
were also immunoreactive when overlaid with DG1C-HIS6. However these spots are 
considerably weaker than those seen in the DG1C-HIS6 probed PDE11 array, and as the 
DG2C-HIS6 result was obtained subsequently to the DG1C-HIS6 result, a stripping issue 
cannot be ruled out. A further two regions are immunoreactive in DG2-HIS6 probed 
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PDE11 array, that show no detectable immunoreactivity on HIS6 probed control PDE11 
blots; spot 652, represented by a double solid line 
(THANGQTSSSRGGSGATTPVRKISA, amino acids 245-269) and 703, represented by a 
double dashed line (amino acids 500-524), are immunoreactive in the DG2C-HIS6 probed 
blot. In all cases, “specific” immunoreactive spots do not display immunoreactivity 
comparable to putative positive spots returned by other arrays are, and as such it is 
desirable that the array be re-probed, or alanine substitution arrays generated representing 
these areas to verify the interaction. Certainly, these are not immunoreactive to an extent 
that they can be considered to constitute putative sites of interaction. 
 
6.11 DG1 Array 
A peptide array representing the sequence of DG1 was produced in collaboration with Dr 
Allan Dunlop, and was probed with Middle-HIS6 protein, as a putative direct interaction 
was found when the PDE11 array was probed with DG1C-HIS6 protein. Time did not 
permit the probing of the array with the other DmPDE11 fusion proteins. One aspect of the 
protocol was changed for the DG1 arrays; ECL Plus Western Blotting Detection Reagent 
(Amersham) was used, which gives a wider dynamic range compared to ECL Western 
Blotting Detection Reagent. This had the effect of reducing the necessary time of exposure, 
and also had increased reactivity with the membrane itself. As such, blots of 5 minutes or 
over had overly high levels of background, and so these are not shown. 
6.11.1 DG1 array probed with HIS6 
As a control, the DG1 array was probed with a control peptide, HIS6, at a concentration 
approximately equimolar to that of the gene – HIS6 fusion proteins that were subsequently 
applied, and non-specific spots were identified with an anti-HIS5 HRP conjugated 
monoclonal antibody (figure 6.17). 
 
 
 
202 
Figure 6.17: DG1 array probed with HIS6. The DG2 array was probed with HIS6 
protein. Non-specific spots were identified by staining with an anti-HIS5 HRP conjugated 
monoclonal antibody. Array exposed to film for 2 min 30 s. 
 
6.11.2 DG1 array probed with DmPDE11 Middle-HIS6 
The DG1 peptide array was probed with Middle-HIS6 in order to detect any putative 
interaction sites (figure 6.18).  
Figure 6.18: DG1 array probed with Middle-HIS6, shown alongside HIS6 control. The 
DG2 array was probed with Middle-HIS6 protein. Interacting spots were identified by 
staining with an anti-HIS5 HRP conjugated monoclonal antibody. Array exposed to film 
for 1 min. 
 
PDE11 array probed with HIS6. Array exposed to film for 2 min 30 s. 
 
 
Spots 104-105, highlighted by a solid line, 
(LVKLHREIHKLKSVLQQTTNNLNVTREIHK, amino acids 60-90)  are strongly 
immunoreactive compared to control probed arrays, and furthermore these spots give no 
immunofluorescence in a control exposed for 5 minutes (data not shown). There are two 
further spots that give immunofluorescence in the Middle-HIS6 probed DG1 peptide array; 
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spots 169-170, highlighted by a dashed line 
(EETELRTLSRGDYFGEQALINEDKRTANII, amino acids 360-390), and spots 233-235 
highlighted by a double solid line 
(ISRWAVQLIKRLCRDVPSERLGYQTGGIQDIKKHK, amino acids 680-715) (figure 
6.19). 
 
Figure 6.19: DG1, with putative regions of interaction with sequence represented by 
the Middle-HIS6 fusion protein. Exposures of 1 min (Middle-HIS6 probed) and 2 min 30 
s (HIS6 probed) shown. Top array control, bottom array probed with DG2C-HIS6. 
 
 
 
 
 
 
The first two putative regions of interaction identified in the Middle-HIS6 probed DG1 
array localise to a region of the N terminus not well characterised – the N terminus 
contains the dimerisation and regulatory domains, but the exact location of these is 
unknown - and to the second CNB domain. The third putative region of interaction falls 
within the catalytic domain of the enzyme, which is sequence represented by the DG1 C 
terminal truncate. DG1C-HIS6 showed two putative regions of interaction within 
DmDPE11 when applied to the PDE11 array. As two of the putative regions of interaction 
with PDE11 are represented by DG1N-HIS6, it would be desirable to probe the PDE11 
peptide array with this truncation in order to screen for a reciprocal interaction. Alanine 
substitution arrays would provide further proof that these regions interact, and identify 
individual amino acids within these regions vital to the interaction.  
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6.12 DG2 Array 
A peptide array representing the sequence of DG2 P1, which incorporates the amino acid 
sequence of DG2 P2 in its entirety, was available from a collaboration between Dr Matt 
Macpherson and Dr George Baillie. As putative direct interactions were found when the 
PDE11 array was probed both DG2 HIS6 fusion proteins, the DG2 array was probed with 
every HIS6-tagged fragment of DmPDE11, in order to detect any putative interaction sites. 
6.12.1 HIS6 Control 
As a control, the DG2 array was probed with a control peptide, HIS6, at a concentration 
approximately equimolar to that of the gene - HIS6 fusion proteins that were subsequently 
applied, and non-specific spots were identified with an anti-HIS5 HRP conjugated 
monoclonal antibody (figure 6.20). 
 
Figure 6.20: DG2 array probed with HIS6. The DG2 array was probed with HIS6 
protein. Non-specific spots were identified by staining with an anti-HIS5 HRP conjugated 
monoclonal antibody. Array exposed to film for 15 min. 
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6.12.2 DG2 array probed with DmPDE11-HIS6 
6.12.2.1 BN-HIS6  
The DG2 array was probed with BN-HIS6 protein. Specific interacting spots were 
identified by staining with an anti-HIS5 HRP conjugated monoclonal antibody, and 
comparing these to the equivalent control (figure 6.21). 
Figure 6.21: DG2 array probed with BN-HIS6, shown alongside HIS6 control. The 
DG2 array was probed with BN-HIS6 protein. Interacting spots were identified by staining 
with an anti-HIS5 HRP conjugated monoclonal antibody. Array exposed to film for 15 min. 
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DG2 array probed with HIS6. Array exposed to film for fifteen minutes. 
 
The BN-HIS6 probed array showed a weaker signal than other DG2 array exposures; the 
reason for this is unknown. The BN-HIS6 probed DG2 array show no novel spots when 
compared to the HIS6 control DG2 array. This data suggests that there is no direct 
interaction between DG2, and the section of DmPDE11B represented by BN-HIS6, which 
incorporates from the unique B N-terminus until the end of the first GAF domain.  
6.12.3 CN-HIS6 
The DG2 array was probed with CN-HIS6 protein. Specific interacting spots were 
identified by staining with an anti-HIS5 HRP conjugated monoclonal antibody, and 
comparing these to the equivalent control (figure 6.22). 
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Figure 6.22: DG2 array probed with CN-HIS6, shown alongside HIS6 control. The 
DG2 array was probed with CN-HIS6 protein. Interacting spots were identified by staining 
with an anti-HIS5 HRP conjugated monoclonal antibody. Array exposed to film for fifteen 
minutes. 
 
DG2 array probed with HIS6. Array exposed to film for fifteen minutes. 
 
The CN-HIS6 probed DG2 array shows no novel spots when compared to the HIS6 control 
DG2 array. This data suggests that there is no direct interaction between DG2, and the 
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section of DmPDE11C represented by CN-HIS6, which incorporates from the unique C N-
terminus until the end of the first GAF domain. 
6.12.3.1 Middle-HIS6 
The DG2 array was probed with Middle-HIS6 protein. Specific interacting spots were 
identified by staining with an anti-HIS5 HRP conjugated monoclonal antibody, and 
comparing these to a control exposed for 15 min as this showed equivalent background 
(figure 6.23). 
Figure 6.23: DG2 array probed with Middle-HIS6, shown alongside HIS6 control. The 
DG2 array was probed with Middle-HIS6 protein. Interacting spots were identified by 
staining with an anti-HIS5 HRP conjugated monoclonal antibody. Array exposed to film 
for 5 minutes. 
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DG2 array probed with HIS6. Array exposed to film for fifteen minutes. 
 
The Middle-HIS6 probed DG2 array showed a strong signal after 5 min of exposure, and so 
this is compared to a HIS6 control array exposed for 15 min. Comparison shows no novel 
spots when compared to the HIS6 control DG2 array. There are two spots that appear after 
5 min on the Middle-HIS6 array that are barely visible after 15 min of exposure on the 
HIS6 control blot. However, as background is higher on the Middle-HIS6 probed DG2 
array than control, it would be desirable to repeat the assay, using a different anti-
(poly)HIS antibody, or a GST-tagged Middle fragment. 
6.12.3.2 End-HIS6 
The DG2 array was probed with End-HIS6 protein. Specific interacting spots were 
identified by staining with an anti-HIS5 HRP conjugated monoclonal antibody, and 
comparing these to a control exposed for 15 min as this showed equivalent background 
(figure 6.24). 
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Figure 6.24: DG2 array probed with End-HIS6, shown alongside HIS6 control. The 
DG2 array was probed with End-HIS6 protein. Interacting spots were identified by staining 
with an anti-HIS5 HRP conjugated monoclonal antibody. Array exposed to film for two 
minutes thirty seconds. 
  
DG2 array probed with HIS6. Array exposed to film for fifteen minutes. 
 
At an exposure time of 2 min 30 s, novel spots are seen at E22 – J22 (highlighted by a 
solid line), representing the sequence 
SNAPHSSTTVDAPPRPADVDVATVPVATPAPPPQQPVSNLFYADYQKLQP, C16 – 
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D16 (highlighted by a double solid line), representing the sequence 
YHQPSPGSSQPVAIPGATCHSPTQLQPPNT, G16 - H16 (highlighted with a dashed 
line), representing the sequence SPTQLQPPNTLNLQQQMQSLRISGCTPSGT, and C9 
(highlighted by a double dashed line), representing the sequence 
RGDYIVRQGARGDTFFIISKGKVRV. However, multiple spots present as background 
on the control DG2 array are not immunoreactive on End-HIS6 probed DG2 array. The 
reason for this is unknown. Furthermore, background was sufficient on the End-HIS6 
probed array at exposure times of five or more minutes to obscure previously clear spots. 
When purifying higher concentrations of End-HIS6 protein, non-mobile, insoluble, 
immunoreactive protein transferred to the membrane in a manner that suggested it had not 
migrated from the wells; i.e., it had formed inclusion bodies, and so End-HIS6 is partially 
insoluble, which most likely explains the high levels of background. The array was 
repeated with a different batch of purified protein in an attempt to reduce background, but 
as the DG2 array had been stripped twice, the exposures actually had more background and 
so again these results are omitted. These issues prevent these data from being taken to 
indicate a putative interaction. Were the experiment to be repeated, soluble protein would 
be necessary. Optimisation of growth conditions was attempted, but clearly optimum 
conditions were not achieved. The addition of Triton-X 100 when purifying the 
recombinant protein may render the protein soluble. Were this approach to fail, the 
generation of an N-and C-terminal tagged End-GST fusion protein may yield a more 
soluble protein. However, repeat of the experiment would also need a new DG2 array to be 
produced, as those used have been stripped numerous times. 
6.13 Discussion 
In this chapter, peptide arrays were used to determine whether the interaction between 
DmPDE11 and the cGKs DG1, and the DG2 isoforms P1 and P2 are direct or indirect. A 
peptide array representing the sequence of DmPDE11, including the novel N-termini of the 
B and C isoforms, and the novel sequence of the C-termini of the short isoforms was 
generated, and probed with HIS6 fused cGK protein. While DG1N-HIS6 was expressed at 
the predicted size, repeated attempts to affinity-purify the protein failed. The PDE11 array 
was probed with DG1C-HIS6 peptide. Comparison of the control and DG1C-HIS6 probed 
PDE11 arrays reveals two areas of putative interaction. The first occurs within the second 
of the GAF domains. GAF domains perform a multitude of roles, and are present in several 
classes of protein (Martinez et al., 2002a). They have been shown to modulate the function 
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of several mammalian PDEs. The GAF domains of PDE2, PDE5 (Zoraghi et al., 2004), 
and PDE11 have been shown to bind cGMP, and the GAF domain of PDE10 binds cAMP  
(Gross-Langenhoff et al., 2006). GAF domains have been shown to mediate 
oligomerisation in PDE2 (Martinez et al., 2002b), PDE5 (Zoraghi et al., 2005), PDE6αβ 
and PDE6α´α´ (Muradov et al., 2003), and PDE11A (Weeks et al., 2007), where 
phosphorylation of two cGK phosphorylation sites in the N terminus of the PDE11A 
modulates the process (Gross-Langenhoff et al., 2008). GAF domains function to relieve 
autoinhibition in PDE2 (Martinez et al., 2002b) and PDE5 (Rybalkin et al., 2003).  GAF 
domains have also been implicated in protein-protein interaction, where binding of cGMP 
to the GAF domains of PDE6 R mediates the interaction of the catalytic domain with the 
inhibitory subunit Pγ (D'Amours and Cote, 1999). Within this context, a direct protein-
protein interaction with DG1 at this site could have any number of implications. Were 
DG1 interaction at this site to affect any of these processes, this would modulate PDE11 
activity, and therefore modulate the activity of the cGK itself. Within this region there are 
no cGK or PKA consensus phosphorylation sites. The second putative area of interaction 
lies between the second GAF domain and the catalytic site of DmPDE11. Although this 
area contains no putative cGK phosphorylation sites, there is a putative cGK 
phosphorylated serine residue two amino acids proximal to the immunoreactive 25mer. 
Furthermore, this 25mer represents an entire putative phosphorylation site, and this spot is 
immunoreactive when compared to control. However, this spot was only mildly 
immunoreactive compared to its neighbour, visible after 5 minutes opposed to 10 seconds. 
This area of DmPDE11A has had no function ascribed to it as yet; furthermore the putative 
phosphorylation site is not present in HsPDE11A. As such the significance of this putative 
interaction is not clear. An in vitro or in vivo phosphorylation assay would show whether 
or not PDE11 is a bona fide phosphorylation target of DG1. These sites of interaction can 
only be considered putative; an alanine substitution array representing these spots would 
confirm whether the interaction is bona fide, and would identify essential residues in the 
region.  
As both of the regions identified in the PDE11 array as putative regions of interaction with 
DG1C-HIS6 fell within the PDE11 Middle-HIS6 protein, and time remaining in the lab was 
short, the DG1 array was only overlaid with this DmPDE11 fusion protein. Three putative 
regions of direct interaction were identified. The first putative region of interaction maps to 
the N-terminus of the DG1, which contains the dimerisation and regulatory domains. The 
second maps to the second CNB domain, and the third to the catalytic domain. The first 
two regions of interaction are incorporated within the DG1 N terminal truncate. As such it 
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is desirable that this protein is applied to the PDE11 array, in order to screen for a 
reciprocal interaction. The third putative region of interaction is represented within the 
DG1 C terminal truncate, which showed two putative regions of interaction within 
DmDPE11 when applied to the PDE11 array. Again, alanine substitution arrays would 
provide further proof that these regions interact, and identify individual amino acids within 
these regions vital to the interaction. However, the putative data corresponds with the co-
immunoprecipitation data presented in chapter 5. Further putative regions of interaction 
may be identified if the DG1 array is probed with the other DmPDE11 truncations, and so 
it is desirable that these assays are performed. Importantly, such an interaction must be 
confirmed by two other methods; as an interaction has been shown using co-
immunoprecipitation, yeast two hybrid or mutagenesis and subsequent co-
immunoprecipitation would confirm the interaction as direct. 
The PDE 11 array was probed with DG2N-HIS6, which incorporates the dimerisation and 
regulatory domains, and DG2C-HIS6, which incorporates the twin CNB, catalytic, and 
AGC kinase C terminal domains, in order to determine putative sites of protein-protein 
interaction. Two putative sites of interaction were identified when the PDE11 array was 
probed with DG2N-HIS6, one immediately proximal to, and one immediately distal to the 
twin GAF domains. However, these spots were mildly immunoreactive in control arrays of 
equivalent background. Despite this, immunoreactivity of these spots on the DG2N-HIS6 
probed array was significantly, convincingly stronger. Repeat of the array using DG2N 
tagged with GST would clarify if the immunoreactivity was indeed due to bound, 
interacting protein, assuming these spots would not be immunoreactive in control blots. 
Alanine substitution arrays would likely suffer similar background if probed with DG2N-
HIS6 protein, and so these would also benefit from use with GST tagged DG2N protein. 
When probed with DG2C-HIS6, four putative sites of interaction were identified, including 
two in common with the two identified in DG1C-HIS6 probed PDE11 array, in the GAF-B 
domain, and immediately distal to this GAF domain. The two novel regions were found in 
GAF-A, and in the N terminus of PDE11. However, all four regions, although not at all 
immunoreactive in control blots, showed immunoreactivity at a lower intensity than on 
spots “positive” on other blots. As such none of these interactions are as convincing, and 
require further investigation; either a repeat of the assay, or use of GST tagged DG2C 
fragment.  
The DG2 peptide array was probed with (DmPDE11)BN-HIS6, CN- HIS6, Middle-HIS6, 
and End-HIS6 protein. Background for this array was higher than the other two arrays 
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probed, despite none of the 25mers containing 5x or 4xHISmers. The arrays were produced 
over a year before they was used; were new arrays to be generated background may be 
reduced. The two fusion proteins representing the N termini of DmPDE11B and C showed 
no putative interactions with the DG2 array. When probed with Middle-HIS6, a number of 
spots showed a higher intensity than on the control array, but no novel spots were 
identified. Probing with the End fragment identified two putative regions of interaction. 
However, there were a number of issues with this array, including apparent problems with 
the solubility of End-HIS6, and as such the data cannot be taken to indicate a putative 
direct interaction. As the End fragment is small, tagging this fragment with N- and C-
terminal GST tags would still result in a protein of a size that would facilitate expression in 
E. coli, and as the GST tag increases solubility, would hopefully prevent the formation of 
inclusion bodies, and reduce the background seen in the End-HIS6 overlaid DG2 array. 
Anti (poly)HIS antibodies recognise 4xHISmers or 5xHISmers. In the course of this study, 
an anti-HIS5 monoclonal antibody was employed, which resulted in the unavoidable 
immunoreactivity of spots containing 5xHISmers, and thus “non-specific” interactions 
with antibody prevent the identification of a putative interaction with overlaid protein on 
any of these spots. The occurrence of these spots was unavoidable in the PDE11 array, as 
the C terminal of DmPDE11 contains histidine-rich regions. However, the antibody also 
showed non-specific interaction with spots containing 4xHISmers, and indeed spots 
containing no HISmers, and so background levels were higher than anticipated. This would 
justify the additional probing of these arrays with GST (or other) tagged protein, as a 
higher number of non-immunoreactive spots would be probed with protein of interest, and 
thus the likelihood of false negative results would be lowered. 
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7.1 Summary 
This chapter describes work performed on DmUAS-PDE11 RNAi and DmPDE11 deletion 
lines to investigate the role of this phosphodiesterase in immunity. Data previously 
obtained suggested that cGMP and PDE11 may modulate diptericin levels in Drosophila. 
PDE11 has also been implicated in whole organism survival under septic immune 
challenge from E. coli. The role of PDE11 in immunity was investigated in flies with 
reduced PDE11 transcript levels, both in UAS-PDE11 RNAi flies, with expression driven 
either in Malpighian tubule principal cells or ubiquitously, and in the PDE11 deletion 
mutant PDE11▲121, by septic challenge with E. coli. The data suggests a role for PDE11 
in immunity, but needs further investigation. 
7.2 cGMP modulates innate immunity in Drosophila 
As discussed in the introduction, NO has been shown to play an important role in 
Drosophila immunity. NOS modulates the immune response to lipopolysaccharides 
through the upregulation of diptericin (Foley and O'Farrell, 2003). In the Malpighian 
tubule, NOS has been shown to be upregulated following immune challenge, and has been 
shown to activate the IMD pathway (McGettigan et al., 2005). NO can activate cGMP 
signalling by the activation of sGC. Recent findings show that cGMP modulates 
expression of AMPs in the Malpighian tubule in a dose dependent manner. When tubules 
are incubated with nanomolar [cGMP], there is an increase in diptericin expression, 
whereas incubation with micromolar [cGMP] reduces diptericin transcription. This effect 
is not seen in the fat body (Aitcheson). 
cGMP dependent protein kinases have been shown act as immune effector proteins. 
Diptericin expression is increased when DG1 is overexpressed in the principal cells of the 
tubule, whereas overexpression of DG2 P1 or P2 has the opposite effect, resulting in a 
reduction of diptericin expression (Aitcheson, 2009a). Furthermore, modulation of cGK 
expression in only the principal cells of the tubule is sufficient to modulate whole fly 
survival, when septically challenged with the gram-negative bacteria E. coli (Aitcheson, 
2009e). In the Malpighian tubule, cGKs have been shown to affect the translocation of the 
transcription facor Relish, an NF-kappaB homologue (Dushay et al., 1996), to the nucleus, 
downstream of imd. This modulation of Relish localisation occurs in an antagonistic 
manner, via an unknown mechanism. DG1 appears to positively regulate the translocation 
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of Relish to the nucleus; overexpression of DG1 results in Relish translocation to the 
nucleus, even in the absence of immune challenge, whereas knockdown of DG1 via RNAi 
inhibits this translocation, even under immune challange. DG2, conversely, appears to 
inhibit Relish translocation to the nucleus. Overexpression of DG2 P1 or P2 inhibits Relish 
translocation to the nucleus, even under immune challenge (Aitcheson, 2009b). cGK 
function is tightly regluated by PDEs.  The Malpighian tubule expresses all of the PDEs 
(Day et al, 2005), and so there are several candidates to modulate the immune function of 
the cGKs. 
 
Data obtained by Aitcheson implicating PDE11 in the immune response against gram 
negative bacteria is summarised in appendix 5. Briefly, her findings were that increased 
cGMP in the Malpighian tubule decreases diptericin expression, and that this can be 
phenocopied by the reduction of PDE11 transcript levels in the principal cell. Furthermore, 
it was found that immune challenge of UAS-PDE11 RNAi/c42 progeny (thus PDE11 
expression is reduced in tubule principal cells) results in reduced survivorship compared to 
UAS-PDE11 RNAi (line 1) parental control. As such, the role of PDE11 in immunity was 
investigated. 
 
7.3 Immune challenge of UAS-PDE11 RNAi driven in 
tubule principal cells 
I investigated the role of PDE11 in immunity using UAS-PDE11 RNAi line 9, as this line 
had been shown to give knock down of PDE11 expression by Q-PCR analysis, as detailed 
in chapter 3. These lines differ in the chromosomal localisation of the pWIZ-based UAS-
PDE11 RNAi insertion. Thus, the two lines may achieve differing knockdowns, and any 
difference in results could be due to the extent of the knock down achieved by the RNAi. 
E. coli was grown overnight to static phase, harvested by centrifugation, and the flies were 
stabbed with a 0.35mm bore needle dipped into the E. coli solution; mock stabbings were 
performed with a dry needle, as detailed in materials and methods. The experiment had an 
additional control to the experiment of Aitcheson presented in appendix 5, the addition of 
c42 mock- and E. coli-challenged survival assays. The below data represents the pooling of 
two survival experiments, with one set of controls (figure 7.1). 
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Figure 7.1: c42/UAS-PDE11 RNAi immune assay. No significant decrease in survival 
upon challenge with E. coli using a 0.35mm gauge needle was recorded when PDE11 
expression was reduced via expression of PDE11 RNAi, driven in tubule principal cells. 
Error bars show standard error of the mean. Survivorship on Y axis shown between 50 – 
100% for clarity. 
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Although the number of mock controls was lacking, there was no decrease in survival in 
the c42/UAS-PDE11 RNAi (line 9) progeny when compared to survival of the parental 
strains under challenge of E. coli. 
 
7.4 Immune challenge of UAS-PDE11 RNAi driven 
ubiquitously 
It was reasoned that if PDE11 plays a vital immune role in barrier epithelia and perhaps 
other tissues, expression of UAS-PDE11 RNAi ubiquitously using the Act5C-GAL4/GFP 
CyO driver line would lead to an increased immune phenotype, were such a phenotype to 
exist. Although DmUAS-PDE11 RNAi (line 9) is 90% lethal at the larval stage when 
driven ubiquitously by Act5C-GAL4, the cross is non-lethal at 18˚C, and the adults viable. 
Thus, UAS-PDE11 RNAi (line 9) parental flies were crossed with the Act5C-GAL4/GFP 
CyO driver line, and these flies were subjected to immune challenge with E. coli as above 
(figure 7.2). Negative control genotypes used were Canton S, and the other resultant 
progeny from the UAS-PDE11 RNAi (line 9) x Act5C-GAL4/GFP CyO cross, UAS-
PDE11 RNAi (line 9)/GFP CyO. As a positive control, Relish e20, a complete Relish null 
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mutant (Hedengren et al., 1999), were also assayed. Relish is an NF-κB homologue found 
in the imd antimicrobial pathway. This data is excluded for clarity, but total death was seen 
within two days maximum in every assay performed  
 
Figure 7.2: cAct5c-GAL4/UAS-PDE11 RNAi immune assay. Survival experiment 
showing no significant decrease in survival upon challenge with E. coli using a 0.35mm 
gauge needle when PDE11 expression is reduced via expression of UAS-PDE11 RNAi 
when driven ubiquitously. Error bars show standard error of the mean. Survivorship on Y 
axis shown between 60 – 100% for clarity. 
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This experiment was performed in triplicate, and the data were merged. None of the 
experiments showed a significant, or even a qualitative reduction in survival in flies where 
PDE11 expression had been ubiquitously reduced, when analysed individually or when the 
data were pooled. 
 
7.4.1 DmPDE11 deletion line  
The PDE11RB deletion line (courtesy of Prof. David Morton, Oregon), PDE11▲121, is 
balanced over the homozygous lethal balancer CyO. The existence of straight winged, red 
eyed flies demonstrates that the deletion is homozygous viable. The increased proportion 
of del/CyO flies suggests that the deletion has a lethality effect (table 7.1). 
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Table 7.1: PDE11▲121 produces viable homozygous flies when balanced with CyO. 
Heterozygous deletion flies were crossed and the progeny scored for the phenotypic 
marker CyO. Del/Del = PDE11▲121/ PDE11▲121, +/+, Del/CyO = PDE11▲121/CyO; 
+/+ 
 
♂ ♀
Del/Del 14 16
Del/CyO 30 26  
 
However, Q-PCR with RB specific primers has not been performed, and so it is not clear if 
the deletion is a true null. Homozygous males have a deeper red eye colour than females; 
the reason for this is unknown; perhaps there is another insertion on the Y. Homozygous 
PDE11▲121 males are sterile, and this contributed to the fact that for individual 
experiments, a sufficient number of PDE11▲121 flies were not obtained to perform both 
an E. coli and a mock immune challenge, and as such flies were only challenged with E. 
coli, with the rationale that it would increase the chances of finding a significant 
phenotype, and that this could later be verified by the inclusion of mock-challenge 
controls. This lack of flies also dictated the pooling of homozygous and heterozygous flies; 
ideally, the two genotypes would be assayed separately within the same experiment. 
Pooled PDE11▲121/CyO and PDE11▲121/PDE11▲121 flies were assayed for an 
immune phenotype by septic challenge with E. coli as above, alongside the wild type fly 
Canton S, as a negative control, and Relish e20 deletion flies as a positive control (figure 
7.3). This figure represents the pooling of 6 datasets.  
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Figure 7.3: DmPDE11∆121 immune assay. Survival experiment showing a significant 
decrease in survival upon challenge with E. coli using a 0.35mm gauge needle in PDE11 
homozygous and heterozygous deletion flies (pooled) compared to controls. Error bars 
show standard error of the mean. Survivorship on Y axis shown between 60 – 100% for 
clarity. 
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PDE11▲121 flies showed significantly lower survivorship than E. coli challenged Canton 
S flies, where P< 0.0001 using a Log-rank (Mantel-Cox) test. 
The above assay was repeated with the appropriate mock stabbed controls, assaying 
homozygous and heterozygous deletion flies separately. Injections were performed using a 
Nanoject II Auto nanoliter injector, where E. coli was grown to an OD600 of 2.0 (which 
represents static phase), harvested by centrifugation, resuspended in an equal volume of 
PBS, and injected in a volume of 69nl just below the first abdominal turgite. This 
represents a lower dose than stabbing with a 0.35mm needle, although the difference 
cannot be quantified as the dose delivered with a 0.35mm needle is impossible to quantify. 
Mock stabbings were performed with PBS. The data presented represents the pooling of 
two immune assays (figure 7.4). 
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Figure 7.4: DmPDE11∆121 immune assay. Survival experiment showing no difference 
in survival upon challenge with E. coli using a Nanoject II Auto nanoliter injector between 
PDE11 homozygous or heterozygous deletion flies (pooled) and PBS injected controls. 
Error bars show standard error of the mean. Survivorship on Y axis shown between 80 – 
100% for clarity. 
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No difference in survival following immune challenge was seen between Canton S and 
homozygous or heterozygous PDE11▲121 flies. 
 
7.5 Conclusion for the role of DmPDE11 in immunity 
Epithelial tissues have been shown to play a major role in immunity, expressing all of the 
known anti microbial peptides (Tzou et al., 2000), and the Malpighian tubule in particular 
has been shown to act as critical immune tissue, where NO and cGMP signalling play vital 
roles in the imd immune pathway (Aitcheson, 2009c; Davies and Dow, 2009; McGettigan 
et al., 2005). As a dual specificity PDE expressed in all epithelia (Chintapalli et al., 2007), 
DmPDE11 is capable of modulating cGMP signalling, and thus the role of DmPDE11 in 
immunity was investigated by subjecting flies with reduced PDE11 transcript levels to an 
immune challenge, and screening for a change in mortality. PDE11 deletion and UAS-
PDE11 RNAi lines were used to reduce DmPDE11 transcript levels both ubiquitously, and 
in a tissue specific manner. 
UAS-PDE11 RNAi line 9 was crossed to the Malpighian tubule GAL4 driver line c42, and 
both parental lines and the resultant progeny were subjected to an E. coli stabbing assay. 
The progeny did not display an increase in mortality under immune challenge. If reduction 
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of DmPDE11 transcript levels in the Malpighian tubule did not impact upon fly survival, 
then it was reasoned that a ubiquitous knock down of transcript levels may produce a 
phenotype. Thus, UAS-PDE11 RNAi (line 9) was crossed to the ubiquitous GAL4 driver 
line Act5C-GAL4. Progeny from this cross displayed no apparent increase in mortality 
when compared to parental controls. As the extent of the knockdown conferred by RNAi 
may not have been sufficient to confer a survival phenotype, the PDE11 deletion line 
PDE11▲121 was subjected to multiple E. coli stabbing assays, where a 0.35mm needle 
was dipped into an E. coli solution and survivorship recorded, and the data pooled. The 
data revealed a highly (P< 0.0001) significant reduction seen in PDE11▲121 line 
compared to Canton S under E. coli challenge. Where Canton S flies showed around 10% 
mortality after 100 h, PDE11▲121 showed around 20% mortality. However, homozygous 
and heterozygous flies were pooled in the above experiments, and a mock injection was 
not included, which is critical to proving that a reduction in survival is not due to increased 
susceptibility to the stab itself or a general reduction in the flies‟ viability.  
As a lethality phenotype would be expected to be more pronounced in the homozygous 
null mutant that in the heterozygous, the experiment was repeated, with the genotypes 
assayed separately, using a new delivery system that permitted tighter control of the dose 
delivered, at the cost of having to reduce the dose of E. coli. Perhaps as a result of this 
reduced dose, no difference in survival was seen between Canton S controls and either 
homozygous or heterozygous PDE11 deletion flies. As such, a repeat of this experiment at 
the original dose would be desirable, including the mock stab controls. In addition to this, 
the extent of the deletion must be determined.  
UAS-PDE11 RNAi line 9 did not show any immune phenotype when crossed to the GAL4 
lines c42 and Act5c. Given that a reduction in survival was identified where UAS-PDE11 
RNAi line 1 was crossed to c42 and the progeny subjected to immune assay alongside a 
parental control (Aitcheson, 2009e), as detailed in appendix 5, it may be that a higher 
knockdown was achieved with these flies. As such, Q-PCR using the primers used to 
screen line 9 should be used on line 1, and if a higher knockdown is achieved then that fly 
line should be employed. However, it is also possible that the apparent reduction in 
survival of the UAS-PDE11 RNAi (line 1) when crossed to c42 could be due to the low 
number of flies used for certain genotypes screened.  
If PDE11 does indeed play a immune role, it is not a vital one; where a significant 
reduction in survivorship was achieved when assaying PDE11▲121, the increase in 
mortality was ~10% greater than controls after 100 hours at ~20% compared to ~10%, 
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whereas the Relish e20 deletion mutant showed 100% mortality after around a day. As the 
deletion has not been shown to be a true null, there may be sufficient expression of PDE11 
to mask the phenotype to an extent.  
If indeed it is shown that a reduction in PDE11 transcript levels reduces survival against E. 
coli, it may relate to the finding in the Malpighian tubule that expression of the 
antimicrobial peptide diptericin is modulated by cGMP. When tubules are incubated in 
cGMP, diptericin expression is reduced compared –cGMP incubated controls. Non cell-
permeable extracellular cGMP is transported into the tubule (Riegel et al., 1998), and can 
induce cellular signalling events such as fluid transport (Davies et al., 1995). This suggests 
that the large decrease in diptericin expression induced by the incubation in 100μM cGMP 
is caused by transport of extracellular cGMP into the tubule, and by a subsequent increase 
of intracellular cGMP. 
This increase in cGMP, and the subsequent reduction in diptericin expression, is 
phenocopied by reduction of PDE11 transcript levels in Malpighian tubule principal cells, 
as c42/UAS-PDE11 RNAi (line 1) tubules not incubated in cGMP display a similar level 
of diptericin expression to UAS-PDE11 RNAi (line 1) parental tubules incubated in 
cGMP. Furthermore, c42/UAS-PDE11 RNAi (line 1) incubation with cGMP does not 
further decrease diptericin expression. This data is presented in appendix 5 (Aitcheson, 
2009c, d).  This would suggest that PDE11 modulates an immune induced cGMP signal in 
a manner relevant to Diptericin expression, which directly affects Drosophila survival 
under immune challenge. This would be the first time a PDE had been shown to play an 
immune role. Taken together, the data in this chapter suggests that the role of DmPDE11 in 
immunity deserves further investigation. 
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Chapter 8 
A study of H. Sapiens PDE11A using the Malpighian 
tubule, a polarised epithelial tissue 
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8.1 Summary 
The HsPDE11A family has recently been characterised biochemically, but the 
physiological role it plays it not well understood. Drosophila PDE11 was first described in 
2005, and has four splice variants. Using the powerful genetic model organism Drosophila 
melanogaster, we have further investigated this family of phosphodiesterases, both fly and 
human, in an organotypic context. HsPDE11A3 expression is confined to testis in both rat 
and human (Yuasa et al., 2001), and has been shown to regulate spermatozoa physiology 
(Seftel, 2005). DmPDE11 -/- null male mutants are infertile, and so function may be 
conserved. 
The DmPDE11 isoforms were aligned with all HsPDE11A isoforms, compared with 
respect to sequence identity and homology, and were subjected to phylogenetic analysis. 
These results suggested that HsPDE11A3 is a DmPDE11 orthologue. 
HsPDE11A3 pP[UAST] constructs were generated, and the transgene expressed in S2 cells 
and fly. The protein showed predominantly nuclear localisation when expressed in S2 
cells. In Malpighian tubule principal cells at low levels of expression, the protein localised 
predominantly to the nucleus, but was localised to the cytosol when the transgene was 
driven by stronger GAL4 expression. 
8.2 Introduction 
The Human phosphodiesterase-11A (PDE11) family consists of four splice variants 
HsPDE11A1 (PDE11A 004), HsPDE11A2 (PDE11A 003), HsPDE11A3 (PDE11A 002), 
and HsPDE11A4 (PDE11A 001) (Fawcett et al., 2000; Hetman et al., 2000; Yuasa et al., 
2000). I will use the common nomenclature HsPDE11A1-4 herein.  HsPDE11A isoforms 
hydrolyze cAMP and cGMP via a conserved carboxyl-terminal (C-terminal) catalytic 
domain. The amino-termini (N-termini) of the four isoforms vary in length and amino acid 
sequence. HsPDE11A2, HsPDE11A3, and HsPDE11A4 contain one or more GAF (cGMP-
binding phosphodiesterase, Anabaena adenylyl cyclase, and Escherichia coli FhlA) 
domains, which have been shown to affect oligomerisation, and affinity both for substrates 
as well as the structurally unrelated inhibitors vardenafil and tadalafil (Weeks et al., 2007). 
The structure of the four isoforms is shown in figure 8.1. 
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Figure 8.1: PDE11A1-4. Diagram shows the PDE11A isoforms. S = Serine, Black bar = 
catalytic domain, light blue bar = GAF-A domain, white bar = GAF-B domain, angled 
dashed bar = unique sequence. Modified from (Weeks et al., 2007).  
 
8.3 Alignment of DmPDE11-B and -C protein against 
HsPDE11A protein 
Previous published work assigned D. Melanogaster PDE11 as a homologue of H. sapiens 
PDE11A3 or A4 (Day et al., 2005), due to high sequence similarity at the amino acid level, 
the dual-specificity PDE activity of the enzymes, and the twin GAF domains of these 
isoforms (figure 8.2). 
 
Figure 8.2: DmPDE11 contains twin GAF domains and a dual-specificity PDEase 
domain, in common with HsPDE11A. 
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This analysis was performed with the amino acid sequence of DmPDE11RA. This has been 
replaced on Flybase with two new isoforms, DmPDE11RB and DmPDE11RC; two novel 
short isoforms were cloned in the course of this study, so that both the DmPDE11RB and 
DmPDE11RC have long and short isoforms, as detailed in chapter 4. As such, further 
homology analysis was performed. Following alignment of protein sequence, (materials 
and methods 1.12), percentage identity/similarity was calculated following alignment of 
each of the DmPDE11 isoforms with the HsPDE11A gene family using ClustalW 
alignment (table 8.1).   
 
Table 8.1: HsPDE11A1-4 similarity/identity with DmPDE11. Percentage similarities 
and identities of amino acid sequences between DmPDE11 and each HsPDE11A isoform 
were calculated using ClustalW alignment. 
Dm PDE11RBl vs Identity (%) Similarity (%)
Hs PDE11A1 (004) 15.8 22
Hs PDE11A2 (003) 17.8 25.8
Hs PDE11A3 (002) 20.5 29.7
Hs PDE11A4 (001) 22.7 33.6
Dm PDE11RBs vs Identity (%) Similarity (%)
Hs PDE11A1 (004) 19.7 27.5
Hs PDE11A2 (003) 22.2 32.2
Hs PDE11A3 (002) 25.6 37.1
Hs PDE11A4 (001) 28.3 42
Dm PDE11RCl vs Identity (%) Similarity (%)
Hs PDE11A1 (004) 16.3 22.7
Hs PDE11A2 (003) 18.4 26.6
Hs PDE11A3 (002) 21.1 30.6
Hs PDE11A4 (001) 23.4 34.7
Dm PDE11RCs vs Identity (%) Similarity (%)
Hs PDE11A1 (004) 20.5 28.6
Hs PDE11A2 (003) 32.1 33.4
Hs PDE11A3 (002) 26.6 38.5
Hs PDE11A4 (001) 29.4 43.6  
 
For each Drosophila PDE11 isoform, the order of highest – to – lowest sequence similarity 
and identity with the HsPDE11A 1-4 isoforms, is HsPDE11A4, HsPDE11A3, 
HsPDE11A2, HsPDE11A1. Interestingly, it is apparent that between the four Drosophila 
PDE11 isoforms, the short isoforms of B and C have higher sequence similarity and 
identity to each HsPDE11A isoform compared to their respective long isoforms, and that 
the long and short C isoforms have higher sequence similarity and identity to each 
229 
HsPDE11A isoform, when compared to their respective B isoforms,. That the short C 
terminus isoforms are of higher homology than those with a long C terminus is not 
surprising, as the human isoforms do not have an extended C terminus. This may suggest 
that the C terminus evolved later, to perform some unknown function; as shown in chapter 
4, it does not affect protein localisation.  
 
The above analysis scores positively for identical or similar amino acids following 
sequence alignment. However, it does not negatively score for gaps, or highly dissimilar 
amino acids. Sequences were aligned with using a gonnet series matrix, and a best tree 
Phylogram was generated using neighbour-joining tree building and uncorrected “p” 
distance calculation. As a control, bootstrap analysis (1000 repetitions) was performed 
(materials and methods 1.12). Distance between nodes is presented in phylogenetic units, 
where a value of 0.1 corresponds to a difference of approximately 10% between two 
sequences. The data is presented in figure 8.3. 
 
Figure 8.3: Phylogenetic analysis comparing DmPDE11 with HsPDE11A 1-4. 
Sequences were aligned using a gonnet series matrix, and a Phylogram was generated. 
Distances between nodes shown in phylogenetic units. Bootstrap analysis (1000 
repetitions) was performed; numbers at branches refer to the % occurrence of the branch. 
Table shows distance between nodes in phylogenetic units. B long (A), B short (B), C long 
(C), C short (D). d = D. melanogaster, h = H. sapiens. 
 
A 
 
dPDE11 B long
hPDE11A 004 {a1}
hPDE11A 001 {a4}
hPDE11A 003 {a2}
hPDE11A 002 {a3}
0.264
0.264
0.007
0.011
-0.019
0.019
0.019
-0.019
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hPDE11A001 {a4} hPDE11A 002 {a3} hPDE11A 003 {a2} hPDE11A 004 {a1}
Dm PDE11 B long 0.5785 0.5385 0.5325 0.5134  
 
B 
 
 
hPDE11A001 {a4} hPDE11A 002 {a3} hPDE11A 003 {a2} hPDE11A 004 {a1}
Dm PDE11 B short 0.5796 0.5399 0.5343 0.5155
 
 
 
 
 
 
dPDE11 B long
hPDE11A 002 {a3}
hPDE11A 004 {a1}
hPDE11A 001 {a4}
hPDE11A 003 {a2}
 78
 98
 98
dPDE11 B short
hPDE11A 002 {a3}
hPDE11A 004 {a1}
hPDE11A 001 {a4}
hPDE11A 003 {a2}
0.265
0.265
0.01
0.007
-0.019
0.019
0.019
-0.019
dPDE11 B short
hPDE11A 002 {a3}
hPDE11A 004 {a1}
hPDE11A 001 {a4}
hPDE11A 003 {a2}
 77
 77
 98
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C 
 
hPDE11A 004 {a1} hPDE11A 003 {a2} hPDE11A 002 {a3} hPDE11A 001 {a4}
Dm PDE11 C long 0.5785 0.5385 0.5325 0.5134  
 
D 
 
 
hPDE11A001 {a4} hPDE11A 002 {a3} hPDE11A 003 {a2} hPDE11A 004 {a1}
Dm PDE11 C short 0.5796 0.5399 0.5343 0.5155
 
dPDE11 C long
hPDE11A 002 {a3}
hPDE11A 004 {a1}
hPDE11A 001 {a4}
hPDE11A 003 {a2}
0.264
0.264
0.011
0.007
-0.019
0.019
0.019
-0.019
dPDE11 C long
hPDE11A 002 {a3}
hPDE11A 004 {a1}
hPDE11A 001 {a4}
hPDE11A 003 {a2}
 77
 98
 98
dPDE11 C short
hPDE11A 002 {a3}
hPDE11A 004 {a1}
hPDE11A 001 {a4}
hPDE11A 003 {a2}
0.265
0.265
0.01
0.007
-0.019
0.019
0.019
-0.019
dPDE11 C short
hPDE11A 002 {a3}
hPDE11A 004 {a1}
hPDE11A 001 {a4}
hPDE11A 003 {a2}
 80
 80
 98
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In contrast to the above results, a ClustalW algorithm-generated phylogenetic tree shows 
that each Drosophila PDE11 isoform aligns in order of closest to furthest to HsPDE11-A1, 
-A2, -A3, then -A4. For each DmPDE11 isoform, HsPDE11-A1 was assigned as the 
closest orthologue, scoring ~0.02 phylogenetic units (~2%) less than -A2. HsPDE11-A2 
and -A3 were typically separated by less than 0.05 phylogenetic units (~0.5%). 
Intriguingly, HsPDE11A4, which scored highest for sequence similarity/identity with 
DmPDE11, was designated the most distant of orthologues, 0.04 phylogenetic units (~4% 
distal). However, when bootstrap analysis is considered, it is notable that at the 
branchpoints separating HsPDE11A3 from HsPDE11-A1, -A2, and –A4, occur in ≤ 80% 
of the bootstrap replicates of each phylogenetic tree. Likewise, for the small isoforms of 
DmPDE11 B and C, the branchpoint separating hPDE11-A2 and –A4 occurred in ≤80% of 
the bootstrap replicates of each phylogenetic tree. What is consistent is the occurrence of 
the branchpoint between HsPDE11-A4 and -A2, at 98% for each phylogenetic tree, 
suggesting that the higher phylogenetic distance allocated to HsPDE11A4 is perhaps the 
one significant finding of this analysis. Thus, as with the Day 2006 analysis of 
DmPDE11A, DmPDE11 B long, B short, C long, and C short isoforms were designated as 
HsPDE11A3 orthologues. That HsPDE11A4 shows the highest sequence 
similarity/identity with the DmPDE11 isoforms, yet shows the highest phylogenetic 
distance from each of the DmPDE11 isoforms when considering phylogenetic analysis, 
suggests that the N terminus of this protein may be of recent evolutionary origin. These are 
two Ser residues (S117 and S162) N terminal of the GAF-A and GAF-B domains of 
HsPDE11A4 which have been shown to be phosphorylated by PKA and cGK, which 
reduce the EC50 for cGMP ~3 fold when phosphorylated (Gross-Langenhoff et al., 2008). 
Analysis of DmPDE11 B and C for putative phosphorylation sites N terminal of the GAF 
domains returns three Ser residues that return a high score for either PKA or cGK 
phosphorylation, although only S268 (B isoform)/S224 (C isoform) is predicted as a 
putative phosphorylation site (threshold < 0.5 using the NetPhosK phosphorylation 
prediction tool (Blom et al., 2004)) for both cGK and PKA (figure 8.4). 
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Figure 8.4: Prediction of phosphorylation by PKA and cGK on residues N-terminal of 
the GAF domains of DmPDE11. Sequences were analysed for putative PKA/cGK 
phosphorylation sites using the NetPhosK phosphorylation prediction tool (Blom et al., 
2004). 
   
S-258 (B isoform)/ S-214 (C isoform)    PKA    0.74 (TSSSRGGSGATTPUR) 
S-268 (B isoform)/ S-224 (C isoform)    PKA    0.67 (TTPVRKISAHEFFRG)    
S-268 (B isoform)/ S-224 (C isoform)    cGK    0.77 (TTPVRKISAHEFFRG)       
S-306 (B isoform)/ S-262 (C isoform)    PKA    0.70 (NGSVGGSCSNLQNV)  
 
Following this analysis, constructs to express HsPDE11A3, with and without a YFP tag, 
were generated for expression in flies and S2 cells. 
 
8.3.1 Generation of constructs 
pP{UAST} and pP{YFP UAST} constructs for the expression of HsPDE11A3 were 
generated for expression in flies and S2 cells, using a pcDNA3.1 HsPDE11A3 plasmid as 
template, generously provided by Prof. Miles Houslay. Primers were designed to amplify 
the HsPDE11A3 ORF with unique restriction sites at the 5‟ and 3‟ ends. Reverse primers 
with and without a stop codon were designed, to facilitate in-frame fusion to a YFP tag. 
The ORF was amplified with Pfu DNA polymerase, TOPO cloned into a TOPO vector to 
generate pMT/V5 TOPO HsPDE11A3 (stop) and pMT/V5 TOPO HsPDE11A3 (no stop), 
and sequenced for fidelity (data not shown). The ORF was digested from the TOPO vector, 
gel purified, and directionally ligated into digested pP{UAST} and pP{YFP UAST}.  
 
8.3.2 Western blot to confirm expression of transgene 
To confirm that HsPDE11A3 will express in Drosophila, S2 cells were transiently 
transfected with pMT/V5 TOPO-HsPDE11A3 (no stop), and the lysate subjected to 
western analysis (figure 8.5). 
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Figure 8.5: Western analysis of S2 cell lysate transiently transfected with (1) no 
plasmid control (2) pMT/V5 TOPO-HsPDE11A3 (no stop). Equal amounts of protein 
(20 g) were separated on a 10% SDS acrylamide gel, blotted and probed with anti-V5 
mouse monoclonal primary antibody at 1:2000, anti-mouse HRP-conjugated secondary at 
1:5000. Band sizes were calculated by comparison to Amersham Full-Range Rainbow
™
 
Molecular Weight Markers. 
 
 
 
 
 
 
 
When fused in-frame with a V5 tag, the HsPDE11A3 ORF encodes a protein of 79 KDa. 
S2 cell lysate produced a single immunoreactive band not present in the negative control, 
which runs to the expected size. An additional band at ~55 kDa was also present in mock-
transfected S2 cell lysate, and so was non specific. As such it was accepted that YFP-
HsPDE11A3 is faithfully translated into a stable protein product in S2 cells. 
 
8.3.3 Anti-HsPDE11A polyclonal antibody design 
Antibodies were designed against two epitopes, QRQTKTKDRRFNDE and 
SKGEYDWNIKNHRD, selected on the basis of antigenicity. The epitope sequences were 
screened for short near-exact matches against the Drosophila proteome using the BLASTP 
tool (http://www.ensembl.org/Multi/blastview), and returned no significant hits.  
QRQTKTKDRRFNDE is on the boundary between sequence unique to HsPDE11A3, and 
sequence shared with HsPDE11A4 within GAF-A. In future, were a HsPDE11A3-specific 
polyclonal antibody required, an antibody-specific peptide QRQTKTKDRR would only 
purify antibody specific to HsPDE11A3 by epitope purification. SKGEYDWNIKNHRD is 
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found in HsPDE11A-002, -006, -203, 003, 004, 202, 204, 001. Antibodies were generated 
by Genososphere Biotech. Antibodies were IgG purified, and the purified IgG fraction was 
epitope purified (materials and method 1.7). 
 
8.3.4 Antibody testing 
Immunocytochemistry was performed on S2 cells transiently co-transfected with YFP-
HsPDE11A3 pP[UAST] and DES GAL4 as a GAL4 source, using pre- and post-immune 
serum at 1:100, 1:500, IgG purified antibody at 1:50, and epitope purified antibody at 1:2, 
staining with anti-rabbit TEXAS RED secondary antibody at a 1:500 dilution. For both 
antibodies, none of the YFP fluorescent cells displayed positive texas red staining above 
background staining, even using serum (data not shown). The antibody was not tested 
using western analysis. 
 
8.3.5 Immunocytochemistry 
8.3.5.1 Expression in S2 cells 
HsPDE11A3 protein subcellular localisation was determined in S2 cells. S2 cells were 
transiently transfected with YFP-HsPDE11A3 pP{UAST}, using DES GAL4 as a GAL4 
source. Cells were fixed, and DAPI stained to stain the nucleus (figure 8.6).  
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Figure 8.6: Localisation of YFP-HsPDE11A3 in S2 cells. S2 cells were transiently 
transfected with pP{UAST} HsPDE11A3 YFP, using DES GAL4 as a GAL4 source. Cells 
were fixed and stained with DAPI to visualise nuclei. YFP-HsPDE11A3 (green), DAPI 
(blue). 
 
In S2 cells, YFP-HsPDE11A3 is predominantly localised to the nucleus, and also shows 
cytoplasmic localisation, strongest at the membrane.  
8.3.5.2 Localisation in Malpighian tubule 
YFP-HsPDE11A3 expression was driven in tubule principal cells by the c42 GAL4 driver 
line. Tubules were fixed, and YFP-HsPDE11 expression visualised (figure 8.7). 
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Figure 8.7: Localisation of YFP-HsPDE11A3 in the Malpighian tubule driven with 
c42 GAL4. UAS YFP-HsPDE11A3 transgenic flies were crossed to c42 GAL4, a principal 
cell GAL4 driver line. The Malpighian tubules were dissected, fixed, and imaged using 
confocal microscopy. YFP-HsPDE11A3 (green). 
 
Expression of YFP-HsPDE11A3 in c42 GAL4/YFP-HsPDE11A3 progeny occurred at low 
levels, hence the high level of background noise in the confocal image. However, although 
DAPI staining was not employed, expression appears similar to that of S2 cells; 
predominantly nuclear, with some cytoplasmic (basolateral) expression. To drive 
expression levels to a higher level, UAS-YFP-HsPDE11A3 flies were crossed to a heat 
shock GAL4 driver line. Following three thirty minute 37˚C heat shocks, expression levels 
were much higher, and the localisation of the protein changed (figure 8.8).  
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Figure 8.8: Localisation of YFP-HsPDE11A3 in the Malpighian tubule driven with 
heat shock GAL4. UAS YFP-HsPDE11A3 transgenic flies were crossed to heat shock 
GAL4, a ubiquitous GAL4 driver line. The Malpighian tubules were dissected, fixed, and 
the nuclei visualised by DAPI staining, and imaged using confocal microscopy. YFP-
HsPDE11A3 (green), DAPI (blue). 
 
When YFP-HsPDE11A3 expression is driven by heat shock GAL4, there is a dramatic 
change in protein subcellular localisation. The protein is now excluded from the nucleus, 
and shows localisation to the basolateral membrane, and the apical microvilli. It appears 
that localisation is dependent upon protein concentration. Imaging of Malpighian tubules 
from YFP-HsPDE11A3/HSG4 exposed to varying lengths of heat shock would confirm 
this. 
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8.3.6 Update of gene model 
The gene model for HsPDE11A in the March 2009 release of Ensemble was as described 
above 
(http://mar2009.archive.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG0000012865
5). The June 2009 release 
(http://jul2009.archive.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000128655
) contained several newly predicted transcripts, from the same gene (table 8.2). 
 
Table 8.2: The newly predicted HsPDE11A isoforms. Only protein coding isoforms 
shown (adapted from Ensemble). 
Name  Transcript ID  Protein ID  Description
PDE11A4 (001) ENST00000286063 ENSP00000286063 protein coding
PDE11A3 (002) ENST00000358450 ENSP00000351232 protein coding
PDE11A2 (003) ENST00000389683 ENSP00000374333 protein coding
PDE11A1 (004) ENST00000409504 ENSP00000386539 protein coding
PDE11A-006 ENST00000433879 ENSP00000416884 protein coding
PDE11A-007 ENST00000436700 ENSP00000406922 protein coding
PDE11A-201 ENST00000431253 ENSP00000410190 protein coding
PDE11A-202 ENST00000449286 ENSP00000390599 protein coding
PDE11A-203 ENST00000450799 ENSP00000387964 protein coding
PDE11A-204 ENST00000457922 ENSP00000402534 protein coding  
Beyond the isoforms listed in table 8.2, a further five transcripts, HsPDE11A005, and 
HsPDE11A009 – 012, are processed transcripts that are not translated into a protein 
product. The transcript and protein structure of these newly predicted HsPDE11A isoforms 
are found in figure 8.9 (Ensemble). 
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Figure 8.9: Transcript and Protein structure (where translated) of all HsPDE11A 
isoforms. From Ensemble, 
(http://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000128655). For 
protein structure, Yellow: low complexity region. Blue: superfamily domain. Green: 
SMART domain. Red: prints domain. Grey: Pfam domain. Orange: PROSITE patterns. 
Multiple colours: variations. Scale bar: amino acid position 
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HsPDE11A-006, -007, -201 and -203 are further truncations of the N terminus compared 
to the original HsPDE11A1-A4 isoforms, truncated beyond the GAF domains to the 
catalytic domain. Of the newly predicted HsPDE11A isoforms, only HsPDE11A-202 and -
204 contain a GAF domain. 
In order to determine if any of these new isoforms were of higher sequence homology to 
DmPDE11, sequence similarity/identity was calculated (tables 8.3 – 8.6). Phylogenetic 
analysis was performed as above between the two previously closest aligned, HsPDE11A 
001 {A4} and HsPDE11A 002 {A3}, and the two newly predicted isoforms 202 and 204, 
as these contain GAF domains; HsPDE11A 202 contains one GAF domain, and HsPDE11 
204 contains one whole and one partial GAF domain (figure 8.10). 
Table 8.3: DmPDE11 B long similarity/identity with the HsPDE11A gene family. 
Percentage similarities and identities of amino acid sequences between DmPDE11 B long 
and all the HsPDE11A isoforms were calculated using ClustalW alignment. 
 
Dm PDE11RBl vs Identity (%) Similarity (%)
hPDE11A1 (004) 15.8 22
hPDE11A2 (003) 17.8 25.8
hPDE11A3 (002) 20.5 29.7
hPDE11A4 (001) 22.7 33.6
hPDE11 006 13.7 19.9
hPDE11 007 1.7 4
hPDE11A 201 4.8 7.1
hPDE11A 202 17.8 25.8
hPDE11A 203 15.8 22.1
hPDE11A 204 19 27.4  
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Figure 8.10: Phylogenetic analysis comparing DmPDE11 B long with HsPDE11A-001 
(A4), -002 (A3), -202, -204. Sequences were aligned using a gonnet series matrix, and a 
Phylogram was generated. Distances between nodes shown in phylogenetic units. 
Bootstrap analysis (1000 repetitions) was performed; numbers at branches refer to the % 
occurrence of the branch. Table shows distance between nodes in phylogenetic units. 
 
 
hPDE11A 001 {A4} hPDE11A {002 A3} hPDE11A 202 hPDE11A 204
Dm PDE11 B long 0.5785 0.5385 0.5317 0.5267  
 
Table 8.4: DmPDE11 B short similarity/identity with the HsPDE11A gene family. 
Percentage similarities and identities of amino acid sequences between DmPDE11 B short 
and all the HsPDE11A isoforms were calculated using ClustalW alignment. 
Dm PDE11RBs vs Identity (%) Similarity (%)
hPDE11A1 (004) 19.7 27.5
hPDE11A2 (003) 22.2 32.2
hPDE11A3 (002) 25.6 37.1
hPDE11A4 (001) 28.3 42
hPDE11 006 17.1 24.9
hPDE11 007 2.1 5
hPDE11A 201 6 8.9
hPDE11A 202 22.2 32.2
hPDE11A 203 19.7 27.6
hPDE11A 204 23.7 34.2  
 
dPDE11 B long
hPDE11A 204
hPDE11A 202
hPDE11A 001 {a4}
hPDE11A 002 {a3}
0.265
0.265
0.009
0.008
-0.013
0.017
-0.019
0.019
dPDE11 B long
hPDE11A 002 {a3}
hPDE11A 204
hPDE11A 202
hPDE11A 001 {a4}
 98
 98
 96
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Figure 8.11: Phylogenetic analysis comparing DmPDE11 B short with HsPDE11A-
001 (A4), -002 (A3), -202, -204. Sequences were aligned using a gonnet series matrix, and 
a Phylogram was generated. Distances between nodes shown in phylogenetic units. 
Bootstrap analysis (1000 repetitions) was performed; numbers at branches refer to the % 
occurrence of the branch. Table shows distance between nodes in phylogenetic units. 
 
hPDE11A 001 {A4} hPDE11A 002 {A3} hPDE11A 202 hPDE11A 204
Dm PDE11 B short 0.5818 0.5429 0.537 0.5317  
 
Table 8.5: DmPDE11 C long similarity/identity with the HsPDE11A gene family. 
Percentage similarities and identities of amino acid sequences of DmPDE11 C long and all 
the HsPDE11A isoforms were calculated using ClustalW alignment. 
Dm PDE11RCl vs Identity (%) Similarity (%)
hPDE11A1 (004) 16.3 22.7
hPDE11A2 (003) 18.4 26.6
hPDE11A3 (002) 21.1 30.6
hPDE11A4 (001) 23.4 34.7
hPDE11 006 14.1 20.6
hPDE11 007 1.8 4.1
hPDE11A 201 5 7.3
hPDE11A 202 18.4 26.6
hPDE11A 203 16.3 22.8
hPDE11A 204 19.6 28.2  
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Figure 8.12: Phylogenetic analysis comparing DmPDE11 C long with HsPDE11A-001 
(A4), -002 (A3), -202, -204. Sequences were aligned using a gonnet series matrix, and a 
Phylogram was generated. Distances between nodes shown in phylogenetic units. 
Bootstrap analysis (1000 repetitions) was performed; numbers at branches refer to the % 
occurrence of the branch. Table shows distance between nodes in phylogenetic units. 
 
 
 
hPDE11A 001 {A4} hPDE11A 002 {A3} hPDE11A 202 hPDE11A 204
Dm PDE11 C long 0.5785 0.5385 0.5317 0.5267  
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Table 8.6: DmPDE11 C short similarity/identity with the HsPDE11A gene family. 
Percentage similarities and identities of amino acid sequences between DmPDE11 C short, 
and all the HsPDE11A isoforms were calculated using ClustalW alignment. 
 
Dm PDE11RCs vs Identity (%) Similarity (%)
hPDE11A1 (004) 20.5 28.6
hPDE11A2 (003) 32.1 33.4
hPDE11A3 (002) 26.6 38.5
hPDE11A4 (001) 29.4 43.6
hPDE11 006 17.8 25.9
hPDE11 007 2.2 5.2
hPDE11A 201 6.3 9.2
hPDE11A 202 23.1 33.5
hPDE11A 203 20.5 28.7
hPDE11A 204 24.6 35.5  
 
Figure 8.13: Phylogenetic analysis comparing DmPDE11 C short with HsPDE11A-
001 (A4), -002 (A3), -202, -204. Sequences were aligned using a gonnet series matrix, and 
a Phylogram was generated. Distances between nodes shown in phylogenetic units. 
Bootstrap analysis (1000 repetitions) was performed; numbers at branches refer to the % 
occurrence of the branch. Table shows distance between nodes in phylogenetic units. 
 
 
hPDE11A 001 {A4} hPDE11A 002 {A3} hPDE11A 202 hPDE11A 204
Dm PDE11 C short 0.5818 0.5429 0.537 0.5317  
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When sequence similarity/identity is considered, HsPDE11A3 has the highest homology to 
each DmPDE11 isoform compared to HsPDE11A4, HsPDE11202, and HsPDE11204. 
Phylogenetic analysis was again employed. However, bootstrap analysis this time returned 
no lower than 95% at any branch of the phylogenetic tree, suggesting that this data is of 
greater significance. Figures 8.10 – 8.13 suggests that amino acid sequence specific to 
HsPDE11A4 is of furthest phylogenetic distance from the DmPDE11 isoforms, although 
this branchpoint is of the lowest % score when considering bootstrap analysis. 
HsPDE11A3 is of around 0.01 phylogenetic units more distal than 202 and 204 to the 
DmPDE11 isoforms in each phylogenetic tree, which equates to around 1% lower 
homology. The bootstrap analysis assigns 98% or 99% to the branchpoint separating 
HsPDE11A3 from the other isoforms, and so a difference in phylogenetic units of ~0.01 
may not be significant. HsPDE11A204 is virtually identical to HsPDE11A3, except for the 
unique N terminus of HsPDE11A3, two adjacent, changed amino acids, and a single amino 
acid deletion. As such, the unique N terminus of HsPDE11A3 should be used to determine 
which is closer. The unique N terminus of HsPDE11A3 was aligned with DmPDE11 B 
long using ClustalW analysis (figure 8.14). 
 
Figure 8.14: The unique N-terminus of HsPDE11A002 (A3) aligns with DmPDE11 B 
long from amino acid ~435 of DmPDE11 B long to amino acid ~530.  
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The unique sequence of the N terminus of HsPDE11A3 was found to align between amino 
acids 435 – 530, sequence common to both the B and C DmPDE11 isoforms. Alignment of 
HsPDE11A 204 with DmPDE11 B long revealed an alignment from amino acid 530 
onwards (figure 8.15). 
Figure 8.15: HsPDE11A 204 aligns with DmPDE11 B long from amino acid 530 of B 
long onwards. First ~400 amino acids of ClustalW alignment shown. 
 
 
Multiple methods of sequence analysis designate amino acids 420 to 750 (using B long as 
a reference) of DmPDE11 as encoding twin GAF domains (figure 8.16). 
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Figure 8.16: DmPDE11 (B long shown) has twin GAF domains between amino acids 
420 to 750. From Ensemble. 
  
As the unique N terminus of HsPDE11A3 aligns within this region, and furthermore aligns 
to sequence just adjacent to the region of GAF-A that HsPDE11204 aligns to, it would 
appear that this sequence constitutes novel GAF-A sequence, and thus forms a novel GAF-
A. As such, it was considered that the designation of HsPDE11A3 as the closest DmPDE11 
homologue/orthologue remains valid. 
 
8.4 Conclusions and future work 
Using Drosophila melanogaster to study the in vivo function of vertebrate PDEs has been 
shown to be worthwhile in previous studies. The vertebrate PDE11A family has been 
characterised biochemically, but the physiological role it plays it not well understood, with 
the only role so far assigned is a role in spermatogenesis. Drosophila PDE11 was first 
described in 2005, which also has four splice variants. The four isoforms of DmPDE11 
were aligned with the HsPDE11A isoforms, and compared in terms of sequence identity 
and homology, and were subjected to phylogenetic analysis. These results, when 
considered alongside the strong homology between the unique N terminus of HsPDE11A3 
and GAF-A of DmPDE11, suggest that HsPDE11A3 is the closest orthologue to 
DmPDE11 of the HsPDE11A isoforms. 
HsPDE11A3 pP[UAST] and HsPDE11A3pP [YFP UAST] constructs were generated, and 
the transgene expressed in S2 cells and fly. The protein showed predominantly nuclear 
localisation when expressed in S2 cells, and the principal cells of the Malpighian tubule at 
low levels of expression, but was localised to the cytosol when the transgene was driven by 
stronger GAL4 expression. Analysis of HsPDE11A3 using the PREDICTNLS nuclear 
localisation signal prediction tool shows that the protein does not contain a nuclear 
localisation signal (Cokol et al., 2000). Therefore, it must be piggybacking its way into the 
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nucleus with another protein. As for the change in localisation at higher concentration, 
reasons for this are unknown. Immunohistochemical studies concerning HsPDE11A have 
tended to focus on the distribution among tissues (D'Andrea et al., 2005; Loughney et al., 
2005); one study looked at the subcellular localisation of HsPDE11A, which was shown to 
localise to the cytosol of nerve cell bodies of the trigeminal ganglion (Kruse et al., 2009). 
The nuclear localisation of two PDEs has been investigated; PDE1A localises to the 
nucleus in neointimal synthetic vascular smooth muscle cells, but localises to the 
cytoplasm in contractile vascular smooth muscle cells. The basis for this change in 
localisation is not currently understood (Nagel et al., 2006). Certain PDE9A isoforms 
localise to the nucleus, but this is due to a nuclear localisation signal (Wang et al., 2003). 
Thus, the mechanism of translocation of HsPDE11A3 to the nucleus is unknown, but 
appears to be dependent of the concentration of protein. 
Transgenic expression in Drosophila of HsPDE11A3 gives a protein of the predicted size, 
which shows a distinct subcellular localisation. Time did not permit to perform PDE 
assays, and so it is unknown whether the PDE is active in Drosophila. PDE11 -/- mice 
display reduced sperm concentration, rate of forward progression, and percentage of live 
spermatozoa (Wayman et al., 2005), and inhibition of HsPDE11A has also been shown to 
negatively impact spermatozoa quality (Pomara and Morelli, 2005), as HsPDE11A 
regulates spermatozoa physiology (Seftel, 2005).  DmPDE11 -/- null mutant males are 
infertile, as detailed in chapter 4, and so function may be conserved. Spermatogenesis in 
Drosophila is highly analogous to mammalian spermatogenesis (White-Cooper, 2009), and 
so Drosophila could be used to delineate the role of HsPDE11A in spermatogenesis. 
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Chapter 9 
Summary and further work 
9  
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9.1 Summary 
Initial attempts to characterise DmPDE11 focused on two resources; the DmPDE11RA 
ORF, and UAS-PDE11 RNAi flies. While work performed on the ORF of DmPDE11RA 
ultimately proved to be void, due to the replacement of the gene model with two newly 
predicted ORFs, B and C, which encoded two novel polypeptides, work performed on the 
RNAi line is fortunately still valid, due to the targeted sequence being conserved in the B 
and C isoforms. The role of DmPDE11 in the Ca
2+
 response to capa-1 was investigated, as 
Ca
2+
 and cGMP crosstalk occurs in non-excitable cells (Bruce et al., 2003). No difference 
in the cytoplasmic calcium response was seen in tubules with reduced DmPDE11 transcript 
levels compared to control. Treatment of tubules with cGMP induces fluid transport (Dow 
et al., 1994), and the possible involvement of DmPDE11 in modulation of this cGMP 
signal and therefore fluid secretion was investigated by driving DmPDE11 RNAi in the 
principal cells of the Malpighian tubule and comparing the cG-induced fluid secretion of 
these to parental control, where no difference was seen. 
Flybase release 5.2 predicted that the previously predicted gene model for CG34341 was 
incorrect. The previously predicted transcript, DmPDE11RA, was replaced by two 
transcripts, DmPDE11RB and DmPDE11RC. These transcripts were shown to be 
transcribed in vivo by a combination of RT-PCR from cDNA from several tissue sources, 
and by the analysis of EST databases not used in the Flybase analysis. In the course of this 
analysis, a novel exon/exon boundary was identified within exon 17, where the novel exon 
18 encodes 4 amino acids, followed by a stop codon. This results in a truncated 
polypeptide. RT-PCR analysis demonstrated that both DmPDE11RB and RC were 
transcribed with both full length and a truncated isoforms. The generation of transgenic 
flies expressing these isoforms tagged with YFP allowed the verification of these isoforms 
as bona fide dual specificity PDEs. Importantly, the RNAi lines generated against 
DmPDE11RA targeted a region unchanged in the new isoforms, and so work done with 
these lines remained valid. 
Analysis of the subcellular localisation of these isoforms showed that DmPDE11B and C 
display markedly different subcellular localisation, and that the long and short isoforms of 
these do not show distinct subcellular localisation. DmPDE11B localises predominantly to 
the apical and basolateral membranes of the Malpighian tubule, and DmPDE11C localises 
to an unknown organelle or vesicles. 
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 As DmPDE11B and C only differ in the sequence of the first exon, this must encode 
protein sequence that influences the subcellular localisation of the protein. Indeed, analysis 
of the protein sequence of DmPDE11B with the coiled coil prediction software COILS 
(Lupas et al., 1991) predicts a coiled coil in the unique N terminus. Coiled coils facilitate 
the formation of homo- and heteromeric protein-protein interactions (Strauss and Keller, 
2008), and thus protein complexes (Langosch and Heringa, 1998). The subcellular 
localisation of this isoform to the membrane suggests that this region may be responsible 
for an interaction with a protein that tethers DmPDE11 to the membrane. The differing 
subcellular localisation of the B and C isoforms will lead the isoforms to sample and 
modulate different pools of cyclic nucleotides, and thus they may modulate different 
aspects of the cyclic nucleotide signalling pathway (Omori and Kotera, 2007). 
DmPDE11 was shown to co-localise with the cGKs DG1 and DG2. This may be of 
extreme importance, since phosphorylation of PDE11A4 and PDE5A by cGKs has been 
shown to modulate catalytic function (Corbin et al., 2000; Gross-Langenhoff et al., 2008; 
Turko et al., 1998; Yuasa et al., 2000), and the co-localisation and mutual modulation of 
function of PDE5 and cGK1β in platelets is essential in modulating IP3R mediated Ca
2+
 
release from the ER (Wilson et al., 2008). DG2 modulates the cG-PDE activity of an 
unidentified PDE in the Malpighian tubule (MacPherson et al., 2004), and so 
demonstrating that the subcellular localisation of these overlap renders any interaction 
worthy of further investigation. 
Peptide arrays were used to show whether any interaction between these proteins may be 
direct. A DmPDE11 array probed with the C-terminal half of DG1 (from the end of the 
second nucleotide binding domain onwards) tagged with HIS6 gave a number of positive 
spots compared to control, and the reciprocal assay, where a DG1 array was probed with a 
HIS6 tagged fragment representing the middle of DmPDE11 (from the second GAF domain 
to the end of the catalytic domain) also gave positive spots. However, this data must be 
considered preliminary, as alanine substitution arrays have not been performed, and 
peptide arrays must be validated by a further two pieces of interaction data such as co-IP 
and Y2H analysis, and in this case only co-IP data has been obtained. Peptide arrays 
investigating a putative DG2/DmPDE11 interaction were non-informative, and 
unfortunately N-terminal DG1 truncate could not be successfully purified and so was not 
applied to the DmPDE11 array. 
Previous findings by Lorraine Aitcheson suggested that DmPDE11 may modulate 
expression of the anti-microbial peptide diptericin, and that a reduction in DmPDE11 
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expression in principal cells of the Malpighian tubule affects survival upon immune 
challenge with E. coli. The possibility that flies with reduced DmPDE11 transcript levels 
may be immunocompromised was investigated by delivering a septic challenge with E. 
coli to a DmPDE11 deletion line, DmPDE11∆121, and UAS-DmPDE11 RNAi flies 
crossed to GAL4 driver lines. UAS-DmPDE11 RNAi was crossed to Act5c GAL4 and c42 
driver lines, which drive expression ubiquitously, and in the principal cells of the 
Malpighian tubule respectively. The progeny of these crosses did not display a reduction in 
survivorship when compared to controls. DmPDE11∆121 flies showed a highly significant 
reduction in survivorship following immune challenge, although 100 hours following 
septic challenge, these flies only displayed survivorship ~13% lower than Canton S E. coli 
stabbed control. This is a fairly modest, although significant, reduction in survivorship, 
which suggests that the immune role played by DmPDE11 is not a vital one. 
HsPDE11A is the most recently characterised PDE family (Fawcett et al., 2000; Yuasa et 
al., 2000). Phylogenetic analysis of the HsPDE11A gene family suggests that the closest 
homologue to DmPDE11 is HsPDE11A3, which is expressed exclusively in testis in both 
rat and human (Yuasa et al., 2001), and regulates spermatozoa physiology (Seftel, 2005). 
As DmPDE11 -/- males are infertile, function may be conserved. As the physiological role 
of PDE11 is not well understood, HsPDE11A3 pP[UAST] constructs were generated, and 
the transgene expressed in S2 cells and fly. The protein showed predominantly nuclear 
localisation with lower levels of protein in the cytoplasm when expressed in S2 cells. In 
Malpighian tubule principal cells, HsPDE11A3 localised to the nucleus at low levels of 
expression, but was excluded from the nucleus when the transgene was driven by stronger 
GAL4 expression. Such a change to the subcellular localisation may be crucial to its 
function, and so further study of HsPDE11A3 in Drosophila would be worthwhile. 
9.2 Future work 
cA- and cG-PDE assays of HsPDE11A3 
Time did not permit the verification of HsPDE11A3 cA- and cG- PDE activity when 
transgenically expressed in Drosophila. This would be necessary to demonstrate that the 
enzyme is functional when heterologously expressed, and would justify the use of these 
flies to characterise a role for HsPDE11A3 in vivo. 
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DmPDE11C localisation 
As YFP-tagged DmPDE11C transgenic flies were generated, the identification of the 
unknown organelle could be identified by either co-staining of each organelle using 
specific antibodies, or by the crossing of these flies to GFP tagged proteins known to 
localise to a particular organelle, and screening for co-localisation. If the localisation is to 
vesicles, these could be purified, and this fraction subjected to western blotting to confirm 
the presence or absence of DmPDE11C. 
 
HsPDE11A3 localisation 
HsPDE11 localisation appeared to be dependent upon levels of protein, where at lower 
concentrations the protein localises to the nucleus, and at high concentration, the protein is 
excluded from the nucleus. Truncation mutants could be assayed for subcellular 
localisation, in an effort to identify the sequence that modulates this shift in localisation. 
Identification of proteins that interact with DmPDE11 
Although this assay has been performed, the availability of a new polyclonal antibody 
against DmPDE11 would allow the immunoprecipitation of the enzyme, and the 
identification of any putative interactors by analysis of the immunoprecipitate by MALTI-
TOF mass spectrometry.  
Co-immunoprecipitation of DmPDE11 and the cGKs using specific antisera 
Specific antisera against DmPDE11, and the cGKs DG1 and DG2 were generated during 
the course of this study, but unfortunately were produced after my time in the laboratory 
had finished. Upon verification that these antibodies can recognise their antigens both in 
immunoprecipitation and western blot, co-immunoprecipitations could be performed 
against fly lysate. Co-immunoprecipitation from tissue using specific antisera is considered 
the gold standard in co-immunoprecipitation, and would provide evidence of an interaction 
in vivo. 
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Screen for co-localisation of DmPDE11 and the cGKs in vivo 
In order for a putative protein-protein interaction to be relevant, proteins must occupy an 
overlapping subcellular localisation. During the course of this study it was ascertained that 
DmPDE11B long and short localise to the apical and basolateral membranes of the 
Malpighian tubule, whereas DmPDE11C long and short localised to an unidentified 
organelle, or to vesicles. DG1 localises to the basolateral membrane and to the cytosol, 
DG2P1 localises to the apical and basolateral membranes, and DG2P2 localises to the 
apical membrane. Of these, only DG1 could potentially interact with DmPDE11C, which is 
wholly localised within the cytosol. 
Modulation of PDEs by DG2 
When compared to control, DmPDE11 RA overexpressing S2 cells showed no significant 
increase in either cA-, or cG-PDE activity. Co-expression of either DG2P1 or DG2P2 with 
DmPDE11RA further reduced both cA- and cG-PDE activity. Although N=1 for each 
condition, this suggests that over-expressed cGK modulates phosphodiesterase activity or 
protein levels. The experiment mirrors a finding in flies overexpressing DG2P1 and 
DG2P2 in tubule principal cells, the tubules of which show a drastic reduction in 
endogenous PDE activity (Macpherson and Day, 2005). The Malpighian tubule could be 
used to further investigate this. Q-PCR of each PDE gene in DG2 overexpressing tubules 
would reveal whether DG2 modulated PDE activity by a reduction in transcript levels. The 
availability of GST- and HIS6 tagged cGK and DmPDE11 raises the possibility of in vitro 
phosphorylation assays; if DmPDE11 is found to be phosphorylated, the targeted 
mutagenesis of residues predicted as cGK substrates would allow the identification of each 
phosphorylation site. 
 
Confirmation of DmPDE11 role in immunity 
Assay of an increased number of DmPDE11∆121 and other DmPDE11 deletion mutants, 
alongside the appropriate controls, would confirm whether DmPDE11 has a role in 
immunity. As DmPDE11∆121 showed only a modest, but significant, reduction in 
survivorship, it may be that multiple phosphodiesterases modulate the immune response, 
and this redundancy leads a knock-down of DmPDE11 transcript levels to have a modest 
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effect. Immune challenge of flies treated with a broad-spectrum phosphodiesterase 
inhibitor may reveal whether this is the case. 
Repeat of DG2 probed DmPDE11 peptide arrays 
Although several putative sites of protein-protein interaction were identified on the PDE11 
array, when probed with both the N- and C-terminal HIS6 tagged DG2 proteins, there was 
non-specific immunoreactivity at each of these sites on the control PDE11 array. Repeat 
using GST-tagged protein would potentially give different background, and so the putative 
interaction at these sites could be confirmed, in which case an alanine array would be 
generated and overlaid. 
Repeat of DmPDE11 probed DG2 peptide arrays 
Middle-HIS6 and End-HIS6 probed DG2 arrays were compromised; Middle-HIS6 overlaid 
DG2 array showed higher levels of background staining, and so putative spots could not be 
taken as evidence of an interaction, while End-HIS6 overlaid arrays showed staining 
significantly dissimilar to control blots, and so novel immunoreactive spots could not be 
taken as putative interaction sites. Repeat of these assays with GST-tagged protein would 
again give a different background, and hopefully allow the identification of putative 
interaction sites. 
Confirmation of direct DmPDE11-DG1 interaction 
Several sites were determined on DmPDE11 and DG1 which may be regions of direct 
protein-protein interaction. Alanine substitution arrays would confirm whether these 
regions are indeed sites of protein-protein interaction, and furthermore would identify 
those key amino acids within these regions vital for the interaction. As peptide array data 
must be verified by a further two methods, yeast two hybrid and co-IP of deletion mutants 
would confirm the interaction. 
DG1N probed DmPDE11 array 
DmPDE11 and DG1 showed several putative interaction sites on both proteins. Three sites 
were identified within DG1, two of which corresponded to the N terminal fusion protein. 
This fusion protein gave protein of the predicted size at the analytical stage, but failed to 
yield protein following immunoprecipitation. Use of a GST-tagged DG1N terminal fusion 
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protein would hopefully allow the affinity purification of the protein, and subsequently the 
probing of the DmPDE11 array, in order to identify additional putative regions of 
interaction.  
This work has confirmed that DmPDE11RB and RC are transcribed in vivo, and that RB 
and RC each have a short isoform. These show closest homology with HsPDE11A3 in 
terms of sequence. Transgenic Drosophila melanogaster were generated which express 
each of these proteins, and it is hoped that these tools will be used to further characterise 
these biomedically relevant enzymes. Furthermore, the identification of a putative direct 
interaction between DmPDE11 and the cGKs needs to be explored further, as this raises 
the possibility of a new level of feedback in cGMP signalling between the main effectors 
of the pathway, cGMP-dependent protein kinases, and the main regulator of the pathway, 
phosphodiesterases. 
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Appendices 
Appendix 1: Projects undertaken that were halted when the new DmPDE11 sequence 
predictions were released 
Yeast Two Hybrid 
In order to investigate whether the interaction between DmPDE11A and the cGKs was 
direct, a Yeast Two Hybrid screen was undertaken.  The N and C termini of DmPDE11RA, 
and the complete ORFs of DG2P1 and P2 were amplified with proofreading polymerase, 
sequenced for fidelity (data not shown),  digested, and cloned into pACT2 AD, an 
activation domain vector, and pGBKT7, a DNA binding domain vector. The cloning for 
this was completed, and the constructs were transformed and screened for expression. 
However this approach was abandoned in favour of peptide arrays, which not only show 
whether an interaction is direct, but show the peptides responsible for the interaction. This 
data was presented in chapter six. 
Yeast and expertise kindly supplied by Dr. Joe Gray. 
TAP-tagging 
Retrieval of multi-subunit protein complexes utilising tandem affinity purification, and 
their subsequent purification via -mass spectrometry (TAP-tagging) is a technique that was 
pioneered in Yeast (Riguat et al, 1999,) and first used in Drosophila in 2004 (Veraska, 
2004.) TAP-tagging is similar to epitope tagging, except multiple tags are used instead of 
one. The technique involves the cloning of a protein of interest, fused in-frame to a “tap-
tag” at either the C or N terminus. The “tap tag” in our possession consists of two IgG 
binding domains of Protein A from Staphylococcus aureus and a calmodulin binding 
peptide, which are separated by a TEV protease cleavage site (Rigaut et al, 1999). The 
TEV protease site allows the release of the protA units from the matrix-bound IgG under 
native conditions, which should keep native interactions intact, and thus permit the 
purification of interacting protein complexes. Following the elution of these proteins, mass 
spectrometry is used to identify each individual protein. The presence of two tags allows a 
two-step purification process, which provides a reduction in protein background, while the 
native conditions should not inhibit protein binding, thus preventing the loss of proteins 
from the complex. 
The tap-tag can be combined with the UAS/GAL4 binary expression system. This allows a 
cell-specific identification of any interactors, at specific points in the fly‟s development, 
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and to a tissue specific level if the daunting number of dissections could be overcome. 
When this process is coupled to mass spectrometry, proteins at the sub-picomolar range are 
readily identifiable (Bauer and Kuster, 2003). 
The aim of the TAP tagging project was to identify any proteins that interact with 
DmPDE11 and DG2P1. Stable S2 cell lines expressing the TAP-tagged DmPDE11RA, 
DG1, DG2P1 and DG2P2 were generated by co-transfection with a pCoHygro plasmid, 
and selection with hygromycin-B. However these were not validated for expression, as this 
coincided with the release of Flybase release 5.2. The stock was immortalised. 
 
Appendix 2: Data pertaining to DmPDE11 catalytic activity in S2 cells and fly 
 
Analysis of PDE (and PDE truncate) catalytic activity in S2 cells 
Attempts to express full length DmPDE11 in S2 cells failed (Day, 2005). As such the 
catalytic domain was cloned into pMT/V5-His-TOPO, again in frame with the C-terminal 
V5 tag, and subjected to cA- and cG-PDE assays alongside DmPDE6 and DmPDE8 (figure 
A2.1) (Day, 2005).  
 
Figure A2.1: PDE activity of DmPDE6, DmPDE8 and DmPDE11 catalytic domain 
constructs. S2 cell lysate was assayed for cG and cA-specific PDE activity at a spread of 
substrate concentrations. Activities represent PDE-transfected activity minus mock 
transfected activity. Specific PDE activity expressed as pmol cGMP or cAMP/mg/min. 
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Analysis of DmPDE11 immunoprecipitate by PDE assays 
DmPDE11 was verified as a dual specificity PDE by immunoprecipitation using specific 
polyclonal antisera from head lysate, and subjecting this IP to cA- and cG-PDE assays 
(figure A2.2) (Day et al., 2005) 
 
Figure A2.2: DmPDE11A shows significant cA- and cG-PDE activity when 
immunoprecipitated, and subjected to cN-PDE assays. Immunoprecipitate of 
DmPDE11 using specific antisera from head lysate yields significant cA- and cG-PDE 
activity when compared to pre-immune control. N=3. Error bars represent standard error of 
the mean. 
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Appendix 3: DmPDE11B and C isoforms are expressed in hindgut and head 
 
PCR analysis of DmPDE11 expression in hindgut and head 
PCR using primers specific to isoforms B and C was performed on hindgut and head 
cDNA to determine if RB and RC were expressed in each (figure A3.1) (Day and 
Sebastian, unpublished observations, 2007). 
 
Figure A3.1: DmPDE11 RB and RC are expressed in head and hindgut. PCR (30 
cycles) was performed using primers specific to the N termini of DmPDE11 RB and RC 
using head (A; expected product 315 bp) and hindgut (B; expected product 183bp) cDNA, 
and the products verified by agarose electrophoresis. Band size identified using 100bp 
ladder. For both gels: Lane 1: DmPDE11-RB N-termini, lane 2: DmPDE11-RC N-termini. 
(A)                                                           (B) 
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Appendix 4: Data pertaining to an interaction between DmPDE11 and cGKs 
 
DmPDE1, DmPDE6 and DmPDE11 co-immunoprecipitate with cGK activity 
Immunoprecipitates of PDE 1, 6 and 11 using specific IgG purified antisera from 
Drosophila head lysate were assayed for cGK activity (figure A4.1) (Day and Sebastian). 
 
Figure A4.1: Immunoprecipitation from fly head lysate using Drosophila anti-
DmPDE1, anti-DmPDE6, and anti-DmPDE11 polyclonal antibodies yields significant 
cGK activity. PDE was immunoprecipitated from fly head lysate using IgG purified anti-
DmPDE1, anti-DmPDE6, and anti-DmPDE11 specific antisera, and IgG purified pre-
immune serum (“IgG”), and the immunoprecipitate subjected to a kinase assay against a 
“glasstide” cGK substrate. * denotes significant difference of mean P <0.05 against pre-
immune IgG control. 
 
Immunoprecipitation of DmPDE1, DmPDE6, and DmPDE11 each yielded a significant 
amount of cGK activity when compared to pre-immune control (Day and Sebastian), 
suggesting that each DmPDE interacts with cGK(s).   
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DG1 or DG2 co-immunoprecipitate with cG-PDE activity 
DG1 and DG2 were immunoprecipitated using IgG purified specific polyclonal antisera 
from head lysate, and the immunoprecipitate subjected to cG-PDE assay (figure A4.2) 
(Day and Sebastian).  
 
Figure A4.2: Immunoprecipitation from fly head lysate using Drosophila anti-DG1 
and anti-DG2 polyclonal antibodies yields significant cG-PDE activity. DG1 and DG2 
were immunoprecipitated from fly head lysate using IgG purified anti-DG1 and anti-DG2 
specific antisera, and IgG purified pre-immune serum (“Pre-Im”), and the IP subjected to a 
cG-PDE assay. * denotes significant difference of mean P <0.05 against pre-immune 
control. 
 
Both the DG1 and DG2 immunoprecipitates yielded significant cG-PDE activity when 
compared to pre-immune controls (Day and Sebastian), suggesting that both DG1 and DG2 
interact with at least one unidentified cG-PDE.  
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DmPDE11 co-immunoprecipitates with DG2P2 
Wild-type canton S flies were homogenised and subjected to immunoprecipitation with an 
anti-DmPDE11 polyclonal antibody which recognises all four isoforms. The 
immunoprecipitate was resolved on an SDS-PAGE gel, and individual bands were excised 
and sequenced using Matrix-assisted laser desorption/ionisation-time of flight mass 
spectrometry (MALDI-TOF MS). One band yielded several stretches of amino acids 
corresponding to DG2P2 sequence, that have no significant homology to any other 
Drosophila protein when BlastP analysis is performed against the Drosophila proteome 
(Day).  
 
Appendix 5: Previously obtained data implicates DmPDE11 in the gram negative 
immune response 
 
Diptericin expression is modulated by a pool of cGMP that is in turn modulated by 
PDE11 
When UAS-PDE11 RNAi (line 1) expression is driven in the Malpighian tubule principal 
cell with the GAL4 driver c42, there is a significant reduction in diptericin expression. 
While parental tubules incubated in Schneider‟s solution for three hours, either with or 
without 100μM cGMP, show a significant reduction of diptericin expression in the plus 
cGMP condition, c42/UAS-PDE11 RNAi (line 1) flies show a significantly lower level of 
diptericin expression in both conditions, where the addition of cGMP does not result in a 
further reduction of diptericin expression (figure A5.1) (Aitcheson, 2009a).  
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Figure A5.1: Q-PCR analysis of the affect of cGMP on diptericin expression in the 
Malpighian tubule. Q-PCR for diptericin expression in the Malpighian tubule, where 
tubules were incubated in Schneider‟s solution for three hours, in the presence or absence 
of 100μM cGMP. Error bars show standard error of the mean (courtesy of Lorraine 
Aitcheson.) 
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Reduction of PDE11 transcript levels in Malpighian tubule principal cells affects 
whole fly survival in response to a septic challenge with E. coli 
UAS-PDE11 RNAi (line 1) flies were crossed to c42 GAL4. UAS-PDE11 RNAi (line 1), 
and c42/UAS-PDE11 RNAi (line 1) flies were either “mock” stabbed with a dry 0.35mm 
needle, or stabbed with a 0.35 gauge needle dipped in an E. coli solution (at static phase) in 
the abdomen, and survival was monitored for 24 hours (figure A5.2), as detailed in 
materials and methods (Aitcheson, 2009b). 
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Figure A5.2: Preliminary data showing a reduction in survivorship in c42/UAS-
PDE11 RNAi compared to controls when septically challenged with E. coli. Survival 
experiment showing a significant decrease in survival upon challenge with E. coli using a 
0.35mm gauge needle when PDE11 expression is reduced via expression of a PDE11 
RNAi transgene, driven in tubule principal cells. Error bars show standard error of the 
mean (courtesy of Lorraine Aitcheson.)  
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Following septic challenge with E. coli, c42/UAS-PDE11 RNAi (line 1) flies displayed a 
lower level of survival compared to the negative controls. This experiment was performed 
to N=1, using between 19 to 29 flies for each genotype, where N=3 replicates of 30 flies 
per genotype is necessary to perform statistical analysis.  
 
Appendix 6: Drosophila Media 
 
 Standard growth media per litre of water     10 g agar 
               15 g sucrose 
               30 g glucose 
               35 g dried yeast 
               15 g maize meal 
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                       10 g wheat germ 
               30 g treacle 
               10 g soya flour 
 
Grape-juice agar             per litre of water 
               40 g agar 
               52 g glucose 
               26 g sucrose 
               15 g dried yeast 
               50 % (v/v) blackcurrant diluting juice 
                 1 % (v/v) Nipagin 
 
Appendix 7: Escherichia coli growth media and selective agents 
 
L-broth per litre of water                    10 g Bacto-tryptone 
     5 g dried yeast  
     10 g NaCl 
 
L-agar per litre of water                      10 g Bacto-tryptone 
     5 g dried yeast  
     10 g NaCl 
     15 g Bacto-agar 
 
SOC broth    2 % (w/v) Bacto-tryptone 
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     0.5 % (w/v) dried yeast 
     10 mM NaCl 
     2.5 mM KCl 
     10 mM MgCl2 
     10 mM MgSO4 
     20 mM glucose 
 
Selective agents 
 
Ampicillin: 100-200 g/ml ampicillin when being grown on L-Agar or in L-Broth. 
 100 mg/ml stock solution (w/v) in 50% H2O, 50% ethanol and stored at -20C. 
Kanamycin: 50 mg/ml solution (Sigma) and stored at 4C. Selection for kanamycin 
resistance was performed by the presence of 50 g/ml kanamycin on L-Agar or in L-Broth.  
 
Appendix 8: SDS-PAGE and Western blotting solutions 
 
6 x SDS-PAGE Loading buffer 0.35 M Tris HCl,  pH6.8 
10.28 % (w/v) SDS 
36 % v/v glycerol 
     5 % v/v -mercaptoethanol 
     0.012 % w/v bromophenol blue 
in 0.5 ml aliquots stored at –20C 
Tris-Glycine Running Buffer   per 500 ml of H2O 
     7.2 g Glycine 
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     1.5 g Tris Base  
     6 ml 10% (w/v) SDS 
Staining Solution   465 ml Brilliant blue R concentrate (Sigma) 
     535 ml H2O 
Destaining Solution   10 % (v/v) Acetic Acid 
45% (v/v) Methanol 
in H2O 
Poncau S Staining Solution  per 500 ml of H2O 
     1.5 g TCA 
     0.5 g Poncau S stain 
Transfer Buffer   per litre of H2O 
     20 % (v/v) Methanol 
     14.4 g Glycine 
     3 g Tris Base 
1 x PBS    137 mM NaCl 
      2.7 mM KCl 
     10 mM Na3PO4                                                                                          
w                                                                     2 mM KH2PO4,          pH 7.4 
From (Sambrook and Russell, 2001) 
 
Appendix 9: Resolving and Stacking gels for SDS-PAGE 
Each solution is sufficient to prepare 2 x 5ml gels   
6 % gel                                                                              
H2O                                                    5.3 ml                           
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30 % acrylamide mix                            2.0  
1.5 M Tris (pH 8.8)                              2.5 
10 % (v/v) SDS                                   0.1  
10 % (v/v) APS                                   0.1 
TEMED                                              0.008 
7 % gel 
H2O                                                    5ml                                                         
30 % acrylamide mix                            2.3 
1.5 M Tris (pH 8.8)                              2.5 
10 % (v/v) SDS                                   0.1 
10 % (v./v) APS                                  0.1 
TEMED                                              0.007 
10 % gel 
H2O                                                    4.0 
30 % acrylamide mix                           3.3 
1.5 M Tris (pH 8.8)                             2.5 
10 % (v/v) SDS                                   0.1 
10 % (v/v) APS                                   0.1 
TEMED                                              0.004 
 
Sufficient to prepare 2 x 5% 1.5ml stacking gels   
H2O                                                     2.1 ml 
30 % acrylamide mix                            0.5 
1.0 M Tris (pH 6.8)                              0.38                                            
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10 % (v/v) SDS                                   0.03 
10 % (v/v) APS                                   0.03 
TEMED                                              0.003 
From (Sambrook and Russell, 2001) 
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